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ABSTRACT
ELUCIDATING MECHANISMS OF METASTASIS WITH IMPLANTABLE
BIOMATERIAL NICHES
MAY 2020
RYAN ADAM CARPENTER, B.A., UNIVERSITY AT BUFFALO
B.S., UNIVERSITY AT BUFFALO
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jungwoo Lee

Metastasis is the leading cause of cancer related deaths, yet it remains the most
poorly understood aspect of tumor biology. This can be attributed to the lack of relevant
experimental models that can recapitulate the complex and lengthy progression of
metastatic relapse observed in patients. Mouse models have been widely used to study
cancer, however they are critically limited to study metastasis. Most models generate
aggressive metastases in the lung without the use of unique cell lines or specialized
injection techniques. This limits the ability to study disseminated tumor cells (DTCs) in
other relevant metastasis prone tissues. Prolonged observation of the post-dissemination
phase of cancer cell biology and the dormant-to-active transition are additional challenges
to study in mouse models due to the rapid onset of actively growing primary and secondary
tumors that shorten the experimental timeframe. These limitations have left a critical gap
in the understanding of metastasis, specifically the long-term bi-directional crosstalk
between DTCs and their local microenvironment. Previous findings have demonstrated
that subcutaneously implanted inverted colloidal crystal (ICC) hydrogel scaffolds recruit
circulating tumor cells and capture metastatic progression. Here, I introduce new
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implantable tissue engineered metastasis models that overcome the fundamental
restrictions of existing mouse models and substantiate the role of the tumor niche in the
reactivation of dormant DTCs with molecular and cellular detail.
Throughout my dissertation work I engineered DTC niches leveraging ICC
scaffolds to identify critical niche components that enable metastatic progression.
Changing the anatomical location of the implant yielded unique microenvironments with
varying levels of metastatic potential. In a secondary approach, I utilized the
immunomodulatory properties of ICC scaffolds to assist the transplantation of adult lung
and liver tissues into the subcutaneous space for prolonged study of metastasis-relevant
tissues. Next, I leveraged the transplantable nature of scaffold niches to investigate DTC
dormancy and potential triggers of metastatic relapse. I developed a fully humanized mouse
model to explore local niche evolution as human DTCs progress from single cells to small
colonies and overt metastases. The local vasculature and Ly6G+ cells were observed to
play important roles during each step of the transition to aggressive proliferation. The effect
of adjuvant chemotherapy and surgical disruption on DTCs and their niche was also
explored by using a fully immunocompetent mouse model. Lastly, I improved the
fabrication of ICC hydrogel scaffolds to make the process more scalable for widespread
use. The use of expanded polystyrene beads enabled cheaper, faster, and safer production
of ICC hydrogel scaffolds.
Tissue engineering approaches to recreate in vivo DTC microenvironments
represent an exciting opportunity to better understand metastasis. The presented models
and techniques may be enabling tools to aid in the development of anti-metastasis therapies
that significantly benefit patient health.
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CHAPTER 1

CANCER METASTASIS AND EXPERIMENTAL MODELS

1.1 Introduction
Cancer is a disease whereby cells in the body divide uncontrollably. Cancer is
caused by genetic changes that alter genes that are involved in cell growth, division, and
DNA repair1. During cancer progression, cells can gain a malignant phenotype
characterized by the ability to invade local tissues and spread to distant tissues. Metastatic
disease occurs once the cancer spreads to a distant site and proliferates. Patient survival
rates dramatically decline as cancers spread from the local organ of origin to distant organs
(Figure 1.1). For example, the five-year relative survival rate for breast cancer is 99%
when diagnosed locally, and only 27% when diagnosed in distant organs. This
phenomenon is further amplified during aging with five-year survival rates in breast cancer
diagnosed in distant organs dropping to 22% and 15% for patients 65-84 and 85+,
respectively2.

Figure 1.1. 5-year patient survival rate based on stage at time of diagnosis.
Data adapted from National Cancer Institute Cancer Statistics Review2.
1

Metastatic disease presents several clinical challenges3. First, detection of
disseminated tumor cells (DTCs) is not practical and even secondary tumor colonies can
be challenging to find. Some patients may remain asymptomatic until metastatic disease
reaches an advanced stage. Second, treatment options for patients diagnosed with
metastatic disease are severely limited. In most cases there is no cure for metastatic disease.
Instead treatment is used to slow tumor growth and reduce symptoms. Most metastatic
cancer treatment strategies are similar to the primary tumor of origin, however cancer cells
can gain new genetic alterations that make them resistant to therapy.
Although several aspects of metastasis have been uncovered, treatment for patients
has only marginally improved4-7. Current experimental models of metastasis are limited in
their ability to fully recapitulate the metastatic cascade and it remains unclear if these
models provide accurately represent human metastasis. The work of this dissertation aimed
to provide new experimental models to study DTC biology and the evolution of the local
microenvironment during metastatic progression. In this chapter, the current understanding
of metastatic disease progression are highlighted as well as the experimental models to
study circulating, disseminated, and metastatic cancer cells.

1.2 The Metastatic Cascade
The initial step of the metastatic cascade is invasion into nearby normal tissue or
blood and lymphatic vessels. As cancer cells proliferate and form a primary tumor they
may gain additional phenotypic traits that enable eventual metastatic disease. This
hypothesized event is commonly referred to as an epithelial-mesenchymal transition
(EMT). In the early-stage carcinomas cancer cells are generally in an epithelial-like state
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characterized by maintenance of cell-cell junctions, apical-basal polarity, and interaction
with the underlying basement membrane. The transition to the mesenchymal state is
characterized by loss of cell-cell junctions, loss of cellular polarity, degradation of the
basement membrane and reorganization of the surrounding extracellular matrix. Activation
of EMT programs via EMT related transcription factors like ZEB1 and SNAIL in nonmetastatic cells has been shown to increase their metastatic potential8. The phenomenon of
EMT is still not fully understood and evidence of metastases that appear to not undergo
such a transition have been presented.
Invasion into draining lymph nodes is generally the first clinical identification of
potential metastatic disease, however the spread to distant anatomical locations is widely
believed to occur through the blood circulation. Entrance into the blood system presents
cancer cells new challenges including hemodynamic forces9. Circulating tumor cells
(CTCs) are one of the most challenging aspects of the metastatic cascade to study due to
their relative rarity in the blood, inability to detect via platelet shielding, and limited
success in expansion once purified. While in circulation, cancer cells home to new
locations via passive mechanical trapping and active processes such as cell-mediated
adhesion. While this phenomenon is traditionally viewed as the circulation of singular
CTCs, recent findings suggest that CTCs with the highest metastatic potential exist as
clusters10. Once extravasated from systemic circulation, CTCs are considered
disseminated. Like CTCs, DTCs are exposed to a new set of microenvironment pressures
present in the secondary tissue. The microenvironment plays an important role in
determining the proliferative state of the DTCs and are explained in further detail below.
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In the nineteenth century organ specific patterns of metastatic growth were
identified11. A study of 735 breast cancer patients and their resulting metastatic disease
revealed a preference to form in the liver and lungs. These observations initiated research
into the apparent pre-disposition of certain organs to undergo metastasis. Metastatic
organotropism is largely observed in the liver, bone, lung, and brain (Figure 1.2). The liver
is the most common distant site of metastasis from solid tumors. The liver is anatomically
situated to capture many CTCs that enter portal circulation. Additionally, hepatic blood
vessels are fenestrated, providing a low barrier of entry into the parenchymal tissue. The
bone marrow vasculature also consists of fenestrated sinusoidal capillaries that normally
facilitate trafficking of hematopoietic cells12. Besides anatomical and physical features,
several cellular and molecular mechanisms have been uncovered in each tissue
microenvironment that are important for CTC homing and metastasis formation. In the
liver, claudin-2, MIF, CCL2, and IL-6 have been shown to promote metastasis13-15.
CXCL12, RANKL, OPN, and BMPs are important in CTC recruitment to the bone
marrow16. Osteolytic metastasis is characterized by a “vicious cycle” whereby growth
factors, such as TGF-β, embedded in the bone matrix are released and further metastatic
growth occurs. Cancer cells that extravasate into lung tissue can stimulate local fibroblasts
which ultimately increases WNT signaling and promotion of colonization17. DTCs in the
brain can induce astrocytes to establish Notch signaling and endothelin production for
favorable metastasis conditions18-19. In addition to microenvironment features, cancer cells
themselves can develop intrinsic mechanisms that can be identified to predict relapse in
specific tissues. One example of this is breast cancer cells with high expression of CXCR4,
IL-11, osteopontin, and CTGF have been shown to have prometastatic effects in the
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formation of bone metastases20. Although organ specific mechanisms have been identified,
targeting these individual pathways may prove to be impractical. Rather, understanding
potential shared mechanisms of metastatic outgrowth could yield targetable pathways for
more effective treatment.

Figure 1.2. Organotropic behavior of tumor cell dissemination to distant tissues.
Metastatic tumor development primarily occurs in a subset of organs. Here a primary breast
tumor is shown to generated disseminated tumor cells in the brain, bone, lung, and liver.

In the early 2000s, the pre-metastatic niche hypothesis was developed based on the
finding that the presence of non-cancer cells can predict a future metastatic site21. Findings
by Kaplan et al. revealed that soluble factors derived from the primary tumor can activate
VLA-4+ (integrin α4β1) VEGFR1+ hematopoietic bone marrow progenitors, changing their
phenotype to be more mobile and supportive of metastatic growth in visceral organs.
Additionally, tumor derived factors upregulated fibronectin expression in lung fibroblasts
to improve homing of these bone marrow derived cells. Removal of these bone marrow
derived cells prevented metastasis, however their function and the precise mechanism of
soluble factor activation were unknown21. Since these findings, work has been expanded
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to identify the role of the primary tumor has on changing normal host tissue and
hematopoietic response (Figure 1.3). In addition to cytokines, exosomes, small membrane
vesicles that contain functional biomolecules including proteins, lipids, RNA, and DNA,
have been identified as key drivers of pre-metastatic niche development22. Exosomes have
been shown to interact with bone marrow cells and organ-specific niche cells to prepare
pre-metastatic niches. One of the first exosome-mediated steps in the pre-metastatic niche
formation is believed to be the induction of vascular leakiness. Delivery of microRNAs
through exosomes can disrupt the blood-brain barrier and enable the formation of brain
metastases23. Additionally, vascular integrity is decreased in the lung following
upregulation of Angpt2, MMP3, and MMP10 early in pre-metastatic niche development
and prior to tumor dissemination24. The next step in pre-metastatic niche evolution is
activation of resident stroma. Aside from interfering with vascular cells, exosomes have
been shown to increase S100 protein upregulation in lung fibroblasts and liver-specific
Kupffer cells through integrin-mediated binding25. Interestingly, the site of pre-metastatic
niche formation was defined by the integrin expression pattern on the exosome. S100
proteins have been shown to be strong chemoattractants of myeloid and endothelial cells
and appear at several stages of cancer26-27. As explained above, activation of local
fibroblasts has been shown to increase fibronectin deposition in the lung and liver. Tumor
derived exosomes were recently shown to alter perivascular cells to a less differentiated
state, with enhanced extracellular matrix production28. The LOX family of proteins,
involved in collagen crosslinking have also been shown to prime the pre-metastatic niche,
however the source is believed to be from the primary tumor rather than activated
fibroblasts. LOX accumulates with fibronectin, crosslinks collagen IV and enables
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adhesion of myeloid cells. The recruited myeloid cells break down the matrix and create a
feed-forward loop of increased bone marrow derived cell recruitment 29. The final step and
hallmark of pre-metastatic niche formation is the systemic recruitment of immune cells.
Bone marrow derived cells and myeloid derived suppressor cells play an important role in
repressing IFN-γ-mediated immune responses and increasing proinflammatory signaling
to make the microenvironment more permissive for immune evasion, extravasation,
survival, and proliferation of DTCs30. The secretion of MMP9 from recruited
hematopoietic cells aids in additional matrix remodeling. Neutrophils respond strongly to
chemokines, CXCL1, CXCL2, CXCL5, CXCL12 (SDF-1), secreted by stromal cells
activated by exosomes31. A recent study found that recruited neutrophils secrete
leukotrienes, that can convert cancer cell populations into metastasis-initiating cells32.

Figure 1.3. Schematic of pre-metastatic niche formation.
Soluble molecules released from the primary tumor act on CTC-recipient tissue fibroblasts
and the bone marrow to generate a metastasis-prone microenvironment.

Although the pre-metastatic niche hypothesis is an exciting direction to uncover
potential therapeutic targets it does not explain all potential avenues for metastatic relapse.
Once a cancer cell has disseminated it generally does not immediately proliferate. A period
of cellular dormancy can exist for periods ranging from months to years before relapse into
a proliferative metastatic tumor. Clinically, DTCs can be found in the bone marrow years
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after primary tumor removal33-35. CTCs and cell-free DNA can also be found in circulation
in patients in remission36-38. There are three hypothesized mechanisms of dormancy:
cellular, angiogenic, and immunologic39. Cellular dormancy refers to cells that remain in a
singular state due to intrinsic signaling. This is the least understood mechanism of DTC
dormancy due to challenges in identifying single cells and their proliferative state through
histological characterization. Traditionally cellular dormancy was evaluated by negative
Ki67, a marker for proliferation, signal. The ratio of ERK and p38 activity has been found
to also signal dormancy. High ERK:p38 ratio is required for proliferation, whereas low
ERK:p38 ratio is seen in a dormant state40. Dormancy can also be induced by
downregulation of the PI3K-AKT pathway41. NR2F1 upregulation plays a critical role in
driving growth arrest via SOX9, RARβ, and NANOG42. The microenvironment can play a
key role in regulating the dormant phenotype in DTCs. In the bone marrow, GAS6
produced by osteoblasts induces dormancy through Axl, Tyro3, and Mer43. BMP7 secreted
from bone stromal cells causes cancer cells to activate p38 MAPK, p21, and NDRG1 44.
The p38 pathway and associated dormancy was also found to be activated by TGFβ2
signaling in the bone marrow45. Angiogenic dormancy arises from a lack of vasculature to
continually sustain the initial growth of a micrometastasis. Without adequate nutrients, the
tumors fail to become metastases and can undergo apoptosis46. This mechanism of
dormancy is challenged by findings of non-proliferative tumors in direct contact with
endothelial cells47-48. Finally, immunological dormancy describes a hypothesis whereby
immune cells control the growth of proliferating tumors but do not eliminate them. Clinical
observations of patients with transplanted organs containing donor tumor cells have
developed metastasis after immunosuppression suggesting the host immune system was
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keeping the tumor in check49. A preclinical model found that maintenance of metastatic
dormancy was halted once CD8+ T cells were selectively removed50. Adaptive immune
cells may also inhibit pro-angiogenic pathways to prevent growth51. The dual nature of the
immune system in tumor progression have made the mechanisms for potential
immunological dormancy unclear.

1.3 Experimental Models of Metastasis
Despite success in treating primary tumors, metastatic relapse remains a
challenging disease to treat. A great emphasis has been placed in better understanding the
fate of tumor cells that escape the primary lesion. Considerable efforts have been made in
understanding the biology of CTCs and early stage DTCs to identify targets that may
prevent metastatic outbreak. Although limited in study for ethical reasons, human samples
remain the best samples for understanding metastasis and the development of effective
therapies. Alternatively, mouse models provide an invaluable intermediate between
reductionist in vitro approaches and human patients. However, mouse models are often
imperfect and do not always produce translational findings to human patients. There is a
critical need to generate new methods and models to better simulate and investigate disease
progression for translatable outcomes. In this section various techniques are highlighted
that improve understanding of CTC and DTC biology (Figure 1.4).
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Figure 1.4. Schematic of the metastatic cascade and advanced techniques developed
to elucidate the biology of circulating and disseminated tumor cells
Circulating tumor cells can be isolated via microfluidic devices and traditional cell
separation techniques. Captured circulating tumor cells are kept viable in optimized ex vivo
culture conditions and transplantation into mice. Disseminated tumor cells can be captured
in tissue engineered microenvironments for long-term monitoring of progression to
metastases. Intravital imaging windows have been used to visualize extravasation into
scaffold niches.
1.3.1 Isolation and Culture of Circulating Tumor Cells
CTCs are rare cells within the diverse population of cells in the blood. Red blood
cells, leukocytes, myeloid cells, endothelial cells, and various epithelial cells can be found
in the blood. Early research in the field of CTCs utilized existing cell sorting techniques
via antibody targeting 52. EpCAM and cytokeratin are prevalent markers to isolate CTCs
from whole blood samples. CellSearch, the only FDA approved diagnostic tool for clinical
use, detects EpCAM+/Cytokeratin+ CTCs

53

. However, these methods require a cell-

fixation step preventing subsequent functional assays. Additionally, selection of
EpCAM+/Cytokeratin+ cell populations has been shown to be limited in its ability to
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capture all tumor-derived cells as CTCs may have undergone an epithelial-to-mesenchymal
transition during intravasation into the blood stream and no longer display epithelial
markers.
Due to the rarity of CTCs there have been efforts to culture captured cells ex vivo
to increase the yield and accuracy of analytical characterization. Additionally, new
techniques have been developed to isolate CTCs. Several microfluidic devices have been
developed to streamline the isolation process and minimally damage cell populations. In
general, these devices are constructed with PDMS with the flow chambers coated with
EpCAM antibodies 54. Utilizing the unique flow properties of different blood components,
devices have been made to separate CTCs with minimal exogenous processing such as red
blood cell lysis buffers 55. An additional solution to separate CTCs that has shown success
in microfluidic platforms and more traditional immunomagnetic separation techniques is
the depletion of the non-CTC populations mainly composed of immune cells 56. Due to the
heterogenous population of CTCs and the potential for an epithelial-to-mesenchymal
transition, this approach attempts to capture a more complete population of CTCs in whole
blood and minimize the potential for negative downstream side effects due to antibody
binding. Lastly, a simplistic technique to capture CTCs involves the isolation of nucleated
cells via density-based separation, such as Ficoll Paque. Although this does not separate
immune cells from CTCs, during ex vivo culture these immune cells eventually die leaving
an enriched CTC population 57.
Ex vivo culture of CTCs is a challenging endeavor, and very few studies have been
successful. Stable cell lines can take months to develop with low yield. Several groups
have seen success using a cocktail of growth factors including EGF and FGF among others
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to culture CTCs ex vivo

55, 58

. Additionally, ex vivo CTC culture is commonly performed

under hypoxic conditions of <5% O2 56. Those cells that were successful during initial
culture were capable of expansion without growth factors. Another approach to culture
CTCs includes the addition of tumor associate fibroblasts and extracellular matrix proteins.
Three-dimensional culture was still necessary for effective expansion 54. Multiple reports
indicate an enrichment of CD44+/CD24- CTCs which have been previously classified as
cancer stem cells, a highly tumorigenic subpopulation 59.
Even with advances in culture techniques, it is often challenging to expand primary
cells in vitro. Drastic changes in nutrient availability, oxygen tension, cell-cell interaction,
mechanical stiffness, extracellular matrix proteins can overwhelm cells and prevent
proliferation. Human patient-derived xenografts in immunodeficient mice have yielded
physiologically relevant maintenance of tumors. Similarly, CTCs have been
xenotransplanted into murine hosts to enrich the population of cells that could form
metastatic tumors

60

. Similarly to in vitro studies, CD44 was frequently observed in

metastatic disease. Interestingly the CTCs developed markers that were not present in the
primary tumor. This phenomenon is frequently observed in the clinic and is believed to be
a major driver of drug resistance and poor patient prognosis.
In clinics, the capture of patient CTCs may be an important tool for diagnostics and
aid in developing personalized therapeutic strategies to improve patient outcome. Current
technology enables comprehensive CTC genotyping to identify mutations, however cells
may not be fully receptive to drug candidates. CTC lines can be used to screen panels of
single and combinatorial drug candidates. Additionally, better understanding of cells that
can form metastases is also necessary. Data suggests that not all CTCs can form metastases.
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Understanding the intrinsic factors that are unique to metastasis-initiating CTCs is another
key area of study to prevent metastatic disease. Currently these approaches are limited by
the lack of reliable methods to culture patient CTCs and the long periods of time required
to generate cell lines.

1.3.2 In Vitro Models to Study Disseminated Tumor Cells and Dormancy
As techniques improve to isolate and characterize CTCs improve, there has also
been considerable effort in understanding the DTC microenvironment. In vitro models
have been developed to observe tumor cell behavior in controlled environments. Precise
control of soluble molecules, cell ratios, substrate matrix, and external compressive, elastic,
and shear forces can be applied reproducibly61-62. Additional benefits of in vitro systems
include the high throughput nature, easy accessibility for real-time microscopic analysis,
and fabrication with fully human cellular and extracellular components. A co-culture
system of human stromal and endothelial cells was used to mimic lung and bone marrow
microenvironments. Seeding with human cancer cells followed by a cocktail of lamininrich

extracellular

matrix

and

supplement-free

media

created

a

dormant

microenvironment63. Endothelial cell derived thrombospondin-1 kept cancer cells in a
dormant state by suppressing neovasculature and associated TGF-β1 and periostin.
Another in vitro model utilized a microfluidic system to study human breast cancer
extravasation into a human bone marrow microenvironment64. This model consists of a
fibrin gel, seeded with human mesenchymal stem cells and osteoblasts, surrounded by flow
channels separated by a layer of human endothelial cells. Human cancer cells are
introduced in the flow channel and microscopically observed as they extravasate into the
bone marrow mimic. This model demonstrated potential as a drug screening assay for
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compounds that prevent extravasation and metastatic outgrowth. Although complex in
vitro models have been developed, generating fully physiologically relevant models is
challenging ex vivo. Additionally, as highlighted above with the culture of patient CTCs,
certain primary cells are challenging to culture ex vivo. In vitro models have unmet
potential in fully modeling DTC biology and still need time to reach the predictive value
of in vivo models.

1.3.3 In Vivo Models to Study Disseminated Tumor Cells and Dormancy
In vivo models encompass the full complexity and dynamics of a living system and
provide great insight on tumor biology

65-67

. Mouse models have long been the gold

standard to observe tumor progression from a primary tumor to a lethal metastasis. Mice
are relatively cheap, easy to house and handle, and reproduce quickly. Due to the
widespread use of mice in research laboratories a rich infrastructure of tools has been
developed. Clinical imaging modalities such as x-ray, magnetic resonance imaging, and
positron-emission tomography have all been adapted for use in preclinical studies68-69. In
this section traditional mouse models and tissue engineering approaches to study metastasis
are discussed (Figure 1.5).
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Figure 1.5. Traditional methods to generate in vivo mouse models of metastasis.
Primary tumors are commonly formed via cell line inoculation, patient-derived tissue
transplantation, or genetic engineering to create spontaneous tumors. Each method presents
its own unique benefits and drawbacks.

The most common approach to modeling cancer in mice is the inoculation of in
vitro cultured tumor cell lines. Injection of these cells can occur orthotopically, at the site
of original primary tumor, ectopically, not at the site of original primary tumor, or
systemically by directly injecting into circulation. These models benefit from rapid tumor
generation and low cost, an attractive platform for preclinical therapeutic screening.
Allogeneic transplantation into syngeneic immunocompetent hosts have been used for
preclinical drug development since the 1950 and 1960s70-71. However, these models have
shown low predictive value when translated to humans72. The discovery and widespread
use of immunocompromised mice enabled xenotransplantation of human tissues into mice
without host rejection73. Although these models utilize human cells, they still have low
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predictive value for clinical outcomes74-75. The use of tumor cell lines has come under
recent scrutiny as observations of altered in vivo tissue microenvironment development and
irreversible gene expression changes due to culturing in vitro have been made76-77.
Rather than digest tumor tissues, culture and expand the cells on two-dimensional
substrates, and then introduce them into mice several models simply take pieces of tumor
and implant them into mice. Engrafted tumors can be expanded by passaging to new mice
and conserve histological and gene-expression features of the originating tumor78. When
taken from human patients, these models are referred to as patient-derived xenografts
(PDX). Co-clinical trials have been performed assessing the differences between PDX and
patient responses to treatment. PDX models have been shown to accurately model clinical
outcomes 87% of the time, including both positive and negative clinical outcomes79. Due
to the personalized nature of these models, they have been proposed as powerful screening
platforms to predict patient response80. Engraftment rates of patient tumor samples depends
on several factors including sample quality and tumor type. The rate of engraftment can be
on the order of months, making them impractical for personalized care and are additionally
limited by logistical difficulties81. Over time or as the tumor is passaged to new mice,
patient stroma and non-cancerous cells are eventually replaced with host cells.
Another approach is to genetically engineer mice that develop de novo
tumorigenesis in a spontaneous or controlled manner. In early models, oncogenes were
inserted under control of a tissue-specific promoter82. One example of this is the MMTVPyMT mouse that develops a spontaneous breast cancer83. More recently, conditional
models based on site-specific recombinase systems, like Cre-loxP, and CRISPR/Cas9 have
been developed84. Due to de novo tumor generation, these models more accurately model
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immune responses, develop heterogeneity, and progress toward metastatic disease in a
more physiologically relevant manner. The ability to accurately predict patient response
has also been studied extensively85. Genetically engineered models are limited by
aggressive primary tumor burden, limiting their ability in studying metastasis84.
Additionally, generation of new mouse models is time consuming and expensive81.
The efforts described above were developed mostly to study the primary tumor, and
their utilization in metastasis research is not as straightforward or effective. Mouse and
human biology are ultimately different. The high frequency of metastasis in the lung, liver,
brain, and bone observed in humans is not conserved in mice. For example, mice and other
rodent models rarely develop bone metastases spontaneously 86. There have been various
techniques developed to overcome the natural limitations of mouse models; however, these
often involve direct injection into the tissue of interest such as intratibial injections for bone
metastasis86. Although xenograft models have become more accessible and widespread, in
the context of metastasis they lack relevant recipient human tissue stroma. Studying human
DTCs in a mouse microenvironment may reduce the translational power of traditional
mouse models. Although this is ultimately unavoidable when using a mouse host, strategies
to incorporate human recipient tissue for CTCs have been successful.
Early efforts to produce human relevant stroma involved the transplantation of
human fetal lung and bone tissue into immunodeficient mice 87. These implanted tissues
were successful in recruiting human tumor cells and displayed specific human-human cell
interactions not observed in the native murine tissue. Of the nine human small cell lung
carcinoma cell lines intravenously injected, only seven developed metastases and these
only occurred in the human fetal lung implants. Additionally, these studies revealed that
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the freshly implanted tissues were more receptive to generating metastases compared to
implants that had been in the mice for 8-10 weeks. They attributed this to a decrease in
cytokine secretion and expression of adhesion molecules over time. Interestingly, they
were able to recover the ability to recruit CTCs by either sublethal irradiation or IL-1a
treatment. Although this study provided early evidence that human-human cell interaction
is an important factor with xenograft models, ethical considerations, and challenges in
obtaining human samples have limited widespread adaptation of this technique.
In recent years, tissue engineering strategies have been implemented to recapitulate
human stromal microenvironments that attract CTCs from more readily available human
sources. As mentioned above, the lack of metastases in the bone of mice is a critical
challenge faced by the field. Formation of ectopic human bone and marrow tissues has
been achieved via a combination of degradable polymers loaded with bone-inducing
growth factors and seeding of human osteoblast precursors

88-89

. Similar to the studies

performed in fetal human tissues, human tumor cells homed to and proliferated within
ectopic human bone implants

90-94

. Besides bone, human liver microenvironments have

also been developed in vivo, however they have not been utilized to study cancer 95.
A secondary approach utilizes implantable biomaterials to study the metastatic
niche

96-101

. Pre-metastatic niches are transiently formed through inflammatory signaling

from the primary tumor, instigating the recruitment of bone marrow derived cells to tissue
microenvironments, priming the niche for CTCs. Interestingly, the implantation of various
biomaterials has yielded niches with similar metastasis forming potential as traditionally
discovered pre-metastatic niches. Work in our lab has utilized polyacrylamide hydrogel
with an inverted colloidal crystal geometry to generate a highly porous, transparent, and
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non-degradable biomaterial scaffolds

96-97, 101

. When implanted subcutaneously these

niches are receptive to CTCs derived from orthotopic and intravenously delivered tumors.
These scaffolds are discussed in further detail in the following section. Similar efforts to
engineer a pre-metastatic niche have been made with different biomaterial platforms. A
porous poly-lactic and glycolic acid scaffold has been leveraged to identify haptoglobin as
a key signaling molecule to recruit CTCs 99. These scaffolds have also been fabricated with
polycaprolactone and used to track the dynamic immune response during cancer
progression102. Their study revealed a detectable gene signature within the implantable
niches that corresponded with disease progression and an opportunity to better understand
myeloid derived suppressor cells. Besides the biological findings of this work, an exciting
translational opportunity for implantable niches was presented that would enable
diagnostic monitoring of the dynamic immunological profiles that occur during metastatic
progression.

Additional

translational

potential

for

implantable

biomaterial

microenvironments has also been explored with the goal of reducing DTC burden in native
tissues by capturing circulating tumor cells within the tissue engineered niche 103-105.
A secondary problem related to the use of mouse models is the challenge of
studying DTC dormancy. Metastasis is inherently difficult to study regardless of model
due to the nature of its single cell origin. Single DTCs and early stage metastases are
difficult to detect and characterize in patients and mouse models. Following a DTC over
long periods of time amplifies this challenge. Most cancer cell lines used in metastasis
studies are generally aggressive and do not undergo dormancy for timescales observed in
humans. In order to study disseminated cells in many models the primary tumor must be
surgically removed. There have been reports that some primary tumors inhibit the
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metastatic capability of DTCs, and removal activates proliferation106. This does not appear
to affect all models, as several dormancy mechanisms have been discovered via primary
tumor removal. One example is the discovery of p38α/β dormancy activation via TGFβ2
signaling in DTCs in the bone marrow, which utilized a cell line xenograft surgically
resected after reaching 500 mm3 45. The squamous cell carcinoma cell line, HEp3, used in
this study and others, takes on a dormant phenotype after prolonged in vitro passage42.
Another cell line commonly used in dormant DTC studies is the mouse breast cancer cell
line D2.0R. When intravenously delivered these cells remain single and non-proliferative
in the lungs for at least 240 days 107. Genetically engineered mouse models have also been
utilized to study DTC biology. The discovery of early DTCs was made using MMTVHER2 and MMTV-PyMT mice108. As a larger emphasis is put on DTC biology, new tools
and techniques are necessary to better understand dormancy and mechanisms that initiate
proliferation. Implantable biomaterial scaffolds have demonstrated potential for being
powerful tools to study DTCs. Engraftment of a dorsal skin-fold window chamber enabled
imaging of CTCs extravasating into the scaffold niche97. The ectopic nature of the tissue
engineered niche has been leveraged to transplant DTC containing scaffolds into secondary
tumor-free hosts for long-term observation96. Together, the presented features of tissue
engineered niches to study metastasis represent an exciting opportunity to better understand
DTCs and their microenvironment in a new lens. One of the focuses of this dissertation is
expanding the application of implantable biomaterial scaffolds for the investigation of
DTCs as they progress from a single cell to an overt metastasis.
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1.4 Inverted Colloidal Crystal Hydrogel Scaffolds and Implantable Biomaterial
Niches
Colloidal crystals are three-dimensional structures of ordered particles found in
opal gemstones, bird feathers, beetles, sea creatures, and butterfly wings. Also known as
photonic crystals, the structural geometry drives unique optical properties such as
iridescent color. In nature these colloidal crystals consist of spherical particles in the
nanometer scale109-110. Besides their attractive photonic properties, colloidal crystals are
easily self-assembled across a wide range of diameters. Inverse colloidal crystal (ICC)
structures have also been heavily studied for their photonic properties and more recently
as a biomaterial scaffolding for tissue engineering applications111. ICC scaffolds are
fabricated by filling the interstitial space of an initial colloidal crystal material with a
polymer followed by selective removal of the colloidal crystals. The resulting structure
consists of a reproducible interconnected spherical pore array with large surface area
(Figure 1.6). These biomaterial scaffolds have been used in the tissue engineering of
cartilage, liver, bone, and bone marrow, as well as circulating tumor cell attracting niches
in vivo.

Figure 1.6. Inverted colloidal crystal hydrogel scaffold fabrication schematic.
Uniform spherical beads are orderly packed and partially annealed to create a free-standing
colloidal crystal template. A hydrogel precursor solution is added to the template and
polymerized around the template structure. The template material is selectively removed
to create a hydrogel scaffold with an inverted colloidal crystal geometry.
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1.4.1 In Vivo Tissue Development
Any material that enters the body undergoes a reaction known as the foreign body
response. Initially soluble proteins in the host are adsorbed onto the material, accelerating
the recruitment of innate immune cells such as macrophages. Prolonged exposure causes
macrophages to form foreign body giant cells and recruit vasculature and fibroblasts to
encapsulate the material with a fibrotic capsule that effectively seals the material off from
the host. Experiments performed in the 1960s and 1970s found that subcutaneous
implantation of porous poly(hydroxyethyl methacrylate) (pHEMA) sponges resulted in
ingrowth of fibrous tissue, giant cells, blood vessels with a thin surrounding capsule112-113.
Shortly after, an observation was made that pore size played a role in tissue infiltration,
with 0.5 and 8 μm pores preventing infiltration while 40 μm allowing infiltration114. The
introduction of sphere templated scaffolds enabled in depth analysis of tissue development
within pHEMA and poly(methyl methacrylate) (PMMA) scaffolds as a function of tightly
controlled pore size (20, 30, 40, 60, 80 μm)115-116. The effect of pore size on vascularization
was further expanded when larger pore (79, 147, 224, 312 μm) poly (D, L-lactide-coglycolide) (PLGA) scaffolds were implanted subcutaneously116. Smaller pores drove the
formation of high blood vessel density with poor penetration into the scaffold, whereas
larger pores had larger vessels at lower densities that fully infiltrated the scaffold. A follow
up study using multiscale photoacoustic microscopy and optical coherence tomography
confirmed these findings in a comparison of scaffolds with 80 μm pores 200 μm pores117.
Non-hydrogel, β-tricalcium phosphate scaffolds have been explored with larger pore sizes;
300-400, 400-500, 500-600, and 600-700 μm118. Implantation of these scaffolds revealed
that larger pore sizes are beneficial for blood vessel, however cellular infiltration is reduced

22

compared to scaffolds with smaller pores. Polyacrylamide ICC hydrogel scaffolds with
250-300 μm pores were shown to have the highest cellular infiltration and complete
vascularization when implanted subcutaneously97.
Another interesting feature of ICC hydrogel scaffold implantation is the unique
immune microenvironments that form within the pores. Lin-Sca-1+c-kit+ progenitor cells
are recruited to polyacrylamide ICC scaffolds, and the number can be significantly
enhanced by pre-seeding bone marrow stromal cells97. Investigation of the role of
macrophages responding to ICC scaffolds has revealed specific cellular phenotypes arise
at the material surface and within the pore119. Macrophages can be loosely categorized by
their pro-inflammatory or alternative phenotypes. Pro-inflammatory, also referred to as M1
or classically activated, macrophages are characterized by secretion of pro-inflammatory
cytokines, reactive oxygen species, and nitric oxide. Alternatively activated, M2, have
several functions including immunomodulation, matrix deposition, tissue remodeling and
are associated with wound healing. M1 macrophages were found on the pore and outer
scaffold surfaces whereas M2 macrophages were observed in the foreign body capsule and
the central region of larger pores. This phenomenon appears to be driven by direct adhesion
to the biomaterial as these cells occupy adjacent spaces. Physical size has been shown in
non-ICC biomaterial systems to play an important role in modulating the immune
response120. Further study into the immune microenvironments that forms within porous
materials is necessary to better understand the differences observed in the foreign body
response compared to bulk materials. Collectively these results indicate a unique foreign
body response against porous biomaterials (Figure 1.7).
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Figure 1.7. Host response to implanted biomaterials.
Once a biomaterial is implanted, soluble proteins are adsorbed onto the surface. Local
myeloid cells are recruited to the surface of the material and secrete pro-angiogenic
molecules. Additional immune cells are recruited from systemic circulation through the
vasculature. As the wound healing response resolves, a dense fibrous capsule is formed
around the material. ICC hydrogel scaffolds do not undergo encapsulation and remain fully
vascularized.

My own observations with ICC scaffold implantation have aligned with previous
studies in literature. However, the use of polyacrylamide has yielded some unique
differences that warrant further investigation. Several factors change when altering the
polymer composition and material properties. First, ICC scaffolds fabricated with
polyacrylamide hydrogel yield more robust cell migration and infiltration within the pores
compared to ICC scaffolds fabricated with polycaprolactone (Figure 1.8). Second, ICC
scaffolds made with varying percentages of polyacrylamide concentrations (5-50 wt%)
revealed limitations in scaffold stability and cellular recruitment. There was no significant
difference in tissue development from 30-50 wt%, however scaffolds made with 5-15 wt%
polyacrylamide mechanically collapsed after subdermal implantation and inter-scaffold
tissue development was incomplete (Figure 1.9). Finally, 30 wt% polyacrylamide ICC
scaffolds were examined with varying pore diameters from 75-500 µm. Blood vessel
diameters increased with increasing pore sizes, but larger pores (400-500 µm) developed a
more diverse range of vessels. Smaller pore sizes (75-150 µm) induced relatively
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homogenous vascular development but restricted stromal and immune cell migration
(Figure 1.10). These results demonstrate the tunable nature of ICC hydrogel scaffolds to
drive different host responses to generate unique tissue microenvironments.

Figure 1.8. ICC scaffolds fabricated with polyacrylamide and polycaprolactone.
Hematoxylin and eosin staining of scaffolds composed of 30 wt% polyacrylamide and
polycaprolactone with the same bead size. Scaffolds were implanted for 4 weeks.
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Figure 1.9. ICC polyacrylamide hydrogel scaffolds with four different polymer
concentrations.
Gross images of scaffolds after 4 weeks implantation, and hematoxylin and eosin stained
images. Scale bar 200 μm.

Figure 1.10. ICC polyacrylamide hydrogel scaffolds with four different pore sizes.
Hematoxylin and eosin staining of 30 wt% polyacrylamide scaffolds fabricated with
different bead sizes. Scaffolds were implanted for 4 weeks. Increasing pore size, resulted
in larger vascular diameter. Scale bar 250 μm.
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1.4.2 Modelling the Metastatic Cascade
ICC scaffolds made with polyacrylamide have shown robust performance modeling
multiple aspects of the metastatic cascade. The first usage of these scaffolds aimed to
mimic the bone marrow microenvironment97. Human bone marrow stromal cell seeded
scaffolds enhanced the marrow-like environment of the implant and increased recruitment
of intravenously delivered TF-1a cells, a human leukemia cell line. Extravasation was
observed in real-time by surgical engraftment of a skin-fold dorsal window chamber. In
addition to the kinetics of adhesion and extravasation of CTCs, the blood vessel diameter
associated with adhered CTCs was also determined (Figure 1.11a). The second application
of polyacrylamide ICC scaffolds in a metastasis study aimed to uncover cellular and
molecular features of the early metastatic microenvironment96. In this model, scaffolds
were subcutaneously implanted and allowed to fill with tissue before the orthotopic
injection of human prostate cancer cells. Aggressive primary tumor growth required the
removal of the scaffolds prior to the development of metastases. To prolong the study,
scaffolds were transplanted to tumor-free hosts. Metastasis could be monitored
noninvasively through luciferase imaging and showed a gradual increase in signal over a
six week period (Figure 1.11b). The stromal cells in metastasis-positive and metastasisnegative scaffolds was compared using a qPCR array and revealed upregulation in IL-1β,
Mmp-9, Mmp-10, Mmp-13, Flt-4, Etv-4, and Mcam. The functional significance of stromal
cell-derived IL-1β was confirmed in the same model using an FDA approved IL-1 receptor
antagonist (Figure 1.11c). ICC hydrogel scaffolds for application in understanding DTC
biology remains largely unexplored. My dissertation work utilized ICC hydrogel scaffolds
to uncover mechanisms of CTC recruitment and proliferative activation of dormant DTCs.
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Figure 1.11 Foundational work using inverted colloidal crystal hydrogel scaffolds in
a metastasis model.
a, Intravital imaging of extravasating cancer cells into scaffold microenvironment, adapted
from Lee et al., P.N.A.S (2012)96. b, Long-term observation of DTCs and formation of
advanced metastases, adapted from Cancer Research, 2014, 74/24, 7229-38, Bersani et al.,
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic
cancer models, with permission from AACR97. c, Genetic analysis of stromal niche
surrounding DTCs and functional reduction of metastatic relapse using ICC hydrogel
scaffolds, adapted from Cancer Research, 2014, 74/24, 7229-38, Bersani et al.,
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic
cancer models, with permission from AACR97.
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1.5 Dissertation Objectives
This dissertation aimed to provide new tools and techniques to study DTCs and
metastatic relapse in mice. As described to this point, mouse models struggle to fully
reproduce patient-relevant metastasis, specifically organotropism and long-term dormancy
behaviors. This work builds upon the use of a highly porous ICC hydrogel scaffold to
assess niche evolution during metastatic progression in vivo. The reproducible and
standardized tissue formation provides a unique platform to study DTCs with high
analytical power. First, I aimed to engineer new scaffold microenvironments that can be
used to elucidate critical niche components for recruitment and DTC proliferation. Second,
I aimed to leverage the transplantable nature of ectopic scaffold tissue to investigate longterm DTC niche evolution and potential activation mechanisms. Lastly, I aimed to improve
the fabrication of ICC hydrogel scaffolds to make the process cheaper, safer, and faster.
The aims of this dissertation are specified in further detail below.

1.5.1 Aim 1: Engineer unique niches that enable the study of disseminated tumor cells
in vivo
Mouse models are generally limited to the study of lung metastasis without
specialized cell lines or injection techniques. Tissue engineered approaches have opened
the door as an exciting opportunity to study DTCs in controlled environments. Previous
work in our group has utilized a porous scaffold implanted subcutaneously to study
extravasation and niche evolution during metastatic progression. The first focus explored
the potential of altering the implantation site of the hydrogel scaffold in different
anatomical locations to generate unique microenvironments. The hypothesis was that each
tissue niche will have differing CTC recruitment and metastatic potential, enabling the
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elucidation of cellular and molecular signals critical for metastasis. The findings of this
study are presented in Chapter 2.
A secondary approach to introduce new tissue microenvironments leveraging the
unique tissue formation in ICC scaffolds is also presented. Here I aimed to transplant fully
mature tissue from internal organs and transplant them subcutaneously. The rationale
behind this approach was that the subcutaneous space provides greatly enhanced
accessibility and transplantation can be leveraged for the study of human tissues in mice.
The work corresponding to this sub-aim are presented in Chapter 3.

1.5.2 Aim 2: Investigate long term niche evolution and potential triggers of metastatic
relapse in scaffold microenvironments
The evolution of DTCs and their niche are largely unknown following
extravasation. It is widely accepted that DTCs undergo varying periods of dormancy prior
to entering a proliferative state. Previous work with ICC scaffold microenvironments
revealed the capability to expand the observation of DTCs in their niche by transplanting
them into tumor-free mice. The objective of this aim was to further explore the changes to
the local microenvironment that occur as DTCs change from singular dormant cells to
small tumor colonies and eventual overt metastases.
The first study investigated a humanized model consisting of human cancer,
immune cells, and DTC-niche stroma and is described in Chapter 4. Human bone marrow
cell seeded scaffolds were implanted in immunodeficient mice prior to the formation of an
orthotopic human prostate tumor. Peripheral blood mononuclear cells were injected to
instigate inflammatory signaling from human cells. Scaffolds were transplanted to tumorfree mice and the niches were non-invasively monitored for 10 weeks. Histological
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characterization revealed changes to local vascular and innate immune cells as DTCs
progressed from singular cells to metastases.
Finally, a fully immunocompetent mouse model was used to investigate potential
triggers of metastatic relapse. Recent reports have highlighted the possibility of enhanced
risk of metastasis following adjuvant therapies. I aimed to explore the potential of
biomaterial metastasis research to capture this phenomenon and uncover potential
mechanisms of DTC activation. The corresponding work is found in Chapter 5.

1.5.3 Aim 3: Improve fabrication process of ICC hydrogel scaffolds to increase
scalability
Although ICC hydrogel scaffolds have demonstrated great potential as a tool for
metastasis research, the fabrication process is suboptimal. The process is laborious, taking
up to a week to manufacture a batch of polyacrylamide scaffolds starting from soda lime
glass beads. When using glass beads as a starting material safety becomes a major concern
as dissolution of the glass template requires highly toxic hydrofluoric acid. Finally, cost of
fabricating bioactive scaffolds requires the use of expensive crosslinking reagents to
covalently bond collagen to the surface. In Chapter 6 I highlight the work performed to
improve fabrication using expanded polystyrene beads as the starting material and a
polymerization strategy to embed collagen within the polymer matrix.

1.6 Summary
As presented in this chapter, metastasis is a complex and dynamic process that
stems from single cell interactions with their microenvironment and can take place over
the course of months to years. Traditional mouse models designed to study cancer,
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generally primary tumors, are poorly equipped to study the metastatic cascade due to
technical limitations and human-mouse species differences. The work presented in this
dissertation provides new tools to better understand metastasis. To achieve this, a
biomaterial strategy was implemented to engineer receptive niches for circulating tumor
cells. Specifically, inverted colloidal crystal scaffolds composed of polyacrylamide were
used in a variety of ways to investigate circulating tumor cell recruitment, disseminated
cell proliferation, and the cellular and soluble factor microenvironment changes that occur
during the progression to metastases.
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CHAPTER 2
DIVERSIFYING THE IMPLANTATION SITE OF POROUS BIOMATERIALS
TO CREATE TISSUE-SPECIFIC MICROENVIRONMENTS

2.1 Abstract
The formation of metastatic tumors is the leading cause of cancer related deaths.
Circulating tumor cells spread to several distal organs. However, disseminated tumor cells
(DTCs) are reliant on their local tissue microenvironment to foster growth into overt
metastases. Bone, brain, lung, and liver have been identified as favorable to metastatic
growth, whereas tissues such as the muscle and intestine rarely develop metastases. Mouse
models have been widely used to study various aspect of cancer biology, but they are
limited to fully understand metastatic organotropism because metastasis mainly occurs in
the lung. Identifying the common mechanisms that promote or suppress DTC growth
across metastasis prone and resistive tissues is imperative to the development of better
clinical strategies for metastatic disease. Recently, subdermally implanted porous
biomaterials

have

demonstrated

the

ability

to

develop

vascularized

tissue

microenvironments by recruiting near tissue cells and bone marrow derived cells. We have
utilized these microenvironments to observe DTC progression from a single cell to an overt
metastasis. Here, we report a new strategy to create tissue-specific microenvironment by
altering the implantation site of porous biomaterials. In addition to subcutaneous
implantation, porous scaffolds were inserted between liver lobes and within the intestinal
mesentery. After 4 weeks in vivo, histological characterization confirmed recruitment of
near tissue cells and significantly different immune cell profiles. Circulating tumor cells
homed equally to the different implants, however metastasis was enhanced in scaffolds
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implanted subcutaneously. High fibronectin and neutrophils in the subcutaneous scaffold
microenvironment were identified as potential biomarkers of premetastatic niche signature,
aligning with literature. We anticipate further microenvironment analysis using tissue
engineered DTC niches may improve mechanistic understanding of metastatic
development for the benefit of patient health.

2.2 Introduction
More than 90% of cancer-associated death is caused by metastasis. Circulating
tumor cells released from a primary tumor disseminate into distal tissues where they often
lay dormant until their surrounding microenvironments become favorable for re-growth.
In theory, circulating tumor cells can disseminate into a wide variety of tissue sites but
subsequent metastatic relapse occurs non-randomly. Regardless of primary tumor types,
metastasis frequently occurs in brain, liver, lung, and bone. Metastasis seldom takes place
in skin, intestine, and muscle. Even with this knowledge it is challenging to predict the
eventual site of metastasis. Genetically distinct metastasis can also arise simultaneously in
multiple organs. Thus, it is imperative to understand common mechanisms across
metastasis-prone organs and identify key differences among supportive and restrictive
niches to develop therapies that reduce the burden of metastasis and maintain disseminated
tumor cells (DTCs) in an inactive state.
Mouse models are a critical tool for studying metastasis. Syngeneic, xenogeneic,
and genetically engineered models are all limited by differences in their metastatic pattern
compared to humans. The lung is a dominant site for metastasis while only a fraction of
DTCs become metastases in the liver, bone, and brain. While these limitations can be
addressed by directly injecting into target organs, the fidelity of these models is not clear.
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There is a need for better models to study metastasis in mice in a variety of tissues.
Recently, tissue engineering strategies have been exploited to address these limitations.
Ectopic formation of bone containing human cells has had widespread success in recruiting
human tumor cells in humanized mice. Additionally, several groups have identified the
ability of implantable synthetic polymer biomaterials to recruit circulating tumor cells
released from a primary tumor. Although there are reports of this phenomenon happening
in both the subcutaneous and intraperitoneal cavity, the fate of the DTCs homed to implants
located different anatomical sites has not been further investigated. Ultimately, the ability
to monitor DTCs long-term has been challenging due to lethal tumor burden in the host.
We have previously leveraged the ectopic nature of these DTC-containing niches and
transplanted them to tumor-free mice for long-term observation and identified important
niche components during evolution of early metastases.
Here we report a comparative analysis of tissue development, CTC recruitment,
and DTC proliferation in inverted colloidal crystal (ICC) hydrogel scaffolds implanted in
three different anatomical locations. ICC geometry is characterized by a three-dimensional
structure consisting of interconnected ordered spherical pores. Polyacrylamide ICC
scaffolds have shown robust and reproducible vascularized tissue formation and the ability
to capture CTCs and monitor their eventual metastatic outgrowth when implanted in a
subcutaneous pocket. During the foreign body response local and systemic cells are
recruited to initiate a wound healing response. We hypothesized that implantation in
different anatomical locations may capture unique local signatures that may alter the
metastatic potential of the tissue. Due to surgical restrictions, expansion of implant
locations was limited to the intraperitoneal cavity. The liver and intestinal mesentery were
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selected because of their rich vascularization and differing natural metastatic potential.
Unique tissue microenvironments were developed at each of the implant sites, and the
metastatic potential of each niche was assessed using an MMTV-PyMT spontaneous breast
tumor model. We envision that this side-by-side comparative biomaterial strategy will open
the door to future study of local and systemic factors that influence metastasis development
in a standardized manner.

2.3 Results
2.3.1 Implantation of ICC scaffold in subcutaneous, hepatic, and mesentery sites
generates unique tissue microenvironments
ICC scaffolds are fabricated with a sacrificial bead-based template to produce a
highly ordered porous matrix (Figure 2.1A). In this study scaffolds were fabricated with
polyacrylamide surface treated with rat tail collagen. Previous studies have identified
scaffolds consisting of an average pore diameter of 300 ± 15 μm to have robust and
reproducible tissue infiltration and vascular density101. Scaffolds were implanted in a dorsal
subcutaneous pocket, sandwiched between the median and left caudate lobes of the liver,
and wrapped within the small intestine in contact with the mesentery (Figure 2.1B). Gross
images of the scaffolds revealed recruitment of large blood vessels and infiltration of local
tissue cells, embedding the scaffolds within their local microenvironment (Figure 2.1C).
Histological analysis was performed on the scaffolds at 1, 2.5, and 4 weeks post
implantation (Figure 2.1D). Implants followed a similar pattern of tissue infiltration:
extracellular matrix polymerization, initial cellular infiltration, followed by complete tissue
infiltration. Interestingly cells infiltrated the liver scaffold faster than subcutaneous and
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intestine scaffolds. Hepatocyte tissue infiltration was also observed on the outermost pores
of the liver scaffold.

Figure 2.1. Tissue development within the pores of ICC hydrogel scaffolds
implanted in different anatomical locations.
a, Fabrication schematic and brightfield image of ICC hydrogel scaffold. b, Schematic of
implant locations. c, Gross images of ICC hydrogel scaffolds in subcutaneous, liver, and
intestine sites four weeks after implantation. d, Hematoxylin and eosin staining of scaffolds
implanted in different sites 1, 2.5, and 4 weeks after implantation.
2.3.2 Fibronectin and Ly6G rich microenvironments develop in subcutaneous
implants
Scaffolds implanted for four weeks were screened with a panel of antibodies to
evaluate the cellular and molecular components of the niche. Immunohistostaining was
performed on scaffolds removed from the subcutaneous, liver, and intestine
microenvironments (Figure 2.2A). Cell markers, αSMA (myofibroblasts), CD31
(endothelial cell), Ly6G (neutrophils), F4/80 (macrophages), CD3 (T-lymphocytes), CD19
(B-lymphocytes), and molecular markers, fibronectin and MMP9, were selected to assess
the local vasculature, immune, and tissue remodeling activity. Tissue development within
each of the niches was significantly different from one another. Notably Ly6G and
fibronectin were significantly increased in subcutaneous implants and MMP9 was
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significantly higher in implants located near the liver (Figure 2.2B). These results
demonstrate that unique cellular and molecular microenvironments can be generated by
changing the location of an implant.

Figure 2.2. Immunohistological analysis of cellular and molecular niche components
in subcutaneous, liver, and intestine implants.
a, Immunohistostaining comparison of ICC hydrogel scaffolds implanted in different
anatomical locations. b, Quantitative analysis of immunohistostaining images (*P<0.05).
2.3.3 Bone marrow derived cells are recruited to ICC implants
During the wound healing response bone marrow derived cells are activated and
enter circulation to home to sites of inflammatory signaling. Parallels can be drawn
between the inflammatory response that occurs at the site of a foreign object and that of a
premetastatic niche. Previous studies with ICC scaffolds revealed the recruitment of bone
marrow progenitor cells at the site of implantation, however the extent of other bone
marrow derived cells was not investigated97. We hypothesized that bone marrow cells may
be recruited to implants differently depending on the implant location. To test this
hypothesis, we generated a chimeric mouse by performing a bone marrow transplant using
eGFP bone marrow cells injected into a lethally irradiated C57BL/6 mouse. The bone
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marrow was regenerated for 3.5 weeks before implantation of ICC hydrogel scaffolds in
the subcutaneous, liver, and intestinal spaces (Figure 2.3A). Three weeks after
implantation scaffolds were removed and cryosectioned to assess the eGFP cell population
(Figure 2.3B). All implants recruited bone marrow derived eGFP+ cells, however liver
implants had significantly higher tissue area coverage than implants in the subcutaneous
and intestinal niches (Figure 2.3C). The increase in bone marrow derived cells may
correlate to the increased MMP9 secretion observed in the liver implants since MMP9 is
believed to be secreted specifically from bone marrow cells and not local stroma121.

Figure 2.3. eGFP bone marrow cell recruitment to implantable biomaterial niches.
a, Experimental schematic of eGFP bone marrow chimeric mouse generation and scaffold
implantation. b, Fluorescent microscopy imaging of ICC hydrogel scaffolds for
endogenous eGFP and DAPI. c, Quantitative image analysis of eGFP positive area in
scaffold tissue (*P<0.05).
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2.3.4 Circulating tumor cell recruitment comparable
Next, we examined the ability for the three different niches to recruit circulating
tumor cells. A MMTV-PyMT spontaneous breast cancer model on the FVB background
was used to generate CTCs in scaffold bearing mice. The MMTV-PyMT model was chosen
because it is known to generate metastases and closely follow tumor progression observed
in patients. Scaffolds were implanted at 4 weeks of age to maximize the CTC capture
window. Eight weeks after implantation scaffolds were removed and analyzed via
immunohistostaining (Figure 2.4A). Both single DTCs and small metastatic colonies were
observed in scaffolds regardless of implantation site (Figure 2.4B). Quantification of
DTCs revealed no significant difference in recruitment in the scaffolds from each of the
tissues (Figure 2.4C). In this analysis small colonies were considered a singular DTC
event. DTCs were found as colonies more frequently in subcutaneous and intestine
scaffolds compared to liver scaffolds. Analysis of the proliferative status of the DTCs
revealed 6.7% (2/30), 7.8% (4/51), and 15.4% (4/26) were Ki-67+ in subcutaneous, liver,
and intestine implants, respectively.

40

Figure 2.4. Tumor cell recruitment to ICC hydrogel scaffolds in an MMTV-PyMT
spontaneous breast cancer model.
a, Experimental schematic of implantation strategy in MMTV-PyMT mice. b,
Immunohistostaining of scaffold tissue reveals single DTCs and small micrometastases in
subcutaneous, liver, and intestine scaffolds. c, Quantitative image analysis of DTC number
in a single cryosection slice. d, Quantitative assessment of tumor colony number in a single
cryosection slice.
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2.3.5 Metastasis accelerated in subcutaneous microenvironment
Due to the high primary tumor burden in MMTV-PyMT mice, the maximum
duration of scaffold implantation was limited to approximately 8 weeks. To prolong the
observation window scaffolds were orthotopically transplanted into syngeneic tumor-free
FVB mice (Figure 2.5A). The implants were left in the mice for 5 weeks before they were
removed for immunohistostaining. Single DTCs and tumor colonies were observed in all
implants regardless of location (Figure 2.5B). There were no significant differences in the
number of DTCs or colonies in the implants (Figure 2.5C and 2.5D). However, colonies
in the subcutaneously implanted scaffolds were the only ones to become large proliferative
colonies (Figure 2.5E). These data suggest that unique microenvironments with different
metastatic potential were generated by simply changing the site of the implanted ICC
scaffold.

Figure 2.5. Investigation of DTC outgrowth in different anatomical locations.
a, Experimental schematic of transplantation model to extend experimental duration for
the observation of DTC growth. b, Immunohistostaining of single DTCs and colonies in
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scaffold niches. c, Quantitative analysis of DTC number in single cryosectioned tissue
slice. d, Image analysis of tumor colony number in subcutaneous, liver, and intestine
scaffolds. e, Quantitative analysis of tumor colony size in different scaffold tissues
(*P<0.05).

2.4 Discussion
In vivo tissue engineered metastasis models have become an exciting area of
research to probe hypotheses that traditional mouse models are inadequate to perform. For
example, the generation of humanized ectopic bone has enabled the study of human cancer
in a human bone-relevant microenvironment. Previously, we have demonstrated the
potential of a porous ICC hydrogel scaffold to capture the long-term progression of DTCs
and their local niche. Here we have provided a comprehensive analysis of the tissue
formation, tumor cell recruitment, and DTC growth of three different tissue engineered
niches generated by changing the implantation site of ICC hydrogel scaffolds. Although
the scaffold microenvironment is driven by the foreign body response to the material, we
found that the anatomical location drove unique tissue formation. Subcutaneous implants
were characterized by high neutrophil recruitment and fibronectin. Liver and intestine
scaffolds were similar in all markers analyzed except for MMP9, which was the highest in
liver scaffolds. Interestingly bone marrow derived cells homed to the liver implants more
than any other implant. Deeper analysis of the cellular niche via single cell RNA
sequencing may provide additional information about the niche and reveal more intricate
differences between the cellular populations.
Although it is believed that tissue engineered scaffolds enable metastatic tumor
growth via premetastatic niche formation it has not been fully explored mechanistically.
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Premetastatic niches are formed via systemic signaling derived from the primary tumor
activation of bone marrow cells and priming of the local stroma to increase fibronectin
secretion. Recruited bone marrow cells induce tissue remodeling by secreting matrix
metalloproteinases. The foreign body response naturally induces several of these pathways
without the need for priming by a primary tumor, including soluble fibronectin
polymerization and recruitment of bone marrow derived cells. Here we provide evidence
that metastatic growth in scaffold niches required fibronectin and Ly6G cells which were
elevated in subcutaneous implants. Examination of the scaffold microenvironments over
time may provide additional markers that correlate with metastatic niche development. The
ability to tune the microenvironments by seeding engineered or tissue specific stromal cells
onto the scaffolds prior to implantation may enable further mechanistic understanding of
premetastatic niche development. Additionally, further examination of metastasis resistant
scaffold niches may provide clues for keeping DTCs in a dormant state.
The results presented here demonstrate a new approach to engineer tissue
microenvironments to study DTC biology and biomarkers for metastatic relapse. By
utilizing a standardized ICC hydrogel scaffold reproducible tissues were generated and
used for side-by-side analysis. This platform represents a high degree of control and
tunability in tissue formation to address emerging hypotheses. Future studies may examine
the role of biomaterial composition and physical features such as pore size have on driving
tissue development. We believe this biomaterial driven approach will be an important tool
in achieving mechanistic understanding of DTC behavior and yield therapies effective
against metastasis.
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2.5 Materials and Methods
All chemicals and materials were purchased from Sigma Aldrich or Fisher
Scientific unless specified. All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts-Amherst.
2.5.1 Porous hydrogel scaffold fabrication
ICC hydrogel scaffolds were fabricated as previously described101. Soda lime glass
beads were sorted using an Advantech Sonic Sifter using 250 µm and 300 µm collection
trays. Glass beads dispersed in deionized (DI) water were loaded into a 8 x 35 mm glass
vial to a height of 2 mm. Vials were transferred to an oven set to 60 °C to remove the water.
A glass template was made by annealing the beads in a 664 °C furnace for 4 hours. The
annealed glass bead templates were infiltrated with a hydrogel precursor solution via
centrifugation. The precursor solution was composed of 30 wt% acrylamide monomer, 1.5
wt% bis-acrylamide crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine
accelerator, and 0.2 vol% 2-hydroxy-2-methylpropiophenone photoinitiator in nitrogen
purged DI water. The precursor solution was polymerized under a 15 W ultraviolet light
source for 15 minutes. Glass beads were selectively dissolved in alternating washes of
hydrofluoric and hydrochloric acid. Scaffolds were thoroughly washed with DI water to
remove residual acid and lyophilized. Cracked or misshapen scaffolds were removed
before proceeding. Scaffolds were sterilized with 70% ethanol and the scaffolds were
surface treated with Sulpho-SANPAH to covalently crosslink rat-tail collagen. Scaffolds
were stored at 4 °C in sterile phosphate buffered saline.
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2.5.2 Mouse colony
MMTV-PyMT mice on the FVB/N background (002374) and eGFP mice on the
C57BL/6 background (006567) were bred in house from a colony initially obtained from
the Jackson Laboratory. Wild type FVB/N were acquired from MMTV-PyMT breeding
and C57BL/6 (000664) mice were purchased from the Jackson Laboratory. Mice were
housed in sterile conditions with unrestricted access to food and water.
2.5.3 Surgical implantation of scaffolds
Mice used in this study were between 4-8 weeks old at the time of implantation.
Mice were anesthetized with 2% isoflurane before removing the dorsal and ventral hair
with electric clippers and Nair. The skin was sterilized using 70% isopropyl alcohol prep
wipes. Mice received 2 mg meloxicam/kg mouse weight subcutaneously prior to surgery.
For subcutaneous implants a pocket was created by making a 2 mm horizontal incision in
the dorsal space followed by expansion of surgical scissors into the incision and expansion.
The implant was placed into the pocket and the incisions were closed with Reflex 7 mm
wound clips. For liver and intestine implants, a 10 mm vertical incision was made in the
lower abdomen and scaffolds were placed between the median and left caudate lobes of
the liver,and wrapped within the small intestine in contact with the mesentery. The muscle
layer was sutured and with polyglycolic acid sutures (Henry Schein), and the skin was
closed with wound clips.
2.5.4 Frozen tissue preparation and sectioning
At the conclusion of the in vivo experiment, implants were frozen by embedding
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen
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tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides
were stored at -80 °C.
2.5.5 Histology
Hematoxylin and eosin staining was performed by fixing frozen tissue sections with
10% neutral buffered formalin for 10 minutes. After washing with DI water, sides were
transferred to hematoxylin for 30 seconds. Slides were then washed with DI water until
dye was no longer present in the effluent and then transferred to eosin Y for 45 seconds.
Slides were serially dehydrated in 70, 85, and 100% ethanol before xylene. Samples were
mounted in Shandon-Mount and covered with a glass cover slide. Images were taken with
a color camera on an EVOS FL Auto microscope.
For immunohistostaining, frozen slides were fixed in -20 °C acetone for 10 minutes.
Slides were washed with PBST solution 3 times before blocking in a solution containing
10% normal goat serum, and 1% bovine serum albumin for 1 hour. Following blocking
primary antibodies diluted in blocking solution were added to the slides and left in a
humidified chamber overnight at 4 °C. Slides were washed 3 times with PBST and then
incubated with secondary antibodies diluted in blocking solution for 2 hours at room
temperature. Prior to imaging, slides were washed 3 times in PBST and stained with a 10
ng/uL solution of DAPI. Fluorescent images were taken on a Zeiss Cell Observer SD. Αsmooth muscle actin (ab5694), CD31 (550274), Ly6G (557445), F4/80 (565409), CD3
(550277), CD19 (550284), fibronectin (MA5-11981), MMP9 (PA513199), PyMT
(ab15085), and Ki67 (ab16667) primary antibodies and anti-rabbit Alexa Fluor Plus 488
(A32731), anti-rat Alexa Fluor 647 (A21247), anti-hamster Alexa Fluor 488 (A21110),
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and anti-mouse Alexa Fluor 660 (A21054), and anti-mouse Alexa Fluor 555 (A21424)
secondary antibodies were used in this study.
2.5.6 Bone marrow transplantation
C57BL/6 mice were lethally irradiated with two doses of 6 Gy, four hours apart,
from a cesium source. Twenty-four hours later, 20 x 106 bone marrow cells isolated from
eGFP mice were intravenously injected. Engraftment was verified by microscopy for the
presence of eGFP cells in blood collected via needle stick in the tail. Mice were given
acidified antibiotic water (20 μg/mLtrimethoprim, 100μg/mL sulfamethoxazole, pH=3) for
the duration of the experiment.
2.5.7 Orthotopic scaffold transplantation
Scaffolds were harvested from MMTV-PyMT mice and immediately transplanted
to the same anatomical site in tumor-free FVB mice. The method for implantation was the
same as initial surgery.
2.5.8 Image Analysis
All image processing and quantitative analysis was performed in ImageJ. Total
tissue area was determined using the DAPI image for all relevant analysis. DTC counts
were tabulated by assuming small colonies were formed from a single DTC.
2.5.9 Statistics
Unpaired Student’s t tests were performed for comparison of the mean values
between two groups. Statistical significance was determined if p<0.05 for two-tailed
analysis. All quantitative data represent mean and standard deviation.
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CHAPTER 3
SCAFFOLD-ASSISTED ECTOPIC TRANSPLANTATION OF INTERNAL
ORGANS AND PATIENT-DERIVED TUMORS

Adapted with permission from Ryan Carpenter, Hye Jeong Oh, In-Hye Ham, Daeyoung
Kim, Hoon Hur, and Jungwoo Lee. ACS Biomaterials Science & Engineering. 2019 5(12),
6667-6678. DOI: 10.1021/acsbiomaterials.9b00978. Copyright 2019 American Chemical
Society.
3.1 Abstract
Xenotransplantation of human tissues into immunodeficient mice has emerged as
an invaluable preclinical model to study human biology and disease progression and
predict clinical response. The most common anatomical site for tissue transplantation is the
subcutaneous pocket due to simple surgical procedures and accessibility for gross
monitoring and advanced imaging modalities. However, subcutaneously implanted tissues
initially experience a sharp change in oxygen and nutrient supply and increased mechanical
deformation. During this acute phase of tissue integration to the host vasculature,
substantial cell death and tissue fibrosis occurs limiting the engraftment efficiency.
Previously, we demonstrated the implantation of inverted colloidal crystal hydrogel
scaffolds triggers pro-angiogenic and immunomodulatory functions without characteristic
foreign body encapsulation. In this study we examine the use of this unique host response
to improve the ectopic transplantation of tissues to the subcutaneous site. Scaffold-assisted
tissues preserved morphological features and blood vessel density compared to native
tissues, whereas Scaffold-free tissues collapsed and were less vascularized. Notably, the
supporting biomaterial scaffold modulated the foreign body response to reduce localization
of Ly6G+ cells within the transplanted tissues. Co-transplantation of patient-derived gastric
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cancer with a scaffold resulted in a comparable level of engraftment to conventional
methods, however detailed immunehistological characterization revealed significantly
better retention of proliferative cells (Ki67+) and human immune cells (CD45+) by the end
of the study. We envision that leveraging the immunomodulatory properties of biomaterial
interfaces can be an attractive strategy to improve functional engraftment of
xenotransplants and accelerate individualized diagnostics and the development of novel
therapeutic strategies.

3.2 Introduction
Mice have been used as an important model to understand the basic biology of
health and disease and serve as a vital link in the preclinical development of therapies for
human diseases122-126. The development and advancement of immunodeficient mouse
models has enabled the xenotransplantation of human cells and tissues, significantly
improving the clinical relevance of animal studies127. For example, xenotransplantation of
human tumor cell lines, patient-derived immune cells, fetal tissue, organoids, and tumor
fragments have been performed to understand human cell and tissue biology in health and
disease128-134. In particular, patient-derived xenograft (PDX) tumor models have
demonstrated their capability to reflect the human tumor microenvironment, predict patient
response to chemotherapy, and accelerate discovery and validation of preclinical drugs135138

. A co-clinical trial in small lung cell cancer patients and corresponding PDX models

showed consistency in responsiveness to cisplatin therapy, demonstrating the screening
potential of PDX models139. Nevertheless, the fidelity, stability, engraftment efficiency,
and engraftment kinetics of PDX tumors and mature tissues remain critical barriers to
overcome for practical application140. For example, PDX models frequently fail to progress
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to form metastatic lesions in mice141. Additionally, engraftment rates range widely between
studies, from 10% to 95% depending on tumor type, and the time to reach initial
engraftment can take several months to establish proliferative tumors130.
Orthotopic transplantation of human tissues or tumors is most desirable but often
limited by notable size difference between mouse and humans, and technical challenges to
surgically access organs. The subcapsular region of the kidney is an attractive transplant
site because of the richly vascularized environment, yet the small volume limits the size of
transplanted tissues and requires technical expertise142. Alternatively, the subcutaneous
space has been commonly used for transplantation because of the large tissue volume
capacity, proximity to blood supply, simple surgical procedure and ease of accessibility for
various imaging modalities143-144. However, engraftment efficiency of subcutaneously
transplanted tissues remains suboptimal because of acute adaptation processes experienced
by the donor tissue. First, the physical stresses beneath the skin caused by compressive
forces from skin elasticity, and host motion can differ greatly from the donor tissue
microenvironment145-146. This additional strain can cause soft tissue deformation and
trigger abnormal mechano-transduction signaling147. Second, transplanted tissues suffer
from limited oxygen and nutrient supply until blood vessels can reconnect to the host
vasculature or neo-angiogenesis occurs. Delayed vascularization is accompanied by cell
death and transformation of cellular phenotypes148. Third, the host wound response
generates robust cellular recruitment from resident and systemic immune cells149. Acute
local inflammation and fibrosis resultantly decreases donor tissue cell number and cellular
heterogeneity as host cells infiltrate the graft and gradually replace donor tissue150. It is
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imperative to develop strategies to overcome these acute detrimental effects on donor tissue
to improve engraftment efficiency of current xenograft models to the subcutaneous space.
Accumulating data indicate that biomaterial implantation is a compelling route to
modulate the host immune response151-157. Implant geometry, surface topology and
chemistry, material composition, and bioactive delivery of drugs or cells have been
explored to reduce fibrosis around implants and improve the longevity of biomedical
devices120,

158-161

. For example, implantation of medical grade polymers with circular,

triangular, and pentagonal shaped cross sections revealed a circular rod had the lowest host
response162. The degree of foreign body response against spherical biomaterials was shown
to be modulated as a function of implant size120. Synthetic biomaterials composed of
zwitterionic hydrogels that alternate positively and negatively charged functional groups
significantly delayed the foreign body response and resultant fibrotic encapsulation163.
Mechanical properties of synthetic zwitterionic hydrogels have been identified as a potent
parameter to modulate the foreign body response after subcutaneous implantation161.
Extracellular matrix scaffolds have shown to trigger a notably different pattern of local and
systemic immune response compared to synthetic materials by switching from fibrotic
encapsulation to wound healing and tissue repair mechanisms164-165. Hydrogels embedded
with mesenchymal stem cells attenuated macrophage response and reduced fibrotic capsule
thickness166. These results collectively indicate that implantable biomaterials represent an
opportunity to modulate the fate of implanted human tissues to support better functional
engraftment while retaining original tissue complexity.
In the presented work we hypothesized that an implantable biomaterial approach
could be utilized to enhance the ectopic engraftment of mature tissue by improving
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vascularization and altering the migration of immune cells. Furthermore, the biomaterial
would act as a mechanical support to suppress mechanical deformation. We tested these
hypotheses using inverted colloidal crystal (ICC) hydrogel scaffolds consisting of fully
interconnected macroscale spherical pore arrays that have demonstrated mechanical
robustness, and pro-angiogenic and immunomodulatory features after subdermal
implantation96-97, 101. We first examined if co-implanted ICC hydrogel scaffolds promote
the integration of liver and lung tissues retrieved from immunocompetent mice genetically
engineered with DsRed fluorescent reporter protein to the immunodeficient NSG host
mice. We also tested the impact of pre-seeded human bone marrow stromal cells (BMSCs)
in ectopic tissue engraftment, which have been shown to further enhance angiogenesis and
reduce inflammation96-97, 101, 167. Finally, we extended the study to examine the effects of
stromal cell-seeded ICC hydrogel scaffolds on engraftment efficiency and cellular
heterogeneity of human patient-derived gastric cancer samples. We envision this proof-ofconcept study for biomaterial assisted ectopic tissue and tumor transplantation may
improve the usage of mouse models for preclinical cancer research.

3.3 Results
3.3.1. Subdermal co-implantation of mature liver tissue within an ICC hydrogel
scaffold reduces tissue deformation.
ICC scaffolds consist of an interconnected spherical pore array providing a high
surface area-to-volume ratio and elicit a unique foreign body response that results in a
vascularized tissue that does not undergo endogenous host rejection. We hypothesized that
co-implantation of a mature tissue with an ICC hydrogel scaffold may improve the
engraftment of transplanted tissues (Figure 3.1a). A 30 wt% polyacrylamide hydrogel

53

scaffold consisting of 300 ± 15 µm pores was used for this study, which has been shown
to induce a richly vascularized tissue within 3 weeks of subdermal implantation101. To
accommodate transplanted tissue samples, a cylindrical ICC scaffold (height = 2 mm and
diameter = 6.5 mm) was modified by punching out a 3 mm diameter hole centrally. Human
BMSCs were homogeneously seeded at a density of 5x105 cells/scaffold (Figure 3.1b).
We employed DsRed immunocompetent mice as tissue donors and NSG immunodeficient
mice as ectopic tissue recipients. Cells in DsRed mice ubiquitously express red
fluorescence that facilitate rapid identification of surviving donor tissues in the recipient
without staining. Immediately prior to surgery, a 3 mm piece of freshly harvested DsRed
mouse liver tissue was collected using a biopsy punch and placed in the center of a scaffold
prior to subcutaneous implantation. Three different groups of implants were used in the
study, scaffold-free liver (Scaffold-free), unseeded scaffold-assisted liver (Blank-scaffold),
and BMSC-seeded scaffold-assisted liver (BMSC-scaffold). Transplanted tissues were
retrieved after one or two weeks of implantation (Figure 3.1c). Gross images of explanted
tissue after 1 week implantation showed that the color of a liver tissue turned pale due to
the significant loss of red blood cells whereas a liver tissue with a scaffold retained dark
red color with a sign of vasculature (Figure 3.1d). Hematoxylin and eosin (H&E) staining
revealed that Blank-scaffold and BMSC-scaffold transplanted hepatic tissue retained
morphological features present in native liver such as portal veins. A fibrotic capsule was
observed around all sides of Scaffold-free transplants and the host-transplant interface of
Blank-scaffold and BMSC-scaffold transplants. Interestingly, liver tissue at the interface
of the biomaterial scaffold showed less fibrotic tissue formation (Figure 3.1e-f).
Characterization of albumin secretion via immunohistochemistry revealed maintenance of
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liver function in all transplanted tissues (Figure 3.2). We repeated the experiment with
DsRed mouse lung tissue that has more than 25-fold weaker mechanical strength than the
liver tissue

168

. The result revealed clear collapse of alveolar structures in Scaffold-free

transplants (Figure 3.3). Collectively these results indicate that co-implantation of mature
mouse tissues with an ICC hydrogel scaffold better preserve intrinsic tissue structure by
preventing tissue collapse and reduction of fibrotic capsule formation directly at the
transplant interface compared to control scaffold-free transplants.

Figure 3.1. Scaffold-assisted transplants reduce tissue disruption.
a, Schematic of general strategy to improve ectopic engraftment of mature tissues using
ICC hydrogel scaffolds. b, Representative brightfield (top) and fluorescence (bottom)
microscopy images of ICC hydrogel scaffold pore structure and homogeneous seeding of
fluorescently labelled hBMSCs on the surface of the scaffold pores. c, Experimental
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schematic of DsRed mouse liver tissue transplantation into NSG immunodeficient mice
with an ICC hydrogel scaffold. d, Gross images of a liver tissue and a liver tissue integrated
with a hydrogel scaffold and after one week of subcutaneous transplantation. e, H&E
images of native mouse liver tissue structure. f, H&E images Scaffold-free, Blank-scaffold,
and BMSC-scaffold transplants after 1 week implantation. White arrows highlight large
portal veins, a key anatomical structure in the liver.

Figure 3.2. Albumin secretion in transplanted liver tissues.
a-b, IHS of mouse albumin in native liver (a) and transplanted liver tissues (b).

Figure 3.3. Ectopic engraftment of mature mouse lung tissue into NSG mice using
ICC hydrogel scaffolds.
a, Gross images of ectopic subcutaneous lung tissue one week after transplantation. b, Low
and high magnification images of mature lung tissue and transplanted tissues one week
after transplantation. White arrows highlight large alveolar structures.

3.3.2. ICC hydrogel scaffold promotes vascularization to transplanted tissue.
We next examined if co-implanted ICC hydrogel scaffolds promote the formation
of host blood vessels and vascular connection with the transplanted liver tissue. To validate
functional vascular connection between transplanted liver tissue and the host, we
intravenously perfused Evans Blue dye in mice carrying 1 week implants 20 minutes before
sacrifice. Gross examination confirmed rich perfusion of Evans Blue dye in scaffoldassisted transplants whereas limited perfusion was evident in Scaffold-free transplants
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(Figure 3.4a). Spatial distribution of the perfused dye was substantiated with IVIS
fluorescent imaging. In scaffold-assisted transplants, strong fluorescence was localized to
the area containing liver tissue (Figure 3.4b). Quantitative analysis revealed scaffold
assisted liver tissue implants showed at least 2.5-fold higher fluorescence signal than
Scaffold-free implants. Blank-scaffolds showed 25% higher fluorescence than BMSCscaffolds (Figure 3.2c).

Figure 3.4. Characterization of vascular perfusion using Evans Blue.
a, Experimental schematic of Evans Blue perfusion experiment and gross image of
transplanted liver tissue and surrounding subcutaneous tissue. b, Gross and fluorescent
images of explanted tissues substantiating localized Evans Blue dye within transplanted
liver tissue. c, Quantitative comparison of Evans Blue dye fluorescence in hepatic tissues
one week after transplantation. (N=3 implants per group, *P<0.05)

Small sinusoidal blood vessels present in the transplanted liver tissues were
visualized via endomucin antibody staining. In all transplants, intrinsic hepatic sinusoidal
features were preserved. Blood vessels in the surrounding fibrotic capsule were less
organized with branched morphology (Figure 3.5a-d). Quantitative analysis of endomucin
expression in the liver tissue revealed that the overlapping region of endomucin and
endogenous DsRed fluorescence in BMSC-scaffolds was 63 % and 35 % higher compared
to Scaffold-free and Blank-scaffold transplants, respectively (Figure 3.5e). In the
surrounding fibrotic tissue area, blood vessel density was significantly higher in scaffold
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assisted transplants regardless of BMSCs and at least 2-fold higher than Scaffold-free
controls (Figure 3.5f). The discrepancy between Evans blue characterization and
immunohistostaining results may be due to immature vasculature and increased leakiness
in Blank-scaffold samples.

Figure 3.5. Vasculature staining in scaffold-free and scaffold assisted liver tissue.
a-d, Immunohistostaining (IHS) images of native DsRed liver (a), Scaffold-free (b),
Blank-scaffold (c), and BMSC-scaffold (d) transplanted tissues. Higher magnification
images show hepatic sinusoids and newly generated blood vessels that surround the
transplanted tissue. e, Quantitative comparison of endomucin+ hepatic sinusoid retention
in ectopic tissue transplants. f, Quantitative comparison of endomucin+ blood vessel
density in surrounding host tissue. (N=3-5 implants per group, *P < 0.05)

We further characterized vascular reconnection via injecting MDA-MB-231 human
breast cancer cells that stably express eGFP into mice bearing transplanted liver tissues.
Three days after injection, tissue was removed and analyzed for dissemination to the
transplanted liver tissue (Figure 3.6a). Imaging for endogenous eGFP disseminated tumor
cells (DTCs) confirmed the presence of tail vein delivered human breast cancer cells in
liver transplants in proximity to positively stained endomucin blood vessels (Figure 3.6b).
Scaffold-free tissues had significantly fewer DTCs compared to Blank-scaffold and
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BMSC-scaffold hepatic tissues (Figure 3.6c). Taken together these results demonstrated
that BMSC-scaffolds improved preservation of intrinsic hepatic sinusoids and assisted in
reaching stably reconnected vasculature compared to Scaffold-free and Blank-scaffold.

Figure 3.6. Circulating tumor cell dissemination to ectopic liver tissue.
a, Experimental schematic of functional vascular reconnection assay in scaffold-assisted
ectopic transplant via intravenous delivery of human MDA-MB-231 cells. b, IHS of
endogenous eGFP MDA-MB-231 cells, endomucin+ hepatic sinusoids, and endogenous
DsRed+ hepatocytes. White arrow highlights DTC. c, Quantitative comparison of DTCs in
transplanted liver tissues. (N=9 sections from 3 implants per group except Scaffold-free
(N=2), *P < 0.05)
3.3.3. Biomaterial scaffold modulates innate immune cell migration.
Transplantation evokes a foreign body response, during which innate immune cells
are recruited to the transplanted tissue and wound healing mechanisms act to resolve tissue
disruption. We investigated the recruitment of mouse neutrophils and macrophages in the
transplanted tissue microenvironments via IHS of Ly6G and F4/80, respectively (Figure
3.7a-d). Ly6G+ neutrophils are early responders in the foreign body response. Ly6G+ cell
infiltration was significantly higher in transplanted liver tissue compared to native liver
regardless of the presence of a scaffold. However, Scaffold-free hepatic tissue had a 118fold increase in Ly6G+ cells over native tissue compared to 49-fold and 20-fold increase in
Blank-scaffold and BMSC-scaffold groups, respectively. Samples collected two weeks
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after transplantation had no significant differences in Ly6G+ cell infiltration indicating
potential resolution of acute response by Ly6G+ cells. Interestingly, the surrounding tissue
around Blank-scaffold and BMSC-scaffold transplants displayed a 10-fold and 21-fold
increase in Ly6G+ cells compared to Scaffold-free transplants after one week, respectively.
The surrounding tissue of BMSC-scaffolds had the highest infiltration of Ly6G+ cells one
week after transplantation, however by week two the Ly6G+ cell significantly decreased
and was not significantly different from Scaffold-free and Blank-scaffold values (Figure
3.7e). Unlike neutrophils, macrophages are abundant in native liver tissue. Scaffold-free,
Blank-scaffold, and BMSC-scaffold transplants contained at least 4-fold fewer F4/80+ cells
than native liver tissue. There were no differences in macrophage recruitment to the
surrounding tissue in any of the experimental groups. The skewed distribution of F4/80+
cells between the hepatic and the surrounding tissue remained in two weeks after
transplantation (Figure 3.7f). Examination of transplanted lung tissue in Scaffold-free and
BMSC-scaffold transplants showed similar modulation of Ly6G+ cell recruitment and
macrophage response (Figure 3.8). These results demonstrate that the presence of the
scaffold altered the pattern of Ly6G+ cell recruitment during the foreign body response,
while increasing the vascular availability to the transplanted tissue (Figure 3.7g).
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Figure 3.7. Scaffold derived immune modulation.
a-d, IHS images of Ly6G+ neutrophils and F4/80+ macrophages with nucleus (DAPI) and
hepatic tissue (DsRed) in native (a), Scaffold-free (b), Blank-scaffold (c), and BMSCscaffold (d). High magnification images show interface between hepatic tissue implant and
host tissue. e, Quantitative comparison of Ly6G+ neutrophil density in native liver tissue
and ectopic tissue transplants and their spatial distribution between transplanted liver and
surrounding biomaterials 1 and 2 weeks after transplantation. f, Quantitative comparison
of F4/80+ macrophage density in native liver tissue and ectopic tissue transplants and their
spatial distribution between transplanted liver and surrounding biomaterials 1 and 2 weeks
after transplantation. g, Proposed mechanism of improved ectopic tissue engraftment via
pro-angiogenic and immunomodulatory scaffold that improves vascular reconnection
while diverting immune cell recruitment to the biomaterial. (N=3-7 implants per group
except Scaffold-free 2 week (N=2), *P < 0.05).
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Figure 3.8. Immunomodulatory effects of ICC hydrogel scaffolds and immune cell
migration on transplanted lung tissue.
a-c, IHS of Ly6G+ and F4/80+ cells within native DsRed lung (a) and transplanted lung
tissue without (b) and with BMSC-seeded scaffold (c). d, Quantitative analysis of Ly6G+
distribution within transplanted tissue. e, Quantitative analysis of Ly6G+ distribution in
surrounding tissue. f, Quantitative analysis of F4/80+ distribution within transplanted
tissue. g, Quantitative analysis of F4/80+ distribution in surrounding tissue. (N=3 implants,
* P<0.05)

3.3.4. Scaffold-assisted transplantation of patient-derived gastric cancers aids
maintenance of intrinsic tissue heterogeneity.
Next,

we

investigated

the

translational

potential

of

scaffold-assisted

xenotransplantation by transplanting seven human patient-derived gastric cancers into
immunodeficient BALB/c nude mice. Patient-derived gastric cancer poorly engrafts when
transplanted into immunocompromised mice with reported engraftment rates ranging from
15-28 %169-171. As with most PDX models, non-cancerous human cells are often lost during
xenotransplantation into mice. We hypothesized that the co-implantation of patient-derived
gastric cancers with a biomaterial scaffold would assist in tissue engraftment, and in doing

62

so maintain intratumoral cellular heterogeneity (Figure 3.9a). To enhance the effect of the
ICC scaffold, we seeded them with patient-derived cancer-associated fibroblasts (CAFs).
CAFs have been documented to secrete numerous molecules that can stimulate cancer cells
and non-cancerous cells in the tumor microenvironment172-173. The ICC scaffold described
above was altered to accommodate larger tissue pieces by increasing the diameter to 12
mm while maintaining the same chemical composition, pore diameter and surface coating.
Round, 2 cm pieces of gastric cancer tissue were removed from patients and stored in
complete media with antibiotics. The tumor pieces were split into smaller 3-5 mm pieces,
and then placed on top of the prepared scaffold. Scaffold material that exceeded the
diameter of the tumor tissue was carefully removed using a razor blade. Placement on top
of the scaffold rather than within the scaffold was chosen to increase the surface area
between scaffold and PDX samples, increasing the effect of CAF-related soluble factors
(Figure 3.9b). One scaffold-assisted or scaffold-free tumor was implanted into 4-6 week
old male BALB/c nude mice (Figure 3.9c). In each PDX study, engraftment was checked
after 2 weeks via palpation. If at least one tumor from the patient grew we continued the
experiment for a maximum of 6 weeks (Figure 3.9d). Engraftment was considered
successful if tumors remained by the end of the study. At the end of the experiment mice
were sacrificed and the samples were prepared for histological evaluation. Tumor
morphology appeared to be conserved following transplantation in successfully engrafted
tissues (Figure 3.9e). Overall, 11 scaffold-free and 30 scaffold-assisted cancer pieces were
transplanted into mice (Figure 3.9f). The frequency of transplanted tumors that displayed
incremental growth was slightly higher in scaffold-free xenografts than scaffold-assisted
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xenografts (43.3% vs 36.4%) but statistical analysis using a logistic regression did not show
a significant effect of scaffold on PDX engraftment (P=0.5965) (Figure 3.6g).

Figure 3.9. Patient derived tumor transplantation.
a, Experimental schematic of scaffold-assisted human gastric tumor xenograft strategy. b,
Gross images of scaffold-assisted patient gastric tumor biopsy and subcutaneous
transplantation into Balb/c nude mice. c, Gross images of PDX implants beneath the skin
with and without scaffold. d, Gross image of successful PDX engraftment and extracted
sample with scaffold removed. e, Histological comparison of gastric tumor tissue structure
between primary and PDX tumors with H&E staining. f, Table of patient tumor
information, implantation duration and engraftment success. g. Summary of PDX
engraftment with and without scaffold.

Multiple microenvironment (mLy6G, endomucin, alpha-smooth muscle actin),
human tumor (hVimentin, hCytokeratin, hCD45, hCD44) and mitogenic (Ki67) markers
were evaluated in scaffold-assisted and Scaffold-free tumor transplants (Figure 3.10a).
Alpha-smooth muscle actin (αSMA) is expressed by activated fibroblasts174. Vimentin and
cytokeratin are mesenchymal and epithelial cell markers, respectively175. hCD45 is a panleukocyte marker, and hCD44 is a marker associated with cancer stem cells176. Tumors
implanted with a scaffold had significantly more proliferative cells (Ki67+), and human
immune cells (hCD45+) (Figure 3.10b). There was no difference in other tumor related
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markers between the two groups indicating scaffold-assisted transplantation did not
negatively affect the tumor phenotype compared to control. Proliferative human immune
cells (i.e. double positive Ki67 and hCD45) were rare in both scaffold-free and scaffoldassisted PDX transplants (Figure 3.11). Taken together, IHS results demonstrate higher
mitogenic and human immune cell activity in human tumors co-implanted with
biomaterials compared scaffold-free controls.

Figure 3.10. Histological analysis of PDX tissue.
a, IHS comparison of mouse cells, human cells, and mitogenic marker expression of
patient-derived gastric tumor microenvironments engrafted without and with scaffolds. b,
Quantitative comparison of each marker in PDX tumors transplanted without and with
scaffold. (N=4-5 tumors per group, *P < 0.05)
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Figure 3.11. Proliferative status of hCD45 cells in PDX samples.
IHS of mitogenic status (Ki67) of tumor resident human immune cells (CD45)
transplanted without and with scaffold.
3.4 Discussion
The ability to modulate the biomaterial-host immune response is an exciting
enabling step in the realization of many biomedical technologies154,

156

. For example,

biomaterials have widespread success in modulating osteoblast and osteoclast activity
during bone tissue repair177. Biomaterial encapsulation of islet cells has shown promise in
being a functional treatment for diabetic patients178. Immunomodulatory nanomaterials
have been developed to target inflammatory monocytes and alter lymph node activity in
vivo179. Implantable biomaterial-based cancer vaccines take advantage of the influx of
dendritic cells to boost the host immune response against cancer180-181. A removable
biomaterial strategy after subcutaneous implantation leaves behind a fibrotic tissue pocket
that has been exploited for islet cell delivery143. Implantable polymeric biomaterials that
attract circulating tumor cells have shown the feasibility to reduce the risk of metastasis in
vital organs103-104. The inversed spherical pore geometry of ICC hydrogel scaffolds directs
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the formation of distinct inflammatory microenvironments, with a pro-inflammatory milieu
at the pore surface and an immune-suppressive niche within the pore cavity119. This
phenomenon enables enhanced vascularization with reduced fibrotic encapsulation while
maintaining pro-inflammatory immune cell activity116,

182-183

. Previously we exploited

these features in creating humanized metastatic tumor microenvironments consists of
human immune, stromal and tumor cells to study systemic investigation of humanized
tumor microenvironment and identify critical events in metastatic relapse96-97, 101. In the
present study, we demonstrate a new translational opportunity of biomaterials to improve
ectopic and xenogeneic transplantation of tissues and tumors. The findings of this work
can be leveraged to improve preclinical mouse models to better reflect human biology and
disease.
A foreign body reaction is a physiological host response to a foreign object within
the tissue, whereby the object is encapsulated with a fibrotic capsule, effectively sealing it
off from the host149. We intended to exploit the angiogenic activity of the foreign body
response to improve the transplantation of mature tissue into the subcutaneous space by
co-implanting a porous biomaterial scaffold. The effects of this co-implantation strategy
were three-fold. First, mechanical deformation of the transplanted tissue was minimized
due to the structural stability of the scaffold. ICC scaffolds composed of at least 30 wt%
polyacrylamide do not deform when implanted101. This property enabled the preservation
of original tissue structures, maintaining tissue complexity and heterogeneity compared to
collapsed Scaffold-free transplanted tissues. Second, increased inflammatory signaling due
to the presence of the biomaterial scaffold modulated the recruitment of innate immune
cells by attracting them to the biomaterial rather than within the transplanted tissue. Third,
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implantation of biomaterials accelerated vascularization to the transplant by increasing proangiogenic signaling molecules such as molecules such as VEGF184. The pro-inflammatory
and pro-angiogenic milieu generated by co-implanted biomaterial demonstrated a distinct
advantage over scaffold-free transplants. The addition of hBMSCs on the surface of the
ICC hydrogel scaffolds further enhanced the results of the scaffold-assisted approach.
hBMSCs are known to secrete various immunomodulatory and angiogenic molecules101,
167

. We have previously demonstrated hBMSCs can maintain secretory function after long-

term (12 week) subcutaneous implantation49. The large surface area of ICC hydrogel
scaffolds permits the accommodation of a high density of stromal cells. Seeding of tissuespecific stroma may provide further supportive functions to transplanted tissues.
Neutrophils and macrophages are innate immune cells that play an important role
in inflammation, tissue remodeling, and fibrosis. As an early responder, neutrophils create
an inflammatory environment through release of cytokines, chemokines, reactive oxygen
species, and neutrophil extracellular traps (NETs)185-186. Release of reactive oxygen species
and tissue digesting enzymes can be particularly disruptive and cause graft tissue
damage187. However, neutrophil derived matrix metalloproteases and NETs have been
implicated in enhancing angiogenesis188-189. Synthetic polymer scaffolds have been shown
to elicit a strong immunological response compared to extracellular matrix scaffolds155. In
the presented study scaffold-assisted samples have benefited from pro-angiogenic features
of neutrophils without direct, potentially disruptive physical interaction. A recent report
suggests that hBMSCs alter neutrophil response toward an immunosuppressive phenotype,
which in the context of this study may have further enhanced the viability of transplanted
tissues190. Our findings suggest hBMSCs were the cause of increased neutrophil
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recruitment compared to biomaterial alone, but it is difficult to conclude if this was linked
to the increase in angiogenesis. Further transient studies of neutrophils and biomaterial may
elucidate their biological function. Macrophages are another important innate immune cell
type in the foreign body response and secrete a variety of inflammatory signals that can
lead to fibrotic encapsulation191. Here macrophages were predominantly localized to the
surrounding tissues regardless of the presence of biomaterial. Interestingly, we observed a
notable reduction in macrophages derived from donor liver tissue after transplantation,
which is potentially due to a migratory response to the strong inflammatory signals in the
surrounding tissue. The functional consequence of macrophage attrition in ectopically
engrafted liver remains to be determined as tissue resident macrophages play diverse roles
in liver function.
In the presented study we explored the application of scaffold-assisted
transplantation to improve human PDX models in mice. Due to technical challenges,
orthotopic transplantation of PDX tumors is rarely performed therefore subcutaneous
implantation is primarily utilized. Although engraftment can still occur, the difference in
the local stroma can change tumor behavior and growth. PDX models are also hampered
by the rate of engraftment and overall engraftment efficiency. The rate of engraftment
normally takes between 2-8 months before developing a preclinical model130. The
efficiency of gastric cancer engraftment is also low, with over 70 % of xenografts failing
to grow169-171. Finally, the local stroma of PDX models gradually becomes replaced with
mouse cells, leading to a loss of heterogeneity which can skew preclinical testing and result
in poor patient efficacy. Based on the ectopic mouse liver tissue transplant experiments we
adjusted the strategy for the scaffold-assisted PDX model. First, we utilized nude mice,
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which are only deficient in mature T cells to minimize the loss of immunological response
on the tumor. A recent study showed that mice reconstituted with human immune
progenitor cells prevented genetic drift within engrafted PDX tumors by better
recapitulating the tumor microenvironment133. Second, we changed the configuration of
biomaterial and transplant to increase the interface and subsequent effect of CAFs. The
presence of CAFs seeded on the scaffold may have provided supportive cytokines and
growth factors to resident human immune cells in addition to tumor cells to maintain a
heterogeneous microenvironment. Although the presented results of gastric cancer
engraftment were sub-optimal, as tumor engraftment between the two groups was
comparable, detailed IHS characterization distinguished higher percentages of hCD45+ and
Ki67+ cells within the tumor tissue in scaffold-assisted transplants compared to scaffoldfree controls. We believe further exploration into biomaterial strategies of co-implantation
with PDX tumors is warranted.

3.5 Conclusion
Our results demonstrate a new approach to aid in the transplantation of mature tissues to
an ectopic, subcutaneous location. By leveraging the acute host response to biomaterial
implantation, we improved vascularization while keeping potentially disruptive immune
cells away from the transplant. The presented biomaterial strategy may be applicable for
the xenotransplantation of human tissues such as the liver and lung potentially enabling the
study of human disseminated tumors in the context of fully mature human tissues.
Additionally, we have highlighted a modulatory effect on the tumor microenvironment of
human gastric cancer PDXs via this co-implantation strategy. We anticipate this approach
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is an important step in expanding the preclinical value of mouse models and achieve better
understanding of human disease and the discovery of effective therapies.

3.6 Materials and Methods
All chemicals and materials were purchased from Sigma Aldrich or Fisher
Scientific unless specified. All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts-Amherst and Ajou
University Medical Center. Patient-derived samples were approved by the institutional
review board of Ajou University Hospital. Informed consent was received from all patients.
3.6.1 Porous hydrogel scaffold fabrication
Interconnected porous hydrogel scaffolds were fabricated as previously
described101. Soda lime glass beads were sorted using an Advantech Sonic Sifter using 250
µm and 300 µm collection trays. The resulting beads had an average diameter of 275 ± 21
µm. Glass beads were dispersed in deionized water and gradually loaded into an 8 x 35
mm or 12 x 35 mm glass vial to a height of 2 mm. A dense lattice structure was achieved
utilizing an ultrasonic water bath. Water was removed in a 60 °C oven prior to thermal
annealing of the glass beads in a 664 °C furnace for 4 hours. The annealed glass bead
templates were infiltrated with a hydrogel precursor solution via centrifugation. The
precursor solution was composed of 30 wt% acrylamide monomer, 1.5 wt% bis-acrylamide
crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator, and 0.2 vol% 2hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI water. The precursor
solution was immediately polymerized under a 15 W ultraviolet light source for 15
minutes. The next day, excess hydrogel was removed by scraping the glass bead template
with a razor blade on all surfaces. Glass beads were selectively dissolved in alternating
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washes of an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2 M
hydrochloric acid, and 2.4 M hydrochloric acid. Washes were performed on a shake plate
and the solutions were changed every four hours until the beads were removed. Scaffolds
were washed with DI water to remove residual acid and lyophilized. Cracked or misshapen
scaffolds were removed before proceeding. Scaffolds were sterilized with 70% ethanol and
the scaffolds were surface treated with Sulpho-SANPAH to covalently crosslink rat-tail
collagen. Scaffolds were stored at 4 °C in sterile phosphate buffered saline.
3.6.2 Cell culture of hBMSCs and seeding onto ICC scaffold
Human bone marrow aspirates were acquired from Lonza and isolation was
performed as previously described101. Cells were cryogenically frozen in media containing
10% dimethyl sulfoxide (DMSO). Cells were cultured with alpha modified, minimal
essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 2%
penicillin-streptomycin, 0.2% gentamicin, and 1 µg/L recombinant human fibroblast
growth factor. Half a million hBMSCs were seeded onto partially dehydrated scaffolds
and kept in culture for up to one week prior to use. hBMSCs were not used beyond passage
4 and media was changed every 3 days.
3.6.3 Sterile DsRed tissue collection and integration into hBMSC scaffold
A breeding pair of DsRed (005441) was obtained from Dr. Barbara Osbourne. Mice
were housed in sterile conditions with unrestricted access to food and water. Mice used in
this study were between 6-13 weeks old. DsRed mice were euthanized via carbon dioxide
and the liver and lung tissues were harvested in a biosafety cabinet and kept in sterile
phosphate buffered saline (PBS) over ice. A sterile 3 mm biopsy punch was used on the
harvested liver and lung to generate tissue inserts. Additionally, a 3 mm hole was created
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in the center of the hBMSC-seeded scaffolds. The tissue piece was gently inserted inside
the hole of the scaffold using sterile forceps. Completed scaffold-assisted implants were
kept in PBS on ice until implantation surgery.
3.6.4 Subdermal transplantation into NSG mice
A breeding pair of NOD-scid IL2Rgnull mice (005557) was initially obtained from
the Jackson Laboratories. Mice were housed in sterile conditions with unrestricted access
to food and water. Mice used in this study were between 6-13 weeks old. NSG mice were
anesthetized with 1.5 % isoflurane before removing the dorsal hair with electric clippers
and Nair. The skin was sterilized using 70 % isopropyl alcohol prep wipes. Mice received
2 mg meloxicam/kg mouse weight subcutaneously prior to surgery. A subcutaneous pocket
was created by making a 2 mm horizontal incision in the dorsal space followed by
expansion of surgical scissors into the incision and expansion. One Scaffold-free or
scaffold-assisted tissue with or without hBMSCs was inserted into the pocket and the
incisions were closed with two 7 mm wound clips. Each mouse received four implants.
Wound clips were removed after 1 week.
3.6.5 Evans Blue perfusion and quantitative imaging
Prior to euthanization, mice were injected with a 2 wt% Evans Blue dye at a dosage
of 2 mL/kg mouse weight. Dye was allowed to perfuse for 20 minutes before euthanization
via carbon dioxide. Tissues were harvested from the mice and imaged on an IVIS Spectrum
CT using an excitation wavelength of 640 nm and emission wavelength of 680 nm.
3.6.6 MDA-MB-231 cell culture and intravenous injection
MDA-MB-231 human breast cancer cells were cultured with Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin.
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For intravenous cell injections 2 x 106 cells were suspended in 200 µL of PBS and injected
into the lateral tail vein using a 27 gauge needle.
3.6.7 Frozen tissue preparation and sectioning
At the conclusion of the in vivo experiment, implants were frozen by embedding
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen
tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides
were stored at -80 °C.
3.6.8 Immunohistostaining
Frozen slides were fixed in -20 °C acetone for 10 minutes. Slides were washed with
a wash buffer consisting of 0.5 % Tween 20 in PBS (PBST) 3 times before blocking in a
solution containing 10 % normal goat or donkey serum, and 1 % bovine serum albumin for
1 hour. Following blocking, primary antibodies diluted in blocking solution were added to
the slides and left in a humidified chamber overnight at 4 °C. Slides were washed 3 times
with PBST and then incubated with secondary antibodies diluted in blocking solution for
2 hours at room temperature. Prior to imaging, slides were washed 3 times in PBST and
stained with a 10 ng/µL solution of DAPI. Fluorescent images were taken on a Zeiss Cell
Observer SD. A table of primary and secondary antibodies used in this study has been
provided (Table S3.1).
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Table 3.1. List of antibodies used for immunohistostaining
Target
Vendor
Catalog Number
Rat – anti-Endomucin
Invitrogen
14-5851-81
Rat – anti-Ly6G
Becton Dickinson
557445
Rat – anti-F4/80
Becton Dickinson
565409
Mouse – anti-CD44
Becton Dickinson
550392
Mouse – anti-CD45
Becton Dickinson
550539
Mouse – anti-Vimentin
Dako
M072529-2
Guinea pig – anti-Cytokeratin
Lifespan Biosciences LS-C193787
Rabbit – anti-Ki67
Abcam
Ab16667
Donkey – anti-Albumin
Bethel Laboratories A90-134A
Rabbit – anti-α-Smooth Muscle Abcam
Ab5694
Actin
Goat – anti-rat AF488
Life Technologies
A11006
Goat – anti-mouse AF660
Life Technologies
A21054
Goat – anti-mouse AF488
Life Technologies
A32723
Goat – anti-guinea pig AF647
Life Technologies
A21450
Goat – anti-rabbit AF568
Life Technologies
A11011
Donkey – anti-goat AF488
Life Technologies
A11055

3.6.9 Human cancer and fibroblast isolation and transplantation
Human gastric cancer specimens were obtained from patients undergoing tumor
resection surgery at the Ajou University Hospital as previously described172. Fibroblasts
were isolated from gastric cancer tissues and were used within six passages. 2.5 x 105 cells
were seeded onto 12 mm scaffolds. A human gastric cancer specimen (3-5 mm) was placed
on top of cancer associated fibroblast-seeded scaffolds. After removing excess hydrogel
matrix, implants were inserted into a subcutaneous pocket made on the dorsal side of Balb/c
nude mice. The incision was closed using sutures.
3.6.10 Tissue histology
Formalin-fixed paraffin-embedded tissue samples from PDX experiments were
sectioned using a microtome. Sections were cut to a thickness of 6 µm. To deparaffinize

75

sections, slides were treated sequentially with xylenes, 100 % ethanol, 95 % ethanol, and
50 % ethanol before washing with deionized water. For antigen retrieval, citrate buffer (10
mM, pH 6.0) was preheated to 90-95 °C on a hotplate before slides were immersed and
incubated for 20 minutes. The antigen retrieval solution was then removed from the
hotplate and allowed to cool to room temperature. Slides were washed with PBST solution
before beginning the standard blocking and antibody staining procedure. Hematoxylin and
eosin (H&E) staining were performed as previously described101. Brightfield images were
taken on an EVOS FL Auto microscope.
3.6.11 Image analysis
All image processing and quantitative analysis was performed in ImageJ. For
overlapping quantification, DsRed images were used to identify the transplanted tissue
area.
3.6.12 Statistics
Unpaired Student’s t tests were performed for comparison of the mean values
between groups in mouse tissue implantation studies. A logistic regression analysis was
used to evaluate the effect of scaffold on PDX engraftment. Mann Whitney U test was
performed to analyze the statistical significance of immunohistostaining measurements of
markers in PDX tumor experiments. Statistical significance was determined if p < 0.05 for
two-tailed analysis. All quantitative data represent mean and standard deviation.
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CHAPTER 4
IMPLANTABLE PRE-METASTATIC NICHES FOR THE STUDY OF THE
MICROENVIRONMENTAL REGULATION OF DISSEMINATED HUMAN
TUMOR CELLS

Adapted with permission from Ryan Carpenter, Jun-Goo Kwak, Shelly Peyton, and
Jungwoo Lee. Nature Biomedical Engineering. 2018 2, 915-929. DOI: 10.1038/s41551018-0307-x. Copyright 2018 Springer Nature.
4.1 Abstract
Cancer survivors often carry disseminated tumor cells (DTCs), yet owing to DTC
dormancy they do not relapse from treatment. Understanding how the local
microenvironment regulates the transition of DTCs from a quiescent state to active
proliferation could suggest new therapeutic strategies to prevent or delay the formation of
metastases. Here, we show that implantable biomaterial microenvironments incorporating
human stromal, immune and cancer cells can be used to examine the post-dissemination
phase of the evolution of the tumor microenvironment. After subdermal implantation in
mice, porous hydrogel scaffolds seeded with human bone marrow stromal cells form a
vascularized niche and recruit human circulating tumor cells released from an orthotopic
prostate tumor xenograft. Systemic injection of human peripheral blood mononuclear cells
slowed the evolution of the active metastatic niches but did not change the rate of overt
metastases, as the ensuing inflammation promoted the formation of DTC colonies.
Implantable pre-metastatic niches might enable the study of DTC colonization and
proliferation, and facilitate the development of effective anti-metastatic therapies.
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4.2 Introduction
Tumor cell dissemination and subsequent metastatic relapse is the leading cause of
death from nearly all cancers. This insidious event has often already occurred when a
patient is first diagnosed with a tumor. However, not all disseminated tumor cells (DTCs)
develop lethal metastases within the lifetime of the patient because the formation of
aggressive secondary tumors is inefficient and lengthy

192

. Only a few circulating tumor

cells (CTCs) disseminate successfully to vital organs, and the majority of these DTCs
undergo apoptosis or clearance by immune cells 193. Often, CTCs that survive extravasation
do not immediately proliferate, but instead lay dormant for months to decades until the
surrounding milieu becomes favorable for regrowth

194-195

. Emerging evidence suggests

that metastatic relapse may not be explained solely by intrinsic genetic instability of DTCs,
instead bi-directional interaction with the surrounding microenvironment needs to be
considered

22, 196-197

. Understanding how the local milieu surrounding DTCs prevents or

aids in regaining proliferative phenotypes is imperative to developing better therapeutic
strategies to prevent or delay lethal metastasis.
CTCs theoretically spread to a wide range of distant organs, but metastasis limitedly
occurs in a subset of target organs including the lung, bone, liver, and brain. This nonrandom development of metastasis has been recognized as the “Seed and Soil” hypothesis
198

. Recently the “Pre-metastatic Niche” hypothesis further posits that CTCs are actively

attracted to transiently formed pro-inflammatory microenvironments, driven by signaling
from the primary tumor, in these distant organs that better support the survival and growth
of DTCs 21. The key microenvironmental signatures of the pre-metastatic niche include (i)
a vascular network 48, 63 and associated oxygen tension (i.e. hypoxia) 199, (ii) altered local
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deposition of extracellular matrix 200-202, (iii) recruitment of bone marrow-derived cells 21,
29

, and (iv) pro-inflammatory immune cell activity

50-51, 203-204

. These niche factors are

believed to attract CTCs and subsequently direct the fate of DTCs to remain in a dormant
state or proliferate

205

. However, the detailed mechanisms through which dormant DTCs

regain their aggressive phenotype while interacting with the local microenvironment have
remained uncertain due to the lack of relevant experimental models that can faithfully
simulate the post-dissemination phase of a dormant-to-active transition of DTCs with high
analytical power.
Mouse models have been widely used to understand various aspects of cancer
biology. For example, spontaneous and experimental metastasis models simulate invasion,
circulation and dissemination of cells from solid tumors in a physiologically relevant
manner

65-67

. The development of immunodeficient NOD-scid IL2Rgnull (NSG) mice has

improved the ability to study the biology of human cancer cells in the context of living
systems 73. This has greatly advanced knowledge about early stage events in human tumor
metastasis and the functional interplay between human DTCs and the local stromal
microenvironment

96

. However, there are major limitations in current models to study

metastatic relapse of dormant human DTCs. First, experimental metastasis models always
induce both active and dormant DTCs simultaneously, restricting the study of late stage
metastatic tumor recurrence. Second, rare dormant DTCs are impractical to detect.
Metastatic relapse becomes evident only after reactivated DTCs establish a clinically
detectable tumor mass. Third, immunodeficient mice cannot capture the role of the immune
system in microenvironmental regulation of DTC survival and outgrowth. Fourth, most of
these mouse models rely on xenografts wherein human tumor cells interact with mouse
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stromal cells, which does not fully recapitulate human disease. Lastly, these systems offer
little opportunity to manipulate individual properties of the niche, constraining the ability
to distinguish the role of individual factors of the tumor microenvironment in regulating
DTC biology.
Recently, tissue engineering strategies have been applied to address the
fundamental limitations of conventional murine metastasis models 160, 206-207. These efforts
can be divided into two different aspects based on the target tissues. Among the four major
metastatic prone tissues, bone has been the most successful in tissue engineering. A
combination of bone inducing biomaterial selection, porous scaffold design, and
osteogenic growth factors have successfully been applied to generate ectopic bone and
marrow, mostly beneath the skin

88-89

. The addition of human bone marrow stromal cell

(hBMSC)-derived osteogenic cells and subsequently introduced human tumor cells
recapitulate humanized bone-specific metastasis

90-94

. The second approach exploits the

transient foreign body response triggered by biomaterials that attract immune cells along
with CTCs to the site of implantation

96-100

. These approaches have been utilized to

distinguish common biological processes that support aggressive metastatic tumor
formation

96, 99

. Engineered tumor cell attracting niches have also demonstrated

translational potential as they have been shown to significantly reduce metastatic burden
in vital organs and resultantly extend the lifespan of tumor bearing mice

103-104, 208

.

However, tissue engineered microenvironments have not been applied for detailed
investigation of the post-dissemination phase of cancer biology.
In this report, we introduce a new experimental metastasis model to study the
evolution of early humanized DTC niches in immunodeficient NSG mice. Functional pre-
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metastatic niches can arise in multiple tissue sites and share pro-inflammatory features
observed during wound healing and tissue remodeling processes

209

. A recent study

demonstrated that repeated injection of tumor-derived exosomes induced a pre-metastatic
niche in the liver and lung of mice

210

, indicating that a pre-metastatic niche can be

generated by exogenously delivered factors. Based on this premise, we have developed a
tissue engineered pre-metastatic niche by subdermally implanting inverted colloidal crystal
(ICC) hydrogel scaffolds that induce vascularized and pro-inflammatory tissue
microenvironments. This niche was humanized with hBMSCs preseeded on the scaffolds,
followed by recruitment of CTCs released from an orthotopic human tumor xenograft. The
established humanized pre-metastatic niche was applied to determine the long-term impact
of inflammation triggered by human peripheral blood mononuclear cells (hPBMCs) in
directing the fate of DTCs. Many solid tumor patients suffering metastasized lesions
receive chemotherapy and/or radiation therapy and subsequent bone marrow
transplantation. In these patients, graft-versus-tumor effects have been clinically observed,
whereby grafted cells reduce tumor burden of the recipient 211. Therefore, we hypothesized
that the introduction of hPBMCs would reduce long-term metastatic relapse by decreasing
DTCs. Serial transplantation of early humanized DTC niches into syngeneic naive mice
permitted prolonged evolution of the tumor microenvironments. Over a 10-week period,
the kinetics of metastatic relapse were quantitatively monitored under whole body
bioluminescent imaging. At the end of the study, we identified early, intermediate, and
overt stages of the metastatic cascade. Deep multiplex imaging and quantitative analysis
captured the ability of hPBMCs to reduce the number of single DTCs but did not affect the
incidence of overt metastatic tumor development. Additionally, the importance of
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vasculature and innate immune cells in regulating the stable-to-active transition of human
DTCs was substantiated. The presented tissue engineered, humanized, and analytical niche
model may serve as an enabling tool for the study of microenvironmental regulation of the
post-dissemination phase of cancer biology and development of targets for anti-metastatic
therapies.

4.3 Results
4.3.1 hBMSC-seeded inverted colloidal crystal hydrogel scaffolds induce a
vascularized tissue microenvironment in vivo
We hypothesized that engineered implantable biomaterials could create premetastatic niche-mimicking tissue microenvironments by directing the foreign body
response to promote angiogenesis and maintain a pro-inflammatory milieu. An isotropic
porous ICC structure fabricated by a simple and tunable procedure was chosen to
systematically investigate the role of biomaterial design in directing host tissue response
by orthogonally manipulating its physical and chemical properties

212-215

. ICC geometry

consists of fully interconnected spherical pore arrays and provides maximal surface area in
the given volume, increasing the biomaterial-tissue interface to direct the foreign body
response

216

. Cavity diameter and mechanical integrity of the hydrogel matrix were

recognized as important parameters to direct angiogenesis and subsequent systemic
recruitment of cells including immune and bone marrow cells. Ultimately, we determined
that a 6.5 mm diameter, 1 mm thick cylindrical ICC scaffold consisting of 300 ± 15 µm
pores with 30 wt% synthetic PAA hydrogel was optimal to generate a controlled
humanized vascularized tissue at the subcutaneous site (Figure 4.1a).
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Figure 4.1. Subdermally implanted hBMSC-seeded ICC hydrogel scaffolds develop
vascularized humanized niches in immunodeficient NSG mice.
a, Schematic of microsphere template-based fabrication of ICC geometry polyacrylamide
hydrogel scaffolds. Bright-field image shows ICC structure through transparent hydrogel
matrix (top), and SEM images show interconnecting junctions and surface immobilized
type I collagen (bottom). b, Confocal images of tiled top and cross-sectioned scaffolds
demonstrate homogeneously seeded fluorescently labeled hBMSCs into 3D ICC hydrogel
scaffolds with typical mesenchymal morphology after adhesion. c, Representative gross
and histological images of subdermally implanted hBMSC seeded scaffold after 4 weeks
in NSG mice. H&E (top) and trichrome staining (bottom) shows recruitment of stromal
and immune cells, and organized collagen architecture, respectively. d,
Immunohistostaining (IHS) of hVimentin and mCD31 for analyzing spatial characteristics
of hBMSCs and vasculature within the scaffold. e, f, Quantitative analysis of blood vessels
(e), and hBMSC localization (f) (n=3 independent scaffolds). g, Comparison of key human
cytokine secretion from hBMSC-scaffolds before and after implantation for 4 and 12 weeks
(n=3 independent scaffolds). *P<0.05.

A humanized stromal niche was created by seeding 5x105 hBMSCs onto an ICC
hydrogel scaffold coated with type I collagen. hBMSCs are adherent fibroblastic cells
isolated from the human bone marrow that carry multilineage capabilities and high
secretory activity (Figure 4.2)

167

. Confocal imaging confirmed deep and homogeneous

distribution of hBMSCs, displaying a spindle-like cellular morphology (Figure 4.1b). We
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previously demonstrated that subdermally implanted ICC scaffolds preseeded with
hBMSCs significantly enhanced vascularization and hematopoietic cell recruitment

97

.

Four hBMSC-scaffolds were implanted in the dorsal subcutaneous space apart from each
other in a NSG mice. ICC hydrogel scaffolds facilitated rapid and deep migration of mouse
immune cells, which was in turn followed by near tissue cell migration and inter-scaffold
angiogenesis. After 4 weeks, complete inter-scaffold tissue development was confirmed
under scanning electron microscopy (Figure 4.3). Histological analysis revealed that pores
were filled with organized dense collagen extracellular matrix and populated with various
types of hematopoietic cells on the pore surface (Figure 4.1c). Immunohistostaining (IHS)
for mouse endothelial cell marker, mCD31, and human mesenchymal marker, hVimentin,
revealed a richly vascularized tissue throughout the scaffold with hBMSCs (Figure 4.1d).
There was no overlap between mCD31 and hVimentin, indicating that blood vessels were
mouse tissue derived and hBMSCs did not incorporate with mouse vessels. Interscaffold
angiogenesis was directed by the biomaterial geometry as vasculature took on branched
morphology between the scaffold cavities (Figure 4.4). Quantitative analysis revealed that
most blood vessels and hBMSCs resided at the outer regions of the scaffold, gradually
decreasing in number toward the center (Figure 4.1e,f). This indicates that the survival of
hBMSCs was dependent on the rapid formation of inter-scaffold blood vessels. To
determine whether engrafted hBMSCs remained functional, we examined ex vivo secretion
of cytokines from hBMSCs remaining in implanted scaffolds 4 and 12 weeks post
implantation. Explanted scaffolds were cultured ex vivo for 36 hours before conditioned
media was collected and analyzed for a subset of human cytokines (VEGF, IL-6, and IL8) that have implicated importance in angiogenesis and inflammation
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21, 217-219

. Human

cytokine secretion gradually diminished overtime in vivo but was still detectable by ELISA
(>35 pg/mL) 12 weeks after implantation (Figure 4.1g). The directed foreign body
response and hBMSC secretome in ICC hydrogel scaffolds reproducibly form an analytical
tissue microenvironment that recapitulates three key features including (i) vascular
networks, (ii) bone marrow derived cells, and (iii) inflammatory immune cells.

Figure 4.2. Human bone marrow stromal cell (hBMSC) multilineage potential.
hBMSCs isolated from human bone marrow aspirate have capability to differentiate into
adipogenic, osteogenic, and chondrogenic lineage. Undifferentiated, adipogenic, and
osteogenic images are representative brightfield images displaying changes to
morphology. Chondrogenic image was taken following Safranin O staining for
proteoglycans.

85

Figure 4.3. Scanning electron microscope images of complete tissue infiltration into
PAA ICC hydrogel scaffolds.
a, Complete tissue infiltration with minimal fibrotic encapsulation of the PAA scaffold. b,
Vascularization and recruitment of immune cells. c, Initial collagen coating removed from
acrylamide surface.

Figure 4.4. Branched vascular morphology through interconnecting pore in the ICC
scaffold.
a, Representative immunohistostaining (IHS) of mCD31 through the scaffold. Blood
vessels have a branched morphology. b, Vascular branching only occurred in the scaffold
pores and not at interconnecting junction indicating the vasculature is directed by the
biomaterial geometry.

4.3.2 Humanized stromal niches attract human CTCs and permit colonization
We employed an orthotopic xenograft tumor-based experimental metastasis model
with PC3 human prostate tumor cells that has demonstrated robust engraftment and
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subsequent metastasis 220-222. After 3 weeks, hBMSC-scaffold implantation, we performed
an intra-prostate injection of 2x106 PC3 human prostate tumor cells expressing green
fluorescent protein (GFP) and luciferase (Luc). Engraftment and metastatic spread of
human tumor cells was non-invasively monitored via whole-body bioluminescent imaging
(BLI). The efficiency of successful orthotopic engraftment based on BLI was above 90%.
Unsuccessfully engrafted mice were excluded from experiments. BLI+ mice were
sacrificed at 8 weeks because mice became moribund due to continuous growth of the
primary tumor and aggressive metastasis in vital organs (Figure 4.5a). Previous
characterization demonstrated that by this time point, primary tumors grew in weight to
about 400 mg and generated roughly 10-50 CTCs per mL of blood 96. At the end of the
study, gross examination of internal organs confirmed overt metastatic tumor nodules in
the liver (Figure 4.5b). IHS of explanted tissues confirmed the formation of micrometastases in the liver and lung whereas DTCs remained individually in the bone marrow
and spleen (Figure 4.5c). IHS of humanized stromal niches revealed CTCs had
successfully disseminated. DTCs were mostly observed in a single cell state but there were
few colonized DTCs (Figure 4.5d). These results verified that the implanted humanized
stromal niches recapitulated the microenvironmental complexity, tumor cell attracting, and
supportive functions of the pre-metastatic niche.
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Figure 4.5. Humanized implantable microenvironments recapitulate tumor cell
receptive and supportive functions of the pre-metastatic niche.
a, Experimental schematic describing establishment of an orthotopic xenograft tumor and
subsequent metastasis. b, Gross images of the orthotopic xenograft PC-3 human prostate
tumor and liver metastasis. Arrows indicate overt metastatic nodules. c, IHS images of
dissemination and colonization of DTCs in vital organs including the liver, lung, bone
marrow and spleen. Micrometastatses commonly appeared in the liver and lung while
DTCs remained mostly in an individual state in the bone marrow and spleen. d, IHS of
implantable pre-metastatic niche showed both single and colonized DTCs. Green arrow
indicates single DTC.
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4.3.3 Intravenously delivered hPBMCs increased human immune cell complexity
Immune cells, both innate and adaptive, are important components of the premetastatic niche 21, 223. To add human immune cell complexity, we intravenously injected
1 x 107 hPBMCs isolated from healthy adult donors into mice bearing hBMSC-scaffolds 4
weeks after implantation (Figure 4.6a). Initial distribution of hPBMCs was characterized
24 hours after injection. As expected, hPBMCs were primarily localized to the spleen and
lung. A relatively low and comparable level of hPBMCs was confirmed across hBMSCscaffolds, bone marrow, and liver (Figure 4.6b and Figure 4.7). At the same time point,
we also determined whether systemically migrated immune cells initiated local tissue
inflammation. After 36 hours of ex vivo culture, conditioned media for human cytokines
representative of inflammation (TNF-α, IL-6, and IL-10) were compared to non-hPBMC
injected controls. Increased inflammatory cytokine secretion was observed in the lung,
liver, and spleen but not in the bone marrow. hBMSC-scaffolds showed significantly
increased pro-inflammatory IL-6 but decreased anti-inflammatory IL-10 compared to
hPBMC-free controls (Figure 4.6c). We then examined the long-term effect of human
immune cells on tissues and hBMSC-scaffolds by IHS for the pan-leukocyte marker,
hCD45, 6 weeks after injection of hPBMCs. hCD45+ cells displayed a single cell
morphology and were observed widespread across the scaffold (Figure 4.6d and Figure
4.8). Sublineage analysis of human immune cells confirmed both hCD4 and hCD8 Tlymphocytes were present in the scaffold (Figure 4.9). Diffuse mCD31 endothelial staining
in hPBMC-injected mice compared to controls indicated leaky and permeable vasculature,
which is the representative vascular morphology in inflamed tissues

224

. Further

quantitative image analysis confirmed a significant increase in vascular density in the
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scaffold tissue with hPBMCs compared to controls (Figure 4.6e). Taken together,
implantable humanized niches gained enhanced inflammatory characteristics after the
introduction of hPBMCs, however the host animals developed symptoms of systemic graftversus-host-disease and became moribund 10-12 weeks post hPBMC injection 225-226.

Figure 4.6. Implantable humanized stromal niches attract systemic hPBMCs.
a, Experimental schematic describing systemic introduction of hPBMCs followed by
functional and immunohistological characterization. b, Flow cytometry analysis of
hPBMC distribution 24 hours after intravenous injection (n=3 mice). c, Analysis of
inflammatory human cytokine secretion from ex vivo cultured tissues and scaffolds
retrieved 24 hours after injection. Dotted line indicates cytokine levels from control tissue
and scaffolds without hPBMCs (n=3 mice). d, IHS of hCD45 and mCD31 in scaffolds 6
weeks after hPBMC injection with quantitative characterization of hCD45+ cell
distribution within the scaffolds (n=4 independent scaffolds). e, IHS of mCD31 6 weeks
after hPBMC injection shows leaky vascular morphology when compared to non-injected
control and quantitative analysis confirms significantly increased vascular density
following hPBMC injection (n=4 independent scaffolds). *P<0.05, **P<0.005.
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Figure 4.7. Flow cytometry plots of hPBMC migration across various tissue.
N= 3 independent mice.

Figure 4.8. Distribution of hCD45 cells in primary mice liver, lung, and implanted
hBMSC- scaffold 6 weeks after hPBMC injection.
IHS shows more human immune cells in native mouse tissues than hBMSC-scaffolds.
Immune cells in the scaffold remain largely as single cells.
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Figure 4.9. Human CD4 and CD8 IHS 6 weeks after hPBMC injection.
Human CD4 and CD8 cells in hBMSC scaffolds.

4.3.4 Systemic delivery of hPBMCs instigates early stage humanized DTC niches
Next, we challenged humanized early DTC niches with hPBMCs under the
hypothesis that mature, functional human immune cells would decrease metastasis. After
subdermal implantation hBMSC-scaffolds for 3 weeks, 2x106 eGFP-Luc PC3 cells were
injected into the mouse prostate to form an orthotopic human prostate tumor xenograft.
The primary tumor grew for 6 weeks before intravenous injection of 1x107 hPBMCs to
introduce human immune cells to the implanted microenvironments. By this point, the host
animals carried substantial primary and metastatic tumor burden. Thus, 5 days after
hPBMC injection, we euthanized mice and characterized the establishment of the early
humanized metastatic niche in the scaffolds (Figure 4.10a). IHS revealed coexistence of
human stromal (hVimentin), human immune (hCD45), and human tumor (hCytokeratin)
cells residing in the same microenvironment (Figure 4.10b). BLI analysis of explanted
scaffolds revealed 8% of scaffolds produced positive signal from both control (3/36) and
hPBMC (4/44) injected mice. There was no significant difference in overall bioluminescent
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signal intensity between hPBMC-injected and control mice (Figure 4.10c). We expected
hPBMC-induced inflammation of humanized DTC niches altered DTC fate, but these
results indicated that a longer period of implantation was necessary to substantiate the
functional consequence.

Figure 4.10. Instigation of humanized pre-metastatic niches with hPBMCs and longterm monitoring of DTC niche evolution via serial transplantation.
a, Experimental schematic describing the establishment of early stage humanized DTC
niches and subsequent instigation by systemic introduction of hPBMCs. b, Representative
IHS of humanized early DTC niche including hCytokeratin (tumor), hCD45 (immune),
hVimentin (stroma) and mCD31 (vessel). Arrows indicate human immune (white) and
tumor (green) cells. c, Representative ex vivo BLI of explanted scaffolds from primary
mice and quantified bioluminescent signal with and without hPBMCS. The dotted line
represents a threshold used to define BLI+ and BLI-. d, Experimental schematic describing
a strategy to monitor the long-term evolution of humanized DTC niches via serial
transplantation of intact early metastatic niches to naïve secondary syngeneic mice. e,
Representative whole body BLI of primary and secondary mice at different time points.
Gross image of explanted scaffolds from secondary mice showing an overt metastasis. f,
Quantitative analysis of human DTC growth in scaffolds after transplantation into
secondary mice via weekly BLI. Scaffolds were classified as BLI-, BLI+, or overt based
on their bioluminescent intensity. Presented N values are representative of independent
scaffolds.
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4.3.5 Serial transplantation of humanized DTC niches allowed for long-term
monitoring of metastatic evolution
We hypothesized that evolution of the early humanized DTC niches could be
continued by intact transplantation of the microenvironment to the same anatomical site of
syngeneic mice. We followed the aforementioned experimental schedule to generate
humanized DTC niches with and without hPBMCs. Bioluminescent signal from scaffolds
retrieved from primary mice was checked ex vivo, and BLI negative scaffolds were
transplanted immediately to naïve NSG mice 6-12 weeks of age. Subsequent metastatic
relapse was non-invasively monitored on a weekly basis via BLI starting 4 weeks after
transplantation and continued up to 10 weeks (Figure 4.10d). We did not observe
noticeable necrotic tissue areas in histological analysis of serially transplanted scaffolds
(data not shown). Gross observation 3 and 7 days after transplantation showed large blood
vessels surrounding the scaffolds (Figure 4.11). By the end of the study, serially
transplanted microenvironments captured a broad range of the metastatic cascade (Figure
4.10e). Based on bioluminescent intensity and outgrowth beyond the scaffold, we
categorized scaffold microenvironments into three groups: (i) BLI-, (ii) BLI+ and (iii)
Overt. BLI+ microenvironments were defined by signal at least 3 times greater than the
background signal, and the rest were defined as BLI- microenvironments. Background BLI
signal was determined from mice without injection of luciferin. Overt growth, a
subcategory of BLI+, described aggressive metastases where the tumor expanded outside
of the boundary of the scaffold (Figure 4.10f). hPBMC-free mice displayed a gradual
increase in the number of BLI+ scaffolds over the 10-week period whereas in mice with
hPBMCs the number of BLI+ scaffolds stabilized 8 weeks after transplantation. By the end
of the study, 53% (17/32) and 23% (9/40) of scaffolds became BLI+ in hPBMC-free and
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hPBMC-injected mice, respectively. There was no significant difference in the percentage
of scaffolds with overt metastasis between the two groups; 6.3% (2/32) in hPBMC-free
and 10% (4/40) in hPBMC-injected mice. Our results signify the ability of hPBMCs to
suppress human DTC growth but did not affect the incidence of aggressively growing
metastases.

Figure 4.11. Large blood vessel recruitment to the transplanted scaffold after 3 and
7 days in secondary mice.

4.3.6 Complete optical sectioning of BLI- scaffolds captured the impact of hPBMCs
on early DTCs
We hypothesized that BLI- scaffolds still attracted CTCs, but the number of DTCs
were low and the cells entered a dormant state. Conventional IHS and flow cytometry may
not effectively detect rare DTCs due to the technical difficulties of probing entire tissue
volumes and representative cell recovery after tissue digestion, respectively. To overcome
these challenges, we adapted the recently introduced CLARITY technique through which
optically cleared fixed tissues permit microscopic detection of rare cell populations while
retaining spatial resolution in the tissue microenvironment

227

(Figure 4.12a). A PAA

hydrogel meshwork (4 wt%) between fixed cellular proteins was formed before removal
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of light scattering lipids, achieved by passive washing with sodium dodecyl sulfate and
boric acid at 37 °C. Transparency dramatically improved in the scaffold, but light scattering
was still present, possibly due to ICC geometry, or mismatched hydrogel density between
the pore cavities and scaffolds (Figure 4.12b). We cut the scaffolds to a thickness of 250
µm using a cryostat, which allowed complete optical imaging (Figure 4.12c). Sliced
scaffolds were stained with antibodies for mouse α-smooth muscle actin and human
cytokeratin to visualize vasculature and tumor cells, respectively. Analysis of the images
revealed abundant (80-400) single DTCs as well as few (5-30) colonized DTCs throughout
the BLI- scaffolds (Figure 4.12d). DTCs were detected in all characterized BLI- (6/6)
scaffolds regardless of hPBMC injection. Complete counts of single and colonized DTCs
did not show a significant difference between hPBMC-injected and hPBMC-free mice
(Figure 4.12e). Further spatial analysis revealed widespread distribution of DTCs across
inner and outer regions of the scaffolds (Figure 4.13). The frequency of colonized DTCs
in total tumor counts, was two times higher in implants with hPBMCs compared to
hPBMC-free implants (Figure 4.12f). There was no significant difference in DTC colony
size among BLI- scaffolds with an average size of 3,700 μm2 (Figure 4.14). These results
suggest that the implantable pre-metastatic niches effectively attract CTCs and
subsequently maintain the long-term viability of DTCs. hPBMC injection disrupted DTC
survival but did not decrease colonization events.
We then extended cytological profiling of the DTCs to determine intrinsic tumor
cell properties and proliferative state using standard immunohistostaining. First, we
examined CD44 expression in DTCs to identify potential cancer stem cells

228-229

. About

29% of primary tumor cells (N=3 primary tumors) co-expressed hCD44 and hCytokeratin
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whereas all observed DTCs (97 DTCs from 4 independent scaffolds) were double positive
regardless of being in single or colonized states (Figure 4.15). To confirm cellular
dormancy, we examined the functional status of the DTCs. Several studies have reported a
subset of markers that are expressed while DTCs are in a dormant state. These markers
have been shown to be dependent on the microenvironment 43-45, 230. For example, NR2F1
was shown to promote dormancy in the lung and spleen, however did not play the same
role in DTCs found in the bone marrow 42. Additionally, the expression of these markers
is transient and relative, therefore not necessarily informative to distinguish the functional
state of dormancy 40, 231-232. Thus, we focused on expression of the cell proliferation marker
Ki67. All singular DTCs found in the scaffold microenvironments (N=107) were Ki67-,
confirming that these cells were not in a proliferative state. In DTCs that formed colonies,
only 8.3% (24/252) contained at least one Ki67+ cell. We did not observe any colonies in
which all cells expressed Ki67. These results suggest that the majority of initial
proliferating DTCs stop growing and enter dormancy indicating that intrinsic properties of
early DTCs may be important to initiate metastatic colonization but not sufficient to lead
to continuous growth. Comparison between scaffolds with and without hPBMCs revealed
no significant differences in the number of Ki67+ DTCs (Figure 4.12g).
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Figure 4.12. Detection of rare dormant DTCs via whole scaffold tissue clearing and
optical sectioning.
a, Schematic of tissue clearing process describing hydrogel embedding, tissue clearing,
thick sectioning (250 µm), and antibody staining of explanted scaffolds. b, Gross images
of whole scaffold before and after tissue clearing. c, Tiled confocal z-stack images of an
entire scaffold sectioned into 4 slices. d, Representative tissue cleared scaffold images of
DTCs as singular and micro-colonies. e, Comparison of complete single and colonized
DTC counts between BLI- scaffolds with and without hPBMCs. f, Comparison of
normalized frequency of DTC colony per 100 DTCs in BLI- scaffolds with and without
hPBMCs. g, Representative HIS of Ki67+ tumor colony (left) and quantitative comparison
of Ki67+ of single and colonized DTCs between scaffolds with and without hPBMCs
(right). White arrows identify Ki67+ cells (n= 3 independent scaffolds from mice without
and with hPBMCs). *P<0.05
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Figure 4.13. Spatial dissection of DTCs in BLI- scaffolds.
a, Schematic of BLI- scaffold processing and region designation. b, Normalized
distribution of single and colonized DTCs in each region.

Figure 4.14.Colonized DTC size measurements from SLI- scaffolds via whole tissue
analysis.
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Figure 4.15. IHS of Ki67, hCD44 and hCytokeratin in a primary tumor and an
implanted hBMSC-scaffold.
a, Human CD44 and human cytokeratin do not have high overlap in primary tumor.
Proliferative regions of the primary tumor had higher overlap than non-proliferative
regions. b, Nearly all single and colonized DTCs had overlapping human CD44 and human
cytokeratin.

4.3.7 Comparative analysis of niche factors identifies key microenvironmental
regulation of DTCs in single-to-colony transition
Next, we characterized how early DTC niches evolved by probing the local tumor
microenvironments in single and colonized DTCs. By leveraging the uniform pore
geometry of the scaffold, we generated a standardized imaging analysis of the
microenvironment (Figure 4.16a). Antibodies for IHS were chosen to determine the role
of blood vessels (mCD31), human stromal cells (hVimentin), human immune cells
(hCD45), and innate mouse immune cells in the single-to-colony transition of DTCs.
Snapshots were collected in the tumor microenvironment of single cell and tumor colonies
from at least 4 independent scaffolds (Figure 4.16b). We first determined the proximity of
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human immune cells to single and colonized DTCs. hCD45+ cells located significantly
closer to colonized DTCs. About 25% of tumor colonies were infiltrated with hCD45+
cells. However, colocalization of single tumor cell and human immune cells was rare
(Figure 4.16c). Next, we analyzed the correlation between single and colonized DTCs with
respect to the distance from blood vessels. In general blood vessels were found within 50
µm of a tumor cell. Without hPBMCs, over 50% of tumor colonies had at least one
infiltrating blood vessels, but this phenomenon was observed in less than 35% of tumor
colonies in scaffolds with hPBMCs (Figure 4.16d). As expected, the average colony size
infiltrated with blood vessels was significantly larger than those without, but there existed
no significant correlation between tumor colony size and hPBMCs (Figure 4.16e).
Functional characterization between Ki67+ tumor colonies and blood vessel availability
revealed that nearly all (8/9) proliferative colonies had infiltrating vasculature. However
infiltrating vasculature did not guarantee proliferation, only accounting for 26% (9/35)
instances. These observations were not dependent on the presence hPBMCs (Figure 4.17).
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Figure 4.16. Quantitative comparison of vascular, stromal and immune niches
between single and colonized DTCs in single pore microenvironment.
a, Representative images of dormant human DTC bearing scaffold and schematic of pore
imaging targets. b, Representative IHS of microenvironments surrounding single and
colonized DTCs with vascular and cellular niche components including hCD45, hBMSCs,
mLy6G, and mF4/80. Scale bars 100 µm. c, Comparison of distribution profiles of
neighboring hCD45+ cells to hTumor cells between single and colonized DTCs (top) and
frequency mapping of hCD45+ cells (bottom). d, Comparison of distribution profiles of
nearest mCD31+ cells to hTumor cells with and without hPBMC injection (top) and
frequency mapping of mCD31+ cells (bottom). e, Comparison of tumor colony size with
and without infiltrating mVessel. f, Comparison of distribution profiles of mCD31+ cells
to hTumor with and without neighboring hBMSCs (top) and frequency mapping of
mCD31+ cells (bottom). g, Comparison of distribution profiles of neighboring mLy6G+
cells to hTumor cells with and without hPBMCs (top) and frequency mapping of mLy6G+
cells (bottom). Representative values were plotted, selected by ordering datasets and
averaging every 10 points, when N>100. Data collected from 5 biologically independent
scaffolds from each group. *P<0.05, **P<0.005, ***P<0.0005.
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Figure 4.17. Correlation between tumor infiltrating vessels and proliferative tumor
colonies.
Proliferative tumor colonies were always within 25 um of mouse blood vessel. *P<0.05

We extended quantitative analysis of IHS images with other microenvironmental
components. First, the distance between tumor cells and blood vessels was considered
when in the proximity of hBMSCs. Although the existence of DTCs and hBMSCs in the
same pore was rare, as cellularity of hBMSCs decreased over the implantation period,
tumor colonies that formed near hBMSCs were more likely to be infiltrated with a blood
vessel than those not closely associated with human stroma (Figure 4.16f). Next, we
characterized the recruitment and distribution of endogenous mLy6G+, mLy6C+, and
mF4/80+ cells to determine the role of innate immune cells. Abundant mLy6C+ and
mF4/80+ cells were observed at the pore periphery in nearly every pore regardless of
experimental condition indicating that their response was dominantly triggered by the
biomaterial rather than tumor or human immune cell activities (Figure 4.18). Both
mLy6C+ and mF4/80+ cells are known critical players in tissue remodeling, secreting
protease enzymes including matrix metallopeptidase 9 (MMP-9)
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. IHS of MMP-9

confirmed localized tissue remodeling activity at the pore surface (Figure 4.19).
Interestingly, mLy6G+ cells were preferentially localized within tumor colonies, compared
to single DTCs (Figure 4.16g). The distribution of mLy6G+ cells in tumor colonies was
independent of their proliferative status confirmed by Ki67 staining (Figure 4.20). Taken
together these results indicate that increasing vascular connection and recruitment mLy6G+
cells are common and could be important changes in DTC niches during single-to-colony
transition.

Figure 4.18. HIS of mouse F4/80 and Ly6C in hBMSC-scaffold.
a, Representative IHS images of mF4/80 and b, mLy6C staining in disseminated tumor
microenvironment. Widespread staining made quantification difficult and non-conclusive.
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Figure 4.19. IHS of MMP-9 in hBMSC-scaffolds.
Representative IHS images of a, mLy6G, b, mLy6C, and c, mF4/80 staining in scaffold
microenvironment. High amounts of MMP-9 at the biomaterial scaffold interface. d,
Quantification of MMP-9 source reveals mF4/80 and mLy6C cells are main producers.

Figure 4.20. Correlation between mLy6G and proliferative tumor colonies.
No change in local mLy6G cell distribution between proliferative and non-proliferative
tumor colonies. Addition of hPBMCs did not influence distribution. Characterization was
not performed on singular DTCs since all cells were non-proliferative.
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4.3.8 Multiplex IHS of overt metastasis substantiates the importance of innate
immune cell influx in continuous outgrowth of DTCs
To understand how the early DTC microenvironment evolved during metastatic
relapse, we characterized tumors that had progressed beyond the initial awakening events.
A panel of 9 different antibodies, hCytokeratin, hVimentin, mCD31, hCD45, Ki67, hCD4,
hCD8, mLy6G, and mF4/80, and the nucleus stain DAPI were used to visualize and
quantify cellular signatures in the tumor microenvironment (Table 4.1). Eight consecutive
histological sections, 20 µm thick, were stained with sets of 3-5 antibodies to generate a
multiplexed and comprehensive view of the metastatic tumor heterogeneity (Figure 4.21).
Using ImageJ, individual image channels were centered and overlaid. From these
cumulative images, eight zones were manually identified that highlighted regions of
diversity (Figure 4.22a).
Table 4.1. Antibody reagents.
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Figure 4.21. IHS of eight consecutive overt metastasis slices with different antibody
staining.
Individual monochrome images showing individual antibody staining results on eight
consecutive tissue sections.
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Figure 4.22. Multiplex IHS imaging-based characterization of heterogeneity in overt
metastatic microenvironments.
a, Overlaid IHS images from eight consecutive 20 µm thick slices and manually defined
zones representing distinct microenvironment profiles with a list of antibodies and their
associated targets. b, Representative IHS images of each zone with quantitative cellular
complexity. Bar graphs display intra-zone composition of quantified antibody staining.
Radial plots represent inter-zone comparison of cellular markers normalized to the zone
with the highest signal. Top panel highlights human stromal, tumor, and immune
celllocalization. Bottom panel highlights human and mouse immune cell subset. c, Five
functional zones capturing different states of metastatic tumors: (1) necrotic tumor, (2)
active tumor, (3) host tissue, (4) dormant tumor, and (5) intermediate tumor. d, IHS images
of hCD45 cells found within early DTC colonies (n=5) and overt scaffold metastases (n=3)
with quantitative representation of overlapping hCD45+ cell coverage. Arrows show
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infiltrating hCD45+ cells (white). e, IHS image of mLy6G+ cell localization at the
boundary of an actively growing overt metastasis and quantitative comparison of Ki67
stain overlap with human tumor and mLy6G+ cells (n=3). f, Quantitative comparison of
overlapping mLy6G+ cells in early DTCs and overt scaffold metastases (n=3). *P<0.05.

To quantitatively determine cellular and functional signatures of each zone, we
developed an imaging analysis pipeline. Two different characterizations were considered
for quantifying the selected regions (Figure 4.23). The first analysis compared the absolute
pixel number of each stain within each zone to highlight the makeup of each region, which
was displayed as a bar graph. The second was a comparative analysis between zones, which
was plotted on a radial chart broken into two panels; (i) a general overview of cellularity,
and (ii) the diversity of immune cells (Figure 4.22b). Comparison of the different zones
revealed similar phenotypes that were categorized into five separable regions. Zone 1
highlighted a typical necrotic tumor region consisting largely of weak human tumor and
immune cell markers. Mouse macrophages were present but relatively low compared to
other regions. A pocket of mouse tissue, zone 4, was characterized by a low signal in human
cell markers and weak Ki67 signal. Zones 5 and 6 exhibited similar tissue
microenvironments to a dormant DTC niche; a high number of human stromal and immune
cells with relatively few mLy6G+ cells were observed, and overall Ki67 signal was weak.
On the periphery of the scaffold, zones 7 and 8, an increase in vessels and immune cells
was observed (Figure 4.22c). In contrast to our observation of micro-metastases, the
frequency of human immune cells in overt tumor regions was significantly lower (Figure
4.22d). This result was possibly caused by reduction in human immune cells, but IHS of
spleens revealed the presence of hCD45+ cells suggesting that a subset of human immune
cells systemically migrate and proliferate in the secondary host. The frequency of hCD45+
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cells in the spleen was not significantly different between secondary mice with and without
overt tumors (Figure 4.24). Zone 2 and 3 contained actively growing tumors indicated by
high DAPI and Ki67 staining. Zone 2 had higher hCytokeratin signal than zone 3 but only
half the relative Ki67. High hVimentin in zone 3 suggests a more mesenchymal tumor
phenotype, which was linked with higher proliferation compared to the more epithelial
tumor phenotype in zone 2. Colocalization analysis confirmed that Ki67 staining was
mostly derived from tumor cells and not mLy6G+ cells that were also observed in these
actively growing tumor zones (Figure 4.22e). mLy6G+ cells limitedly infiltrated overt
tumor regions and remained on the tumor periphery, opposite to what was observed during
the early stages of colonization (Figure 4.22f.). Considering the relatively short lifespan
of mLy6G+ cells, about 1 day

234

, this result indicates that mLy6G+ cells continuously

migrated to actively growing tumors. This phenomenon was repeatedly observed in three
independent overt metastatic tumors (Figure 4.25). Together these results demonstrate that
the tumor microenvironment evolves during progression to an overt tumor, including
phenotypic changes of tumor cells to a more mesenchymal phenotype, and continual
recruitment of innate immune cells, especially mLy6G+ cells.
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Figure 4.23. Active tumor microenvironment imaging analysis pipeline.
1) Images were centered and canvas size equalized.
2) Scaffold images discretized into 24x24 grid of subimages.
3) For each antibody positive signal separated from background noise. Total tissue
area was calculated by increasing background to include autofluorescent tissue.
4) Positive signal from each subimage was normalized to total tissue area and
displayed as a heatmap.
5) Visual inspection of images revealed 8 zones that housed unique features.
6) Manually determined zones of interest translated to 24x24 grid.
7) The 8 translated zones were overlaid on images with normalized signal. Normalized
signal was recalculated for each of the 8 zones.
8) Intra-zonal composition was performed by dividing the positive pixels for each
stain and dividing by the summation of all positive pixels from all staining except
Ki67 and DAPI. Stain compositions were plotted on a bar plot.
9) Inter-zonal comparison was performed by taking normalized signal from each zone
and dividing by the largest value for each stain. Thusly, the zone with the highest
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value for a particular stain would have a value of 1. Quantitative results were
displayed on a radial plot broken into two different panels.
10) Results of 8 and 9 analyzed to generate groupings of similar features.

Figure 4.24. Human PBMCs enter circulation in secondary mouse host.
Spleens taken from non-injected (control) and hPBMC-injected mice. Non-overt spleens
taken from mice without overt-metastasis bearing scaffolds. Overt spleen taken from mice
with a scaffold with an overt metastasis.
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Figure 4.25. IHS of mLy6G, Ki67, and hCytokeratin in independent over metastasis.
IHS of Ki67 and mLy6G localization in independent actively growing overt tumors beyond
the boundaries of the scaffold.
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4.4 Discussion
Accumulating evidence suggests that systemic spread of DTCs may be unavoidable
235

, but metastatic relapse can be preventable. For example, low-dosage aspirin

canakinumab
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, metformin

238

, and cabozantinib

239

236

,

have demonstrated significantly

reduced risk for metastasis. It is imperative to develop detailed understanding of how these
molecules suppress revitalization of dormant DTCs in distant tissue sites. The lack of
relevant experimental models that can faithfully determine the long-term functional
consequence of therapeutic intervention in the context of humanized tissue
microenvironments has been a critical challenge. The presented tissue engineered premetastatic niche model represents a new opportunity to study the post-dissemination phase
of human cancer biology from three distinct aspects. First, the use of biomaterials to create
a pre-metastatic niche allowed controlled and analytical experimentation to quantitatively
distinguish key features of microenvironmental regulation in dormant-to-active transition
of DTCs. The standardized structure of ICC scaffolds generated reproducible tissue
microenvironments and streamlined multiplex imaging and comparative analysis of DTC
niches. Additionally, optical transparency of PAA hydrogel permitted whole tissue clearing
and complete optical sectioning of tumor microenvironments to detect rare DTCs while
retaining spatial resolution. Implantation of biomaterials in a subcutaneous pocket enables
easy accessibility to various functional characterizations including direct measurement of
tumor growth, BLI, and possible intravital imaging via surgical engraftment of a skinfold
window chamber

97, 184

. The tunable design of ICC hydrogel scaffolds permits easy

manipulation of physical and geometrical parameters. Recently there has been a substantial
progress in understanding the interaction between implantable biomaterials and host tissue
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and immune cells 240. For example, poly-lactic and glycolic acid (PLGA) scaffolds 241 and
methacrylated alginate cryogels

242

manipulate dendritic cell homing and immune

response; scaffolds composed of extracellular matrix proteins have modulated proregenerative systemic immune environments

164

; physical dimensions of biomaterials

influence foreign body response 120. These efforts can further empower an implantable premetastatic niche model to study human tumor metastasis.
Second, in vitro seeding of stromal cells provided additional capability to create
defined and functional implantable pre-metastatic niches. Here hBMSCs were introduced
into the scaffold to create humanized stromal niche and modulate foreign body response
and interscaffold angiogenesis. hBMSCs are known to secrete immunomodulatory and
proangiogenic molecules, which resultantly attenuate foreign body response
enhanced angiogenic activity

97

166

and

in previous studies. Similarly, different types and

combinations of stromal cells can be introduced into biomaterials to induce defined
functionality of microenvironments. For example, genetically engineered stromal cells that
secrete specific human cytokines were used to create defined humanized soluble
microenvironments 134.
Finally, the transplantation strategy separated early metastatic niches from
advanced tumors and prolonged the microenvironment evolution to substantiate functional
mechanisms behind metastatic relapse. Serial transplantation has been commonly
conducted to maintain intrinsic characteristics of human blood cancer cells and solid
tumors (e.g. patient derived xenograft tumors) in the context of living system for extended
periods 243-244. Applying this concept to metastatic tumor microenvironments overcame the
fundamental limitation of mouse model for long-term evolution of the DTC niche beyond
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the lifespan of primary host mice, which enabled observation of the full spectrum of postdisseminated tumor progression. Here we exploited this feature to determine the functional
consequence of acute inflammation triggered by hPBMC injection. Even though the
experiment was halted 10 weeks after transplantation, dormant DTC microenvironment
studies could continue for longer experimental duration. This capability will facilitate
observation of the long-term dormant DTC niche and the screening of drugs for metastasis
prevention.
Intravenous injection of hPBMCs instigated early humanized DTCs niches and
subsequent metastatic relapse became evident 6 weeks after serial transplantation. The
incidence of metastasis was significantly lower and stabilized when compared to hPBMCfree scaffolds. This phenomenon is reminiscent of a graft-versus-tumor response 211, 245-246.
Comparative analysis of single and colonized DTCs revealed a correlation between human
immune cells and colonized DTCs, whereas single DTCs did not directly interact with
human immune cells (Fig. 4.16c, d). Given the observation of reduced DTCs in mice that
received hPBMCs, direct contact between human immune and tumor cells could be a
potential mechanism in the elimination of DTCs. Indeed, a previous study showed that
systemic delivery of hPBMCs prior to the subcutaneous injection of human PC3 tumor
cells in NSG mice significantly decreased ectopic tumor development with increased
primary tumor-infiltration of T-lymphocytes

247

. Additional studies reported that T-

lymphocytes within patient-derived xenografts continually proliferated and systemically
spread to the host NSG mouse 248. Similarly, we confirmed the presence of hCD45+ cells
in the spleens of secondary mice, indicating that a subset of human immune cells migrated
out from the scaffolds and potentially continued growth. This could be the mechanism that
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leads to long-term stabilization of DTC growth in secondary hosts. Although hPBMCs
reduced overall metastatic relapse, the incidence to develop overt metastasis was not
changed. Additionally, complete optical sectioning of BLI- scaffolds revealed an increased
frequency of colonized DTCs in total DTC counts in mice that received hPBMCs (Fig.
4.12f). These results suggest that although hPBMCs decreased DTC burden, during this
process they may also increase the chance to initiate colonization of DTCs possibly due to
local tissue inflammation. However, detailed mechanisms by which human immune cells
promoted colonization of DTCs remains an open question.
Previous studies have highlighted vasculature and immune cell interaction as
critical for reactivation of dormant DTCs

32, 63, 249-252

. Our results provide additional

evidence to support these findings and quantitatively capture the changes in the local DTC
microenvironments from single, to colonized to overt metastasis. The vasculature is
initially used by tumor cells to migrate to distant tissues, however during the period of
dormancy, DTCs remain distant from the vasculature. Quantitative analysis of the blood
vessels surrounding DTCs revealed that tumor cells begin to proliferate without immediate
contact with a blood vessel, but their growth could not exceed a cross-sectional area of
roughly 4,000 µm2 without the connection to a blood vessel. It remains unclear if DTCs
migrate toward a blood vessel, a vessel is recruited by DTCs, or DTCs and vessels meets
opportunistically. Recent studies suggest the source of angiogenic signaling may be
derived from local immune and stromal cells that release proinflammatory or
proangiogenic factors that initiate endothelial tip cell sprouting 63, 253-254, induce phenotypic
switching of perivascular cells to a less differentiated state
vascular remodeling activity.
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28

, or transiently enhance

Additionally, our results substantiate the important role of continuously recruited
innate immune cells in forming a supportive microenvironment for awakening dormant
DTCs. mLy6G+ cells consist of several myeloid cells including monocytes, granulocytes,
and neutrophils. Recent studies have shown that neutrophils are associated with playing a
key role in initiating metastatic outgrowth

32, 249-252

. Deep optical characterization of the

metastatic niche demonstrated their presence within awakening DTC colonies during initial
tumor colonization, however it is unclear how the host neutrophils seek out early stage,
reactivated DTCs and their role in promoting or inhibiting growth. Once a tumor colony
became an advanced large metastasis, mLy6G+ cells no longer infiltrated but remained on
the periphery where they were continually recruited. The lack of infiltrating neutrophils
within overt tumors indicates that the tumor may produce a repulsive microenvironment
once it has formed a large enough mass. The varying activities of mLy6G+ cells within the
different stages of tumor development demonstrate the need for deeper understanding of
myeloid cell biology such as neutrophils in the tumor microenvironment, which may lead
to more effective anti-metastatic strategies 255. It is possible, and likely that many budding
metastases fail to evade immune response at the initial stages of outgrowth and become
terminated. Tumors that can evade microenvironmental control will continue to proliferate
and gain control of the microenvironment and dictate bi-directional interactions with
surrounding cells. From our data, we demonstrated that overt tumor cell proliferation
occurs together with vascularization and exclusion of innate and adaptive immune cells,
while selectively attracting a subset of innate immune cells to the actively proliferative
boundary, allowing for continuous growth (Figure 4.26).
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Figure 4.26. Proposed microenvironmental regulation of DTCs during initial
dormancy, reactivation, and overt metastasis along with the experimental
transplantation strategy from primary to secondary mice for long-term observation.

The presented implantable pre-metastatic niche model has demonstrated enabling
features for detailed observation of awakening dormant DTCs in vivo, yet there is still room
to improve. First, since the established humanized microenvironments are comprised of
three different donors, human immune interactions are allogeneic, which limits the study
of adaptive immune system mediated tumor microenvironment regulation. Creating donormatched microenvironments is possible by obtaining different tissue cells from the same
patient but this involves clinical and ethical considerations 256. One alternative solution is
to use induced pluripotent stem cells that can differentiate into stromal, hematopoietic, and
tumorigenic cells

257

. While the current study has focused on humanized tumor

microenvironments keeping in mind translational opportunity, for mechanistic studies the
experimental system could be adapted to an entirely mouse-based model. Second, hPBMC
injection delivers fully functional human immune cells but the innate immune cell effect is
restricted to a short-term period due to their limited lifespan; the average lifespan of
monocytes and neutrophils are about 1 week and 24 hours, respectively

234, 258

. Instead,

repeated injection of human granulocytes into the humanized mice could replenish shortlived immune cells. Alternatively, the transplantation of human hematopoietic stem cells
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could stably provide human innate immune cells, but differentiated human immune cells
in the mouse bone marrow may not carry full functionality

259

. Emerging data including

our own has demonstrated that innate immune cells play a critical role in regulating the
tumor microenvironment

260-262

. Innate immune cell activity does not strictly rely on the

highly specific binding required for adaptive immune cells, and thus human tumor and
mouse innate immune cell interaction may be clinically relevant. Third, the prolonged
local foreign body unnaturally elevated macrophage activity and may not accurately reflect
physiological situations. Recent studies have shown that locally implanted biomaterials
modulate systemic immune response and host regenerative potential

164, 263-264

.

Additionally, biomaterial-induced myeloid cell responses were shown to be tunable by
incorporating macrophage selective drugs e.g. clodronate for macrophage depletion

184

.

Finally, transplantation of the intact microenvironments possibly caused brief temporal
oxygen and nutrient deprivation. Aside from intrinsic changes to DTCs, their fate can be
critically influenced by the secondary host cells, especially immune cells. We minimized
this potential effect by using syngeneic mice and implanted the microenvironments to the
same anatomical locations. However, a similar clinical scenario has been reported in the
field of organ transplantation where dormant DTCs in the donor organ developed
metastasis in the recipient

49, 265

. Indeed, this feature may provide a new opportunity to

investigate the role of local and systemic tissue microenvironments by altering the recipient
host animal in terms of age, immune competence, and implantation site.
Mouse models play a critical role in advancing our understanding of cancer
metastasis, however their capability to capture the long-term evolution of the metastatic
niche and their relevance to humans remains questionable. Tissue engineered humanized
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metastasis models can reduce the pre-clinical gap and potentially uncover new biological
interactions between human tumors and the surrounding microenvironment. Studies can be
readily extended to characterize the extracellular matrix, and molecular and genetic
profiles. One promising future direction is to combine comparative analysis based on
endpoint IHS characterization with temporal observation of cellular processes via intravital
or ex vivo imaging, which will enable deeper mechanistic understanding of the DTC niche
evolution. The established metastasis model can also be applied to screen the effectiveness
of drugs targeting DTCs and secondary outgrowths. Taken together, we envision that tissue
engineered strategies will provide an invaluable tool to answer provocative hypotheses
emerging in the cancer field and advance clinical translation of anti-metastatic therapeutic
strategies.

4.5 Materials and Methods
All chemicals and materials were purchased from Sigma Aldrich or Fisher
Scientific unless specified. All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts-Amherst.
Experiments and handling of mice were conducted under federal, state and local guidelines.
4.5.1 Type I collagen coated inverted colloidal crystal hydrogel scaffold fabrication
Inverted colloidal crystal hydrogel scaffolds were fabricated following the
previously reported methods (33). Soda lime glass beads were sorted using an Advantech
Sonic Sifter for each range with ~8% deviation. Beads dispersed in deionized (DI) water
were gradually loaded into a glass vial (8 x 35 mm) to a height of 2-2.5 mm and were
mechanically packed into a lattice structure in an ultrasonic water bath. Orderly packed
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glass beads were dried in a 60 °C oven and then thermally annealed between 650 and 680
°C depending on the bead size for 4 hours in a furnace. A hydrogel precursor solution
composed of 5, 15, 30, and 50 wt% acrylamide monomer, 1.5 wt% bis-acrylamide
crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator, and 0.2 vol% 2hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI water was prepared
immediately before use. 150 µL of precursor solution was infiltrated into the glass bead
template and centrifuged in a microcentrifuge at 9,000 RPM for 15 min and subsequently
polymerized under a 15 W ultraviolet light source for 15 minutes. Polyacrylamide
hydrogel-glass templates were removed from the glass vials the next day to ensure
complete polymerization. Excess hydrogel was removed by scraping the glass bead
template with a razor blade on all surfaces. Glass beads were selectively dissolved in
alternating washes of an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2
M hydrochloric acid and 2.4 M hydrochloric acid (Caution: These chemicals are corrosive
and must be used in a fume hood with proper protective gear). Washes were completed on
a shake plate and solutions were changed every four hours until the beads were removed.
Scaffolds were thoroughly washed with DI water to remove residual acid and lyophilized.
Following lyophilization, scaffolds were resuspended in CryomatrixTM embedding resin
and cut to 1 mm thickness on a CryoStar NX70. After thorough washing in DI water,
scaffolds were sterilized with 70% ethanol and stored at 4 °C in sterile phosphate buffered
saline solution (PBS). The final pore dimension of the optimized scaffolds used for the
remainder of the study was 300 ± 16 µm. To support stromal cell adhesion on
polyacrylamide hydrogel scaffolds, type I collagen extracted from rat tails was covalently
immobilized on the pore surface using Sulfo-SANPAH conjugate chemistry.
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4.5.2 Human BMSC isolation and culture expansion
50 mL of bone marrow aspirate obtained from a healthy donor was purchased from
Lonza. Mononuclear cells were isolated via density gradient based centrifugation using
Ficoll Paque (GE) at 1500 RPM for 30 minutes using minimum acceleration and no brake.
Mononuclear cells were plated on T-225 flasks with Minimum Essential Medium Eagle,
alpha modified (αMEM) supplemented with 20% FBS, 2% penicillin-streptomycin, 0.2%
gentamicin, and 1 µg/L recombinant human fibroblast growth factor. After 1 week,
colonies of adherent cells were harvested, cryogenically frozen in media containing 10%
DMSO, and stored in a cryotank. The multilineage differentiation potential of hBMSCs
were tested using standard protocols.
4.5.3 Human BMSC seeding and culture on a 3D hydrogel scaffold
Collagen coated ICC hydrogel scaffolds were partially dehydrated by removing
excess PBS and drying in a biosafety cabinet. 5 x 10 hBMSCs suspended in 20 µL of
5

growth media were dropped on top of a partially dehydrated scaffold. The cell suspension
was drawn into the dried scaffold, facilitating deep and homogenous cell seeding in the 3D
scaffolds. Cell loaded scaffolds were incubated for 20 minutes in a CO2 incubator to allow
initial cell adhesion. Cell-scaffolds were transferred to a 48-well plate containing 500 µL
of media and allowed to grow for up to one week prior to use. Media was changed every 3
days.
4.5.4 Subdermal implantation of hBMSC-scaffolds in NSG mice
A breeding pair of NOD-scid IL2Rg mice (005557) was initially obtained from
null

the Jackson Laboratories. NSG mice were housed in sterile conditions with unrestricted
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access to food and water. In this study 6-13 week age mice were used for implantation.
Mice were anesthetized with 1.5% isoflurane and dorsal hair was removed with electric
clippers and Nair. The skin was sterilized using 70% isopropyl alcohol prep wipes. Prior
to surgery, 2 mg meloxicam/kg mouse weight was subcutaneously injected. 2 mm
horizontal incisions were made in the upper and lower dorsal spaces. A subcutaneous
pocket was formed by inserting surgical scissors into the incision and expanding. One
scaffold per subcutaneous pocket was implanted and the incisions were closed with 2
Reflex 7 mm wound clips. Four scaffolds were implanted per mouse. Wound clips were
removed after 1 week.
4.5.5 Characterization of cytokine secretion of implanted hBMSC-scaffolds
Implanted hBMSC-scaffolds were retrieved at 4 and 12 weeks from NSG mice.
Explanted scaffolds were cut into 1-2mm pieces using surgical scissors and cultured in 500
µL of αMEM media supplemented with 1% mouse serum and 1% penicillin-streptomycin
for 36 hours. For control samples, 1 week in vitro cultured hBMSC-scaffolds were used.
Conditioned media was collected and used immediately for characterization human VEGF,
IL-6 and, IL-8 secretion by DuoSet® ELISA kits (R&D Systems).
4.5.6 Tail vein injection of human PBMCs
Whole blood was obtained from 3 healthy male donors age 20-38 in BD Vacutainer
K2 EDTA blood collection tubes. Mononuclear cells were isolated via density gradientbased centrifugation using Ficoll Paque at 1500 RPM for 30 minutes using minimum
acceleration and no brake. From roughly 30 mL of whole blood we extracted 25-30 million
PBMCs. Isolated mononuclear cells were counted and re-suspended in PBS to a density of
10x10 or 20x10 cells per 100 µL PBS. Scaffold bearing or scaffold and tumor bearing
6

6
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mice were warmed under a heat lamp to dilate the tail vein, placed in a restrainer, and
intravenously delivered by tail vein injection using a 27 Gauge needle.
4.5.7 Human PBMC distribution and cytokine secretion
Mice 6-13 weeks of age were implanted with BMSC seeded scaffolds. 20x106
PBMCs suspended in 100 µL of PBS were intravenously delivered 5.5 weeks after scaffold
implantation. Mice were euthanized 24 hours after PBMC injection. Lung, liver, spleen,
bone, and scaffolds were retrieved. Tissue samples were aliquoted for analysis via flow
cytometry or ELISA. For flow cytometry experiments, freshly harvested tissue samples
were minced with scissors in a 40 µm cell strainer and further digested with Collagenase,
Type II. Stock solution (100 U/µL) was diluted in PBS to 200 U/mL and added to the tissue
for 15 minutes. Tissue pieces were pushed through the 40 µm cell strainer using the back
side of a 1 mL syringe plunger. DMEM media containing 10% FBS was added to quench
the enzymatic reaction before spinning down in a centrifuge at 1500 RPM. Cell pellets
were resuspended in FACS buffer (PBS containing 1% bovine serum albumin (BSA)) and
counted. Cells were spun down again and resuspended to a final concentration of 10
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cells/mL in FACS buffer. 100 µL of the cell suspension was added to a U-bottom 96 well
plate. 100 µL of FACS buffer containing 2.5 µg of Fc Block was added to each well and
incubated for 10 minutes at room temperature. The plate was spun down and supernatant
removed before adding mouse anti-human CD45-PE diluted in FACS buffer 1:100.
Samples were incubated for 30 minutes at room temperature in the dark. Samples were
washed 3 times with FACS buffer before being transferred to FACS tubes and analyzed
with a BD LSRFortessa. BD FACSDiva software was used for both collection and analysis.
For human cytokine secretion, retrieved tissues were kept relatively equal in size and cut
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into 1-2 mm pieces using surgical scissors. Conditioned media was prepared 36 hours after
plating in 500 µL of αMEM media supplemented with 1% mouse serum and 1% penicillin
and streptomycin. Conditioned media was used immediately for characterization using
DuoSet® ELISA kits for human TNF-α, IL-6 and IL-10 (R&D Systems)
4.5.8 Orthotopic xenoengraftment of human prostate tumor
Luciferase (Luc) and green fluorescent protein (GFP) transduced PC-3 Human
Prostate Cancer cells were obtained from the Center for Engineering in Medicine,
Massachusetts General Hospital. Luc-GFP PC3 cells were cultured with DMEM
supplemented with 10% FBS and 1% penicillin-streptomycin. Scaffold bearing mice were
anesthetized with 2% isoflurane followed by ventral hair removal with Nair. Skin was
sterilized with 70% isopropyl alcohol prep wipes. Prior to surgery 2 mg meloxicam/kg
mouse weight was subcutaneously injected. A 10 mm vertical incision was made in the
lower abdomen of the mouse. The bladder was externalized through the opening to expose
the prostate. 2 x 106 Luc-GFP PC-3 cells suspended in 50 µL of matrigel were injected to
the prostate using a 27 G needle. The bladder was returned to the intraperitoneal cavity,
the muscle layer was sutured using polyglycolic acid sutures (Henry Schein), and the skin
was clamped with Reflex 7 mm wound clips. Clips were removed after 1 week.
4.5.9 Monitoring human tumor engraftment and metastasis by bioluminescent
imaging
Two weeks after orthotopic injection of Luc-GFP PC3 tumor cells, whole body
bioluminescent imaging was performed to confirm engraftment and metastasis to distant
organs using an IVIS SpectrumCT (Perkin Elmer). Luciferin was prepared by dilution in
PBS to a concentration of 15 mg/mL in PBS. Mice were anesthetized with 2% isoflurane
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and injected intraperitoneally with 10 µL luciferin solution/g of body weight before being
placed in the imaging chamber. Images were taken every 5 minutes until peak values were
achieved. 6 weeks after orthotopic tumor injection, mice were euthanized, and scaffolds
were retrieved and placed in a 48-well plate. Luciferin stock solution was diluted 1:100 in
PBS and 300 µL were loaded into each well. Bioluminescent imaging was performed every
2 minutes until reaching peak values.
4.5.10 Non-invasive long-term monitoring of metastasis in serially transplanted
scaffolds
Metastatic tumor microenvironments primed in primary mice were retrieved and
immediately transplanted to the same anatomical site in naïve male NSG mice 6-12 weeks
of age following the same method as initial scaffold implantation. Wound clips were
removed after 1 week. Whole body bioluminescent imaging was started 4 weeks after serial
transplantation and continued for an additional 6 weeks with measurements taken weekly.
Images were taken every 5 minutes until peak values were achieved.
4.5.11 Scanning electron microscopy imaging
Microfabricated scaffolds coated with type I collagen were fixed with 2%
glutaraldehyde, serially dehydrated with 50, 70, 90, and 100% ethanol and lyophilized
overnight. The prepared dehydrated samples were deposited with a thin gold film using a
sputter-coating machine (208HR, Cressington) and observed using a Zeiss Ultra55 Field
Emission Scanning Electron Microscope.
4.5.12 Immunohistological staining and imaging
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At the end of in vivo experimentation, tissue and scaffold samples were frozen by
embedding tissue in CryomatrixTM and snap-frozen in a metal beaker containing 2methylbutane cooled by dry ice. Frozen samples were sectioned using a Cryostat (NX70).
Scaffolds were cut to 20-25 µm, while native tissue were cut to 10 µm thickness and
attached to ColorMarkTM Plus glass slides. Remaining frozen tissue blocks and sectioned
slides were stored at -80 °C. Frozen tissue was briefly fixed in pre-chilled acetone for 10
minutes. Following 3 wash cycles in 0.05% Tween-20 in PBS (PBST), samples were
outlined with a hydrophobic marker and blocked with 10% goat serum and 1% BSA in
PBST for 2 hours at room temperature. Primary antibodies were added at a dilution ratio
of 1:200 in blocking solution and left overnight in 4 °C. Samples were washed 3 times with
0.05% PBST followed by secondary antibodies at a dilution ratio of 1:200 in blocking
solution and left for 2 hours at room temperature. Samples were washed 3 times with PBST
prior to addition of 1 µg/mL DAPI solution and a cover slide. When required, streptavidin
conjugated Qdot was added to the samples and left for 1 hour prior to the final washing
cycle. 10 µL of 10 ng/µL DAPI solution was added to samples before imaging. Images
were obtained using a Zeiss Cell Observer SD with 10x and 20x objectives. Tiling was
performed with 10% overlap. Human antibodies were validated against relevant mouse
tissue to rule out cross-reactivity (Figure 4.27). For hematoxylin & eosin and trichrome
staining, frozen tissue sections were fixed with 10% neutral buffered formalin for 10
minutes. After washing with DI water, sides were stained with dye solutions following the
protocol provided by the (American Master Tech).
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Figure 4.27. IHS of hVimentin, hC45, and hCytokeratin against relevant mouse tissue
to rule out cross-reactivity.

4.5.13 Optical tissue clearing and complete optical sectioning of the scaffolds
Mice were transcardially perfused with 20 mL of ice cold PBS followed by 20 mL
of ice cold monomer solution containing 4% acrylamide, 0.05% bis-acrylamide, 0.25%
VA-044 (thermal initiator) and 4% paraformaldehyde in PBS. Tissue samples were
collected and incubated in fresh monomer solution at 4 °C for 48 hours. Air in the tubes
was replaced with nitrogen gas prior to incubation at 37 °C for 3-4 hours to polymerize the
monomer solution. Excess polymer was removed and samples were left in either PBS or
tissue clearing solution (4% SDS, 200 mM boric acid, pH 8.5). Scaffold samples required
thick sectioning to achieve whole tissue imaging. Samples were frozen in CryomatrixTM
and cut to a thickness of 250 µm with a cryostat for a total of 4 slices per scaffold. Sections
were washed thoroughly in 0.1 vol% Triton X-100 in PBS prior to antibody staining. All
of the staining procedures were performed at room temperature. Samples were blocked
with 10% normal goat serum (NGS) and 1% BSA in PBST overnight. Samples were
incubated for 36 hours in primary antibody solution containing chicken anti-human
cytokeratin and rabbit anti-mouse smooth muscle actin diluted 1:200 in blocking solution.
Samples were washed thoroughly with Triton X-100 PBS for 24 hours. Samples were
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incubated in secondary antibody solution containing goat anti-chicken Alexa Fluor 647 and
goat anti-rabbit Alexa Fluor 568 diluted 1:200 in blocking solution for 36 hours. Samples
were washed thoroughly with Triton X-100 PBS before imaging. Refractive index
matching solutions did not enhance scaffold imaging depth, so samples were imaged in
PBS. Samples were transferred to a glass slide with silicone isolators and covered with a
cover slip. Whole tissue Z-stack images were taken with a Zeiss Cell Observer SD with a
10x objective at a 10 µm z-step. Optical slices were observed and compiled in ImageJ.
Single cells and tumor colonies were manually counted and concentric circles were drawn
as previously described. Nikon Elements AR v4.5 was used for 3D rendering and creation
of videos. The videos were annotated in Adobe Premiere Pro CC 2014 and encoded in
Adobe Media Encoder CC 2014.
4.5.14 Image analysis
For characterization of mCD31 and hVimentin distribution in 4-week in vivo
scaffolds, concentric circles were drawn in ImageJ. Three circles were drawn with 1/3 RTotal (Total Radius), 2/3 R-Total and R-Total. Background signal of each individual
channel were removed before measuring the pixel density. Values were normalized by the
zone area and the signal measured from the entire scaffold to generate a relative distribution
across the scaffold. The same analysis was performed for hCD45 distribution in hPBMC
injected mice 6 weeks after intravenous injection. Percent coverage analysis (mCD31,
hCD44, hCD45, Ki67, and mLy6G) was calculated by measuring the overlap between
positive signal and the total area of the appropriate tissue (entire scaffold, hCytokeratin, or
mLy6G+).
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For in depth characterization of the local tumor microenvironment, single cell and
tumor colonies were manually identified by examining tiled images of stained tissue
sections. Nearest vessel, vessel diameter, tumor colony diameter, and nearest cell distance
were measured in ImageJ for all of the identified tumor cells. Data was binned to generate
histograms.
4.5.15 Multiple antibody staining of overt metastatic tumor bearing scaffold
8 consecutive tissue slices, each 20 µm thick, from a single scaffold were stained
with multiple combinations of antibodies, for a total of 11 different stains. All of the images
were aligned in ImageJ. Images were then divided into a grid of 24x24 images, thresholded
and pixel density was measured for each channel. Total tissue area was determined by
setting a low threshold to include background signal. Values from each individual channel
were normalized by total tissue area within each and plotted in a 24x24 heatmap. 10 color
images were generated by combining images from different staining combinations. From
these composite images, regions of interest were manually determined to highlight
heterogeneity. Regions of interest were translated to the 24x24 heatmaps and pixel density
was recalculated for the 8 zones. Pixel densities from each of the zones of interest were
normalized to the maximum value from the 8 zones. Channels that had more than one
replicate were averaged together before plotting on a radar chart. Cellular composition
within each zone was achieved by normalizing the absolute pixel count of each channel by
the total pixel count of the zone.
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4.5.16 Statistics
Unpaired Student’s t tests were performed for comparison of the mean values
between two groups. Statistical significance was determined if p<0.05 for two-tailed
analysis. All quantitative data represent mean and standard deviation.
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CHAPTER 5
INVESTIGATION OF THERAPY-INDUCED METASTATIC RELAPSE VIA
ENGINEERED DISSEAMINTED TUMOR CELL NICHES

5.1 Abstract
The treatment of most primary tumor types has greatly improved, however metastatic
disease remains a substantial clinical hurdle. Disseminated tumor cells (DTCs) are
impractical to detect in patients and can develop resistance to treatment options that
successfully treated the primary tumor. It is widely accepted that DTCs undergo periods of
dormancy that can last years to decades after primary tumor treatment. However, several
clinical and preclinical studies have shown greatly accelerated metastatic recurrence after
the administration of chemotherapy and surgical intervention. The direct causes of
metastatic relapse remain largely unknown and represent a critical gap in understanding to
produce effective treatments. Here we present a biomaterial scaffold driven in vivo model
to understand the implications current treatment strategies have on DTCs and their local
microenvironment. Tissue engineering approaches have been shown to enable the longterm observation of non-metastatic DTCs and provide high analytical assessment of the
cellular and molecular factors that drive metastatic relapse. Investigation of implantable
niches shortly after an adjuvant chemotherapy regimen suggested that DTCs were
eradicated in 50% of treated samples, however long-term analysis revealed all niches had
undergone relapse to the same degree as non-treated implants. Secretome analysis of the
scaffold tissue revealed significant increases in SDF-1 and leptin, and decreases in
proMMP9, MMP8, VEGF, IP-10, IL-10, IL-15, and IFNy following chemotherapy. Direct
surgical manipulation of long-term dormant niches revealed a significant increase in tumor
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burden and an increase in angiogenic and inflammatory cell recruitment. These results
demonstrate the translational potential of implantable niches to uncover mechanisms of
DTC activation in a clinically relevant manner.

5.2 Introduction
Although primary tumor treatments have improved, the overall five-year survival
rate for patients diagnosed with cancer remains under 70%. The main cause of this is the
dissemination of tumor cells to distant tissues and the eventual relapse into metastatic
disease. Treatment of the metastatic disease is challenging due to several factors. First,
metastatic disease can be asymptomatic and is usually detected late into tumor progression.
Second, disseminated tumor cells (DTCs) can develop new mutations and interact with
different stromal cell populations that may aid in resistance to therapies. Third, metastatic
tumors generally proliferate in organs vital to survival, specifically the lung, liver, bone,
and brain. A better understanding of DTC biology is needed to create effective treatments
against metastasis.
Chemotherapeutic agents have been used for the last few decades with successful
application across several tumor types. Chemotherapies aim to interfere with the
proliferation pathways of cancer cells. Following tumor removal, adjuvant chemotherapy
may be administered with the goal of removing residual tumor cells. The ability to monitor
the success or failure of these therapies is difficult in patients. Clinical studies examining
the efficacy of adjuvant therapies tend to demonstrate marginal increases in reducing
remission and prolonging survival266-267. The nature of chemotherapies is not tumor
specific, and the systemic delivery of these drugs yields several off-target effects268-270. A
recent study demonstrated that administration of chemotherapeutic agents in a neoadjuvant
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regimen mobilized bone marrow derived cells and increased angiogenesis leading to tumor
regrowth and relapse271. The local microenvironment has been shown to plays a critical
role in regulating chemosensitivity during adjuvant therapy and can be targeted to improve
treatment effectiveness272. These provocative findings have led to the questioning of
adjuvant and neoadjuvant therapies and their potential negative responses in accelerating
metastatic relapse.
Metastatic recurrence is commonly observed shortly after the surgical removal of
the primary tumor. The act of surgery triggers a wound healing response that can activate
systemic inflammation, and in turn awaken dormant DTCs in distant tissues. A recent study
has demonstrated that surgery can lead to the outgrowth of immunologically restricted
tumors by increasing circulating neutrophils and inflammatory monocytes through IL-6,
G-CSF, and CCL2 signaling. The increased monocyte activity was shown to directly
counter T cell-mediated growth restriction of the tumor273. Additional evidence suggests
that primary tumors themselves may prevent metastatic relapse by releasing systemic
factors106. Although these studies provide mechanisms of escape for larger tumor colonies,
it is unclear how surgery or the wound response to surgery may aid in changing the
phenotype of DTCs that are actively dormant.
Chemotherapy and surgery provide substantial clinical benefits, however they both
induce systemic immune responses that may trigger metastatic relapse. Specifically, we
hypothesized that these treatments stimulate systemic inflammatory pathways and cause
dormant DTC niches to undergo tissue remodeling and trigger metastatic relapse. Mouse
models that are capable of investigating DTC dormancy generally utilize specialized cell
lines that may misrepresent patient phenomenon. We have recently developed a tissue-
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engineered metastasis model using micro-fabricated porous hydrogel scaffolds
subdermally implanted into mice. The scaffold induces the formation of vascularized tissue
microenvironments that recruit bone marrow-derived cells, an emulating key feature of the
premetastatic niche. Circulating tumor cells are attracted to the implants and DTC niches
can be retrieved intact and re-implanted to a secondary tumor-free mouse enabling the
observation of the full spectrum of the metastatic cascade from single DTCs to a fully
metastasized tumor. Isolation of the DTC niche provides high experimental control without
confounding factors such as multiple metastases or diminishing health of the host. The
standardized 3D structure and synthetic hydrogel impart high analytical power when
combined with conventional immunohistostaining and recently introduced tissue-clearing
techniques for whole tissue imaging. Here we use this biomaterial approach to investigate
the impact of adjuvant chemotherapy and local surgery on long-term dormant DTCs.

5.3 Results
5.3.1 Circulating tumor cells from an orthotopic MMTV-PyMT transplant model
home to implantable biomaterial niches
Four

ICC

hydrogel

scaffolds

were

implanted

subcutaneously

into

immunocompetent FVB mice to begin niche tissue development. Two weeks later a
fragment of syngeneic MMTV-PyMT breast tumor was orthotopically transplanted into
the mammary fat pad. This approach was taken to increase the experimental throughput,
as one MMTV-PyMT primary tumor could be split into 15-20 pieces (Figure 5.1A). The
primary tumor was grown until a critical size of 1,000 mm3 was reached. Only tumors that
achieved this size within 10 weeks of implantation (82.1%) were considered for further
experiments (Figure 5.1B). Scaffolds were removed and analyzed for the presence of
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DTCs. Immunohistostaining revealed 100% of scaffolds were positive for DTCs, however
colony development was rare at the time of sacrifice (Figure 5.1C). These results suggest
implantable scaffold niches retain their tumor cell capture abilities in fully
immunocompetent syngeneic tumor models.

Figure 5.1. Orthotopic MMTV-PyMT tumor transplant model generates DTCs in
implantable niches.
a, Experimental schematic of scaffold implantation and orthotopic breast tumor
generation. b, Orthotopic primary tumor growth kinetics and engraftment efficiency. c,
Immunohistostaining revealed all scaffold niches contained DTCs.
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5.3.2 Adjuvant chemotherapy reduces initial DTC burden but does not prevent
relapse
DTC-containing scaffolds were transplanted to secondary tumor-free FVB hosts to
prolong the observation window of cancer cell progression. One week after transplantation,
adjuvant chemotherapy, consisting of doxorubicin and cyclophosphamide, or PBS was
administered intraperitoneally once a week for three weeks (Figure 5.2A). Twenty-four
hours after the final dose of chemotherapy scaffolds were removed from mice to assess the
short-term results of therapy. Microscopic analysis of the scaffolds revealed the presence
of single DTCs and early stage colonies in both experimental groups (Figure 5.2B).
Quantification of DTCs in the scaffolds revealed a significant decrease in cancer cells in
mice given chemotherapy (Figure 5.2C). Additionally, 50% of chemotherapy-treated
scaffolds did not contain any DTCs.
A separate group of mice were sacrificed 10 weeks after the final dose of
chemotherapy to assess long-term impact of adjuvant therapy on DTCs. Surprisingly all
analyzed scaffolds contained an increased tumor burden regardless of treatment (Figure
5.2D). Quantification revealed no significant difference between the final tumor burden
observed in the scaffolds after the 10 week period (Figure 5.2E).
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Figure 5.2. Short and long-term effects of adjuvant chemotherapy in transplantable
niche model.
a, Experimental schematic to investigate the role of adjuvant chemotherapy on DTC
niches. b, Immunohistostaining of samples retrieved 24 hours after the final dose of
adjuvant chemotherapy. c, Quantitative image analysis of DTCs in scaffolds retrieved 24
hours after the final dose of adjuvant chemotherapy. d, Immunohistostaining of samples
after long-term, 10 week, observation. e, Quantitative analysis of total tumor positive area
in long-term samples. (*P<0.05)
5.3.3 Chemotherapy alters soluble factors in local microenvironment
Next, we assessed changes to the soluble microenvironments within the scaffolds
following chemotherapy. Four scaffolds were subcutaneously implanted into FVB mice
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and left for three weeks before starting chemotherapy. Twenty-four hours after the final
dose of chemotherapy scaffolds were harvested and cultured ex vivo for 36 hours (Figure
5.3A). Conditioned media was analyzed with a panel of 45 cytokines (Figure 5.3B).
Secretion of SDF-1 and leptin were significantly increased, while proMMP-9, MMP-8,
VEGF, IP-10, IL-15, IL-10, and IFNγ were significantly decreased (Figure 5.3C). SDF-1
is a ligand connected to immune cell homing. Leptin has been implicated as leading to
chronic inflammation and a pro-tumor factor. The decreases observed appear likely due to
a decrease in immunogenic activity within the scaffold niche due to therapy. The change
in soluble factors may lead to altered immune cell homing and trigger rapid tissue
remodeling once the effects of chemotherapy subside.

Figure 5.3. Secretome analysis of implantable niche tissue following chemotherapy.
a, Experimental schematic of procedure to generate conditioned media for multiplex
secretome analysis. b, Secretion profile of scaffold niches from mice without and with
chemotherapy. c, Subset of cytokines that displayed significant up- or downregulation
following therapy compared to control.
5.3.4 Local surgical intervention increases tumor growth
Surgical intervention was modeled by performing a 4mm biopsy in the center of
the implant tissue and replacing it with an empty ICC hydrogel scaffold. Long-term DTC
niches were generated using the transplantation strategy described above, however
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scaffolds were untreated and left for 15 weeks prior to intervention (Figure 5.4A). Two of
the four scaffolds underwent biopsy surgery and the remaining two remained untouched
(Figure 5.4B). Five weeks after the surgery scaffolds were explanted and analyzed via
immunohistostaining (Figure 5.4C and 5.4D). Tumor burden was over three-fold higher
in scaffolds that underwent surgical intervention (Figure 5.4E). Characterization of the
local microenvironment revealed increases in vasculature (CD31), leptin, MMP9 and
Ly6G in the surgically activated scaffolds (Figure 5.4F). Analysis on the biopsy samples
was performed on the original tissue area and did not include the area accounting for the
newly implanted scaffold. Collectively these results indicate that local surgical intervention
significantly increased tissue remodeling and tumor burden from DTCs.

Figure 5.4. Surgical intervention of long-term DTC niches.
a, Experimental schematic of procedure to generate controlled surgical disruption using a
4 mm biopsy punch. b, Gross images of surgical procedure and explanted scaffolds 5
weeks after surgery. c, Immunohistostaining of long-term control DTC niches.
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d, Immunohistostaining of samples that received surgical intervention. e, Quantitative
analysis of PyMT+ tumor burden in scaffolds without and with surgery. f, Quantitative
image analysis of tissue nice components found in the original scaffold area. (*P<0.05)
5.4 Discussion
The observation that metastatic relapse can occur years after the removal of primary
tumors has provoked extensive research into the understanding of DTC biology. Multiple
efforts have been made to uncover pathways that enabled DTCs to escape a quiescent state
and proliferate into a metastatic tumor. However, this is a challenging phenomenon to
model and reproduce consistently in traditional mouse models. Here we provide evidence
that implantable scaffold niches can reduce this gap and enable the long-term analysis of
DTCs. Transplantation of scaffold niches housing DTCs to tumor-free mice enables
complete isolation of the microenvironment with the added benefit of niche control via
tissue engineering principles. In this study we have applied two stimuli to the niches,
adjuvant chemotherapy and surgery, to provide mechanistic insight toward metastatic
relapse. Although adjuvant chemotherapy showed promise in removing DTCs in the shortterm, long-term observation following the end of adjuvant therapy suggests a substantial
number of DTCs were able to survive and proliferate. In modeling local tissue surgical
intervention, we demonstrated a robust increase in tumor growth in the surrounding tissue
via activation of inflammatory signaling.
Adjuvant chemotherapy given after the resection of a primary tumor is a common
strategy to remove residual DTCs. These methods have recently come under question as
treatment is ultimately unsuccessful over time274. Chemotherapy by nature of the drug
mechanism of action relies on interfering with the proliferative state of the tumor cells.
Most DTCs are believed to be held in a dormant state making these therapies only effective
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once they start growing. However, evidence has been provided that demonstrates
chemotherapy can have negative side-effects such as increased remodeling and
inflammation271. Secretome analysis performed on scaffold microenvironments confirmed
the upregulation of SDF-1 and leptin following chemotherapy. Both molecules have been
implicated as pro-tumor and may accelerate metastatic relapse275-276. The local
microenvironment is believed to be a key regulator in maintenance of DTC dormancy, and
disruption may have unexpected effects107,

272, 277

. Short- and long-term histological

characterization following chemotherapy may provide clues as to how the niche evolves
over time with and without therapy. However, it may be challenging to capture key
biological events without increasing the sampling rate following the end of therapeutic
intervention. The heterogeneous makeup of tumor cells can also lead to drug resistance as
tumor cells can gain resistance to therapy once disseminated278. The findings in this study
confirm the notion that adjuvant chemotherapy is not effective in the prevention of longterm DTC relapse. However, additional factors such as increasing the length of treatment
may yield significant decreases in relapse. An additional aspect that remains unexplored is
the cyclical nature of adjuvant therapy and the associated fluctuations of immune cell
populations. Myeloid and myeloid precursor cells are dramatically reduced during
chemotherapy. Interestingly, the onset of neutropenia after therapy is correlated with
antitumor efficacy and good patient prognosis279. A recent study has shown that repeated
dosing of inflammatory lipopolysaccharide was necessary to aggressively reactivate DTCs
in the lung251. Understanding how the body changes on a systemic level after subsequent
doses of chemotherapy may unveil new drivers of metastatic relapse107.
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Clinical observation of patients after tumor resection has revealed a sharp increase
in risk of metastatic recurrence shortly after surgery280. This early spike in relapse appears
to undermine the concept of DTC dormancy, yet the act of surgery provokes wound healing
responses that may reactivate DTCs. This notion is confirmed by patients that undergo
elective surgeries and an observed increase in metastatic relapse281-282. Aside from surgery,
reports that the primary tumor can maintain dormancy have also been made106. A recent
study however has shown that surgical wounding can disrupt immunologically regulated
tumor dormancy by altering systemic immune cell responses273. Here we demonstrate local
metastatic relapse due to proinflammatory signaling due to surgery including increased
vascular density, leptin, MMP9 and Ly6G. Additional work is necessary to validate the
role of the increased soluble factors. Due to the broad nature of the response stemming
from tissue remodeling, targeting these factors with pan anti-inflammatory molecules may
reduce metastatic spread. In addition to systemic administration of anti-inflammatory
molecules, replacement scaffold inserts can be loaded with drug to increase the effect on
the local tissue.
Additional questions regarding DTCs and potential mechanisms that activate
relapse remain. For example, the effect of aging and senescence of local tissue cells and
hematopoietic cells has not been fully explored. New therapeutic approaches to combat
relapse have been made but will require further investigation before application in patients.
Antibodies have been developed against remodeled laminin to prevent α3β1 integrin
signaling and DTC proliferation107. Direct blocking of integrin function has also achieved
better adjuvant chemotherapy results272. Previously we used ICC hydrogel scaffolds to
demonstrate the modulation of inflammatory signaling with an IL-1 antagonist altered the
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fate of DTCs within the niche96. In addition to understanding fundamental mechanisms,
the standardized tissue-engineered metastasis model presented in this study provides a
unique opportunity to screen anti-metastatic drug candidates. We believe implantable DTC
microenvironments will serve as an indispensable tool across several aspects of metastatic
relapse.

5.5 Materials and Methods
All chemicals and materials were purchased from Sigma Aldrich or Fisher
Scientific unless specified. All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts-Amherst.
5.5.1 Porous hydrogel scaffold fabrication
ICC hydrogel scaffolds were fabricated using soda lime glass beads with sizes
ranging from 250 µm to 300 µm as previously described101. The polyacrylamide hydrogel
was made from a precursor solution composed of 30 wt% acrylamide monomer, 1.5 wt%
bis-acrylamide crosslinker, 0.2 vol% N,N,N’,N’-tetramethylethylenediamine accelerator,
and 0.2 vol% 2-hydroxy-2-methylpropiophenone photoinitiator in nitrogen purged DI
water. The solution was polymerized under an ultraviolet light. Beads were removed with
alternating acid washes of hydrofluoric and hydrochloric acid. Scaffolds were thoroughly
washed with DI water to remove residual acid and lyophilized. Scaffolds were sterilized
with 70% ethanol before they were surface treated with Sulpho-SANPAH to covalently
crosslink rat-tail collagen. Scaffolds were stored at 4 °C in sterile phosphate buffered
saline.
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5.5.2 Mouse colony
MMTV-PyMT mice on the FVB/N background (002374 bred in house from a
colony initially obtained from the Jackson Laboratory. Wild type FVB/N were acquired
from MMTV-PyMT breeding. Mice were housed in sterile conditions with unrestricted
access to food and water.
5.5.3 Orthotopic MMTV-PyMT tumor model implantation of scaffolds
FVB mice at an age between 6 and 12 weeks old were implanted with four scaffolds
subcutaneously. Mice were anesthetized with 1.5% isoflurane before removing the dorsal
hair with electric clippers and Nair. The skin was sterilized using 70% isopropyl alcohol
prep wipes. Mice received 2 mg meloxicam/kg mouse weight subcutaneously prior to
surgery. A subcutaneous pocket was formed and implanted with an ICC hydrogel scaffold.
The incisions with Reflex 7 mm wound clips. Two weeks after scaffold implantation mice
were given a fragment of primary tumor from an MMTV-PyMT mouse. Large tumors were
retrieved from 8 to 12 week old MMTV-PyMT mice and chopped into 2-3 mm pieces using
a scalpel. Tumor fragments were immediately implanted into a subcutaneous pocket
located at the right abdominal mammary gland. Incisions were closed with wound clips.
Tumor measurements were taken weekly using digital calipers and volume was calculated
using the formula V = (Width2 x Length)/2. Once the primary tumor reached 1,000 mm3
scaffolds were harvested for immunohistostaining or orthotopically transplanted to
secondary FVB mice. Transplantation surgery was the same as initial implantation of the
scaffold.
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5.5.4 Adjuvant chemotherapy regimen
Doxorubicin was dissolved in phosphate buffered saline to a final concentration of
0.2 mg/mL. Cyclophosphamide was dissolved in 0.9% NaCl to a final concentration of 12
mg/mL. Drug solutions were stored at -80 °C. One week after transplantation mice received
intraperitoneal doses of doxorubicin (2 mg/kg) and cyclophosphamide (60 mg/kg) once a
week for three weeks.
5.5.5 Multiplex soluble factor analysis
FVB mice were implanted with four scaffolds subcutaneously as described above.
Three weeks after implantation, mice received the adjuvant chemotherapy regimen.
Twenty-four hours after the final dose scaffolds were harvested and cultured ex vivo in
serum-free alpha-Modified Eagle Medium supplemented with 1% penicillin-streptomycin.
Conditioned media was harvested thirty-six hours later and stored at -80 °C. Samples were
shipped on dry ice to Eve Technologies for multiplex cytokine analysis (MD31, MAGP08-107, and MMO-C,O).
5.5.6 Surgical intervention of DTC niches
Fifteen weeks after transplantation DTC niches were subjected to surgical
disruption. An incision was made close to the implant and the connective tissue was broken
on the muscle side of the implant. The scaffold was carefully exposed through the incision
and a 4 mm biopsy punch was used to remove the central region of the implant. A new 4
mm ICC hydrogel scaffold was placed in the void and the scaffold was carefully returned
to its original location. The incision was closed with wound clips.
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5.5.7 Frozen tissue preparation and sectioning
At the conclusion of the in vivo experiment, implants were frozen by embedding
the tissue in Cryomatrix TM and snap-frozen in 2-methylbutane cooled on dry ice. Frozen
tissue was cut to 20 µm using a NX70 Cryostat. Frozen tissue blocks and sectioned slides
were stored at -80 °C.
5.5.8 Immunohistostaining
Frozen slides were fixed in -20 °C acetone for 10 minutes. Slides were washed with
PBST solution 3 times before blocking in a solution containing 10% normal goat serum,
and 1% bovine serum albumin for 1 hour. Following blocking primary antibodies diluted
in blocking solution were added to the slides and left in a humidified chamber overnight at
4 °C. Slides were washed 3 times with PBST and then incubated with secondary antibodies
diluted in blocking solution for 2 hours at room temperature. Prior to imaging, slides were
washed 3 times in PBST and stained with a 10 ng/uL solution of DAPI. Fluorescent images
were taken on a Zeiss Cell Observer SD. PyMT (ab15085), Ki67 (ab16667) Α-smooth
muscle actin (ab5694), CD31 (550274), Leptin (PA1-052), MMP9 (PA513199), and Ly6G
(557445) primary antibodies. Anti-rabbit Alexa Fluor Plus 488 (A32731), and anti-rat
Alexa Fluor 647 (A21247) secondary antibodies were used in this study.
5.5.9 Image analysis
All image processing and quantitative analysis was performed in ImageJ. Total
tissue area was determined using the DAPI image for all relevant analysis. DTC counts
were tabulated by assuming small colonies were formed from a single DTC.
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5.5.10 Statistics
Unpaired Student’s t tests were performed for comparison of the mean values
between two groups. Statistical significance was determined if p<0.05 for two-tailed
analysis. All quantitative data represent mean and standard deviation.
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CHAPTER 6
FABRICATION OF BIOACTIVE INVERTED COLLOIDAL CRYSTAL
SCAFFOLDS USING EXPANDED POLYSTYRENE BEADS

Adapted with permission from Ryan Carpenter, Dalton Macres, Jun-Goo Kwak, Katherine
Daniel, and Jungwoo Lee. Tissue Engineering Part C: Methods. 2020. DOI:
10.1089/ten.TEC.2019.0333. Copyright 2020 Mary Ann Liebert, Inc.

6.1 Abstract
Inverted colloidal crystal (ICC) hydrogel scaffolds have emerged as a new class of 3D cell
culture matrix that represents a unique opportunity to reproduce lymphoid tissue
microenvironments. ICC geometry promotes the formation of stromal cell networks and
their interaction with hematopoietic cells, a core cellular process in lymphoid tissues. When
subdermally implanted, ICC hydrogel scaffolds direct unique foreign body responses to
form a vascularized stromal tissue with prolonged attraction of hematopoietic cells, which
together resemble lymphoid tissue microenvironments. While conceptually simple,
fabrication of ICC hydrogel scaffold requires multiple steps and laborious handling of
delicate materials. Here, we introduce a facile route for ICC hydrogel scaffold fabrication
using expanded polystyrene (EPS) beads making the process cheaper, faster, and safer.
EPS beads shrink and fuse in a tunable manner under pressurized thermal conditions, which
serves as colloidal crystal templates for ICC scaffold fabrication. Inclusion of collagen in
the precursor solution greatly simplified preparation of bioactive hydrogel scaffolds. The
resultant EPS-templated bioactive ICC hydrogel scaffolds demonstrate characteristic
features required for lymphoid tissue modeling in both in vitro and in vivo settings. We
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envision that the presented method will facilitate widespread implementation of ICC
hydrogel scaffolds for lymphoid tissue engineering and other emerging applications.

6.2 Introduction
Three-dimensional (3D) cell culture matrices also known as scaffolds are an
essential component of tissue engineering that provide the biophysical framework and
biochemical complexity to reproduce essential tissue structure and function160. As each
tissue represents different cellular and extracellular matrix (ECM) composition and
organization, biomaterial selection and structural design of scaffolds have been specialized
to reproduce key cellular processes in target tissues283-285. Inverted colloidal crystal (ICC)
hydrogel

scaffolds

have

been

developed

to

reproduce

lymphoid

tissue

microenvironments286-288. ICC geometry consisting of fully interconnected spherical pore
arrays provides a large surface area for adherent stromal cells and the formation of an
intricate stromal network289. Spherical cavities connected via small channels transiently
entrap hematopoietic cells and facilitate their intimate interactions with stromal cells290,
which is a core cellular process in lymphoid tissues. ICC hydrogel scaffolds have
demonstrated biological significance in simulating bone marrow291-292, thymus293 and
lymph nodes214 in vitro. When subdermally implanted in mouse models, ICC hydrogel
scaffolds rapidly induced interscaffold vascularization and attract local and systemic
hematopoietic cells97, 101, 294, which together function as a lymphoid tissue analogue.
The fabrication of ICC scaffolds involves four steps: (i) preparation of colloidal
crystal templates via partial fusion of microspheres with narrow size distribution, (ii)
infiltration of a hydrogel precursor solution and subsequent polymerization, (iii) selective
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removal of the template microbeads, and (iv) if necessary, modification of the pore surface
to support stromal cell adhesion295 (Figure 6.1A). The most critical consideration is the
selection of template bead material as it determines the possible range of pore sizes and
conditions for template preparation and dissociation. Current ICC scaffold fabrication can
be categorized into five groups based on template materials (Figure 6.2B). The first group
is solid polymeric beads synthesized by emulsion polymerization including
poly(methylmethacrylate) (PMMA) and polystyrene (PS) 291, 293, 296-301. ICC geometry was
initially developed for nanostructured photonic crystal materials using submicron PMMA
and PS beads. By increasing the bead size, ICC structures can be utilized for 3D cell culture
experiments. While PMMA and PS beads are commercially available, they are expensive
and limited in size selection, with an upper limit of 160 µm due to the decreasing stability
of emulsions with increasing size. Addition of crosslinkers allows synthesis of larger beads,
but cross-linked beads cannot be dissolved. The second group is polymeric beads prepared
by solvent evaporation from emulsion droplets including polycaprolactone (PCL)302.
Polymers dissolved in organic solvents are microfluidically processed into uniform size
emulsion droplets that in turn solidify as the solvent evaporates303. This method increases
template bead sizes in a cost-effective manner, but the resultant polymeric beads exhibit a
narrow window for thermal and mechanical stability, requiring exceptional care to process
into colloidal crystal templates and ICC scaffold fabrication. The third group is hydrogel
beads generated by in situ gelation including alginate and gelatin. Formation and
dissociation of alginate beads are exploited by ionic cross-linking and a chelating agent,
ethylenediaminetetraacetic acid, respectively304-305. Synthesis and solubilization of gelatin
beads take advantage of their temperature-dependent reversible sol-gel transition306-309.
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Although hydrogel beads made from biocompatible materials are removable without using
toxic chemicals, their weak mechanical properties make them difficult to process and
handle. The fourth group is microbubbles including air and nitrogen gases310-313.
Microbubbles suspended in a precursor solution generated by a flow-focusing microfluidic
device are collected in a confined container and solidified under negative pressure, which
opens the closed pores and enables formation of an open porous ICC structure. This method
is simple, fast, and essentially non-toxic, but requires significant optimization due to the
intrinsic instability of the microbubbles. The last group is glass beads. Glass beads are
commercially available with a broad range of sizes and represents high thermal and
mechanical stability that facilitates streamlined fabrication of ICC hydrogel scaffolds96-97,
101, 134, 314-316

. However, requirement of toxic chemicals (i.e. hydrofluoric acid) to dissolve

the glass beads has been a critical issue. Currently there exists no practical and costeffective method to produce ICC hydrogel scaffolds at high scale under good
manufacturing practices. The development of a better fabrication method remains an active
area of research.
Here, we introduce a simple and robust method to fabricate bioactive ICC hydrogel
scaffolds using expanded polystyrene (EPS) beads, the raw material commonly used for
packaging and insulation products. EPS beads are a closed cell foam material composed of
95-98% air, with robust mechanical and thermal stability317. We have developed a method
to shrink and fuse EPS beads into a free-standing construct that functions as a colloidal
crystal template for fabrication of ICC hydrogel scaffolds. Pore size is tunable by adjusting
the degree of EPS bead shrinkage. Surface modification for bioactive ICC hydrogel
scaffolds was simplified by introducing collagen fibers into the hydrogel precursor solution
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and polymerizing in a single step. The biological significance of EPS-templated ICC
hydrogel scaffolds was demonstrated in vitro via conducting a hematopoietic colonyfoaming assay in the presence of bone marrow stromal cells (BMSCs). The ability to form
vascularized tissue and attract hematopoietic cells after subdermal implantation was
comparatively demonstrated using glass bead-templated ICC hydrogel scaffolds. We
envision that this simple and cost-effective fabrication strategy will facilitate usage of ICC
hydrogel scaffolds for lymphoid tissue modeling and other emerging novel biological
applications.

Figure 6.1. Summary of the state-of-the-art inverted colloidal crystal hydrogel
scaffold fabrication methods.
(A) Schematic illustration of the procedure to fabricate bioactive inverted colloidal crystal
hydrogel scaffolds starting from microbead-based colloidal crystal templates. (B) The
fabrication of ICC hydrogel scaffolds can be divided into five groups based on microbead
materials used for template preparation. (THF: tetrahydrofuran, DCM: dichloromethane)
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6.3 Results
6.3.1 Preparation of colloidal crystal templates using expanded polystyrene (EPS)
beads
For some polystyrene foam products, EPS beads are subjected to steamed
mechanical compression to make a densely packed foam structure without interstitial
space. We hypothesized that EPS beads with increased interstitial space could serve as
colloidal crystal templates for ICC hydrogel scaffold fabrication. To test this hypothesis,
we used a pressure cooker to apply vapor phase water and ethanol solutions to EPS beads
without mechanical compression (Figure 6.2A). Water and ethanol were used as the source
of vapor because they are cheap and relatively safe for scaled operation. EPS beads
(diameters = 1.6 ± 0.19 mm) were placed in a perforated metal container and processed in
an electric pressure cooker for 5, 10, 15, and 30 min. The perforated metal container was
elevated to prevent contact with the liquid phase at the bottom of the cooker. Electronic
pressure cookers are regulated by a pressure setpoint. On the Chefman unit used for these
experiments a gauge pressure of roughly 0.5-0.7 bar is achieved during operation.
Evaluation of the vapor pressure as a function of temperature reveals that the chamber
reaches a temperature of 110-114 °F with water compared to 89-93 °C with pure ethanol.
Pressurized thermal conditions directed shrinkage and fusion of EPS beads to create a freestanding colloidal crystal-like structure. The shape of the template remained identical,
indicating isotropic shrinkage of EPS beads (Figure 6.2B). In pure ethanol, beads
underwent rapid and uneven size reduction, evident by a wider base compared to top. The
overall size reduction was directly correlated to operation time for all ethanol:water
solutions. Increasing ethanol concentration was observed to increase the degree of
shrinkage. Interestingly a 50:50 mixture had less shrinking ability compared to pure water.
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Size reduction was greatest at early timepoints and the rate of reduction gradually slowed
down over time (Figure 6.2C).
We next characterized the size and shape change of the individual EPS beads under
optical microscopy. Increasing operation time and ethanol concentration reduced the size
of EPS beads in an isotropic manner. The interface between the fused beads exhibited
elongated necking. In the pure ethanol condition, uneven shrinkage of templates caused
different size reduction of EPS beads between the top and bottom surface; EPS beads in
the top side showed densely fused morphology whereas EPS beads in the bottom showed
significantly elongated necks (Figure 6.2D). The dynamic shrinking of porous EPS beads
during bead-bead fusion presents a significantly different annealing process. We further
conducted micro-CT scans to visualize the internal packing structure and quantify the
interstitial area. While EPS beads have regular sphericity and about 10 % of size
distribution, their packing density was lower compared to solid beads and microbubbles.
The characteristic interstitial area was about 26.2 % (Figure 6.2E). Quantitative analysis
of EPS beads substantiated rapid and significant reduction of size with increasing
concentrations of ethanol and time (Figure 6.2F).
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Figure 6.2. Preparation of colloidal crystal templates using expanded polystyrene
(EPS) beads.
(A) Gross image of EPS beads in a perforated metal container (Left) and schematic of
experimental set-up and process to fuse EPS beads using a pressure cooker (Right). (B)
Images of free-standing fused EPS beads after a pressurized thermal process in 5 different
ethanol solutions and 4 operating times. Zoomed-in images of side view show nonisotropic size reduction of EPS beads processed with pure ethanol. (C) Quantitative
analysis of overall template diameters (n=4, * P<0.05). (D) Microscopy images of fused
EPS beads after 15 minutes of operation in varying compositions of ethanol solution. (E)
3D reconstruction of micro-CT scanned EPS bead-templated colloidal crystal structure and
quantitative measurement of interstitial area (n=5). (F) Quantitative analysis of shrunken
EPS bead diameters. Due to anisotropic shrinkage of templates, top and bottom side
templates exhibit different size reduction (n=75-100, * P<0.05).
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6.3.2 Fabrication of ICC hydrogel scaffolds using EPS bead-based templates
Complete infiltration of hydrogel precursor solution into the interstitial space of
colloidal crystal templates requires centrifugation, and the templates should endure the
gravitational force. Two critical considerations in using EPS bead-based colloidal crystal
templates include flotation of the structure and insufficient mechanical stability. We
addressed the flotation issue with a laser-cut acrylic structure designed to fit a standard 50
mL centrifuge tube, consisting of thin rings that support a disk with holes which are then
held down with long bracing pieces that become wedged once the cap is screwed on
(Figure 6.3A). In this study, we used a hydrogel precursor solution composed of
acrylamide monomer and bis-arylamide crosslinker activated by ammonium persulfate and
TEMED. After overnight polymerization at room temperature, the polymerized hydrogel
and EPS template were taken out from the tube and excess hydrogel was removed. Finally,
hydrogel-EPS templates were soaked in chloroform for 4-6 hours during which EPS beads
were selectively dissolved, leaving behind an ICC polyacrylamide hydrogel matrix (Figure
6.3B). EPS templates prepared in solutions with less than 80 % ethanol were broken during
precursor infiltration, in which the characteristic ultimate mechanical strength was 1.8 ±
0.2 megapascals (MPa). EPS templates prepared in pure ethanol exhibited the highest
mechanical strength (10.3 ± 1.2 MPa) but were difficult to infiltrate with precursor solution
due to limited interstitial space (Figure 6.3C). When this mechanical correlation was
plotted as a function of the overall template size, it turned out that more than 50 % size
reduction was required to maintain mechanical strength necessary for centrifugation
(Figure 6.3D). Based on these data, we determined that templates processed with 90 %
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ethanol solution were optimal for fabrication of EPS-templated ICC polyacrylamide
scaffolds.
EPS-templated ICC hydrogel scaffolds exhibited spherical pore cavities and optical
transparency comparable to ICC hydrogel scaffolds prepared with glass beads of
comparable sizes (Figure 6.3E). Scaffold pore size was found to be tunable based on the
duration of EPS-templated processing. For example, pore diameters were 1.05 ± 0.2 mm,
9.27 ± 0.18 mm and 8.23 ± 0.15 mm for ICC hydrogel scaffolds fabricated from templates
made with 90% ethanol for 5 min, 15 min and 30 min operation, respectively (Figure
6.3F). The EPS-templated ICC hydrogel scaffold fabrication strategy is flexible and rapid,
enabling creation of different prototypes demonstrated by triangular, square, and hexagonal
shapes of ICC hydrogel scaffolds by changing the initial mold design (Figure 6.3G).
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Figure 6.3. Preparation of EPS-templated ICC polyacrylamide hydrogel scaffolds.
(A) Acrylic structures designed to keep EPS bead-based colloidal crystal templates
submerged during the infiltration of precursor solution and subsequent polymerization. (B)
Schematic of experimental procedures to obtain a hydrogel with an ICC structure. (C)
Quantitative analysis of the ultimate strength of fused EPS beads under varying conditions
and an indication of the optimal operating range. (D) Quantitative correlation of ultimate
strength and diameter change highlighting the minimum mechanical strength to endure
mechanical stress of centrifugation. (E) Camera (top) and microscope (bottom) images of
EPS-templated ICC hydrogel scaffolds. (F) Quantitative analysis of pore diameters of ICC
hydrogel scaffolds fabricated with three different operating periods and 90% ethanol. (n=4,
*P<0.05). (G) Demonstration of conserved EPS template shrinking, and subsequent ICC
hydrogel scaffolds fabricated with varying initial mold shapes.
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6.3.3 Preparation of bioactive ICC hydrogel scaffolds via type I collagen integration
in bulk hydrogel
Polyacrylamide hydrogel is not conductive for cell adhesion and requires
immobilization of collagen fibers or RGD peptides to become bioactive. However, reagents
for the conjugate chemistry are expensive and this procedure is laborious. Instead we
hypothesized that inclusion of collagen fibers directly in the precursor solution would
simplify fabrication of bioactive ICC hydrogel scaffolds. To test this hypothesis, we
fabricated ICC hydrogel scaffolds with precursor solution containing type I collagen fibers
at a final concentration of 2 mg/mL and compared them to scaffolds prepared by attaching
collagen fibers using Sulfo-SANPAH conjugate chemistry (Figure 6.4A). Collagen fibers
in the hydrogel matrix were visualized via second harmonic generation in a multiphoton
microscope. As expected, the conventional method immobilized collagen exclusively on
the pore surface whereas collagen dispersed in the precursor solution appeared both on the
surface and within the bulk hydrogel. Collagen fibers exhibited different morphologies;
stretched thin fibers when surface conjugated and coiled bundles when mixed directly in
the polymer precursor solution (Figure 6.4B). Collagen fibers are known to undergo a
reversible conformational change depending on the surrounding pH
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. For example, at

low pH, collagen fibers adopt an elongated morphology whereas at high pH, collagen fibers
coil. Our results indicate that the alkaline reaction pH of acrylamide polymerization via
addition of ammonium persulfate and TEMED could direct collagen fibers to adopt a more
coiled morphology319.
We next examined whether the collagen embedded within the polyacrylamide of
an ICC hydrogel scaffold could support stromal cell adhesion. Primary BMSCs retrieved
from the femurs of eGFP mice were used to easily visualize stromal cells seeded on the
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scaffold. Fluorescence images taken 3 days after seeding showed that most stromal cells
adhered and displayed an elongated, spread morphology on scaffolds with collagen,
whereas the stromal cells that adhered on control collagen-free hydrogel scaffolds had a
round morphology, indicating poor surface adhesion (Figure 6.4C). Quantitative analysis
of stromal cell morphology revealed 85 % had an elongated morphology on collagen
scaffolds whereas only 15 % of cells adhered on collagen-free scaffolds (Figure 6.4D).
These results indicate that direct introduction of collagen fibers in precursor solution
promotes stromal cell adhesion comparable to conventional conjugate chemistry.

Figure 6.4. Hybridization of collagen and polyacrylamide to achieve bioactive
hydrogel scaffolds.
(A) Schematic illustration of conventional surface modification using conjugation
chemistry and dispersion in precursor solution for direct integration within the hydrogel
matrix during polymerization. (B) Second harmonic generation images of collagen on
polyacrylamide hydrogel scaffolds using multiphoton microscopy. (C) Comparison of
fluorescent confocal images of eGFP BMSCs on the pore surface of ICC hydrogel scaffolds
with and without bulk collagen integration. (D) Quantitative comparison of stromal cell
adhesion morphology. (n=3, *P < 0.05)
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6.3.4 In vitro modeling of bone marrow tissue microenvironments
For an in vitro functional demonstration, we applied EPS-templated ICC hydrogel
scaffolds to model the bone marrow tissue microenvironment focusing on hematopoietic
cell activity as a function of BMSCs. BMSCs are known to secrete a variety of soluble
factors that support and direct hematopoietic activity in the bone marrow320-322. By
changing the availability of collagen we hypothesized that the BMSCs seeded on ICC
hydrogel scaffolds would adopt distinctive soluble factor profiles and differentially direct
hematopoietic colony forming activity. A critical issue in characterizing hematopoietic
colonies in 3D scaffolds is deciphering stroma from hematopoietic cells and their
progenitors using traditional microscopy techniques. To overcome this challenge, we
employed cells from eGFP and DsRed reporter mice that facilitate fluorescent monitoring
of stromal and hematopoietic cell activity while preserving the intrinsic phenotype of both
cell types (Figure 6.5A). We first examined the secretion profile of BMSCs focusing on
key factors involved in bone remodeling: IL-6, osteoprotegerin (OPG), and receptor
activator of nuclear factor kappa-B ligand (RANKL). Increased RANKL and IL-6
stimulate osteoblasts and osteoclasts to promote bone remodeling activity, whereas OPG
secretion suppresses remodeling activity. ELISA data showed that BMSCs secreted
significantly more IL-6 and RANKL and notably lower OPG on collagen-free ICC
hydrogel scaffolds than collagen embedded hydrogel scaffolds (Figure 6.5B-D). These
results indicate that BMSCs seeded on hydrogel matrix with embedded collagen suppress
bone remodeling activity.
We next evaluated if the different soluble environments could direct hematopoietic
colony forming activity. After 1-week culture of eGFP BMSCs on collagen-coated and

163

control ICC hydrogel scaffolds, we introduced freshly harvested femoral bone marrow
cells retrieved from DsRed mice. Before loading, bone marrow cells were dispersed in
methylcellulose medium without hematopoietic cytokines. Subsequent hematopoietic
colony development was monitored with fluorescence microscopy over a 16-day period.
DsRed fluorescent colonies gradually emerged in and around BMSC seeded scaffolds
(Figure 6.5E). This unconventional three-dimensional colony forming assay makes it
difficult to distinguish specific types of hematopoietic colonies. Instead, we focused on the
number of emerging colonies by taking advantage of the endogenous fluorescence. In
stromal cell-free control cultures without essential hematopoietic cytokines, no
hematopoietic colonies emerged, indicating stromal cells play a vital role in supporting the
survival and function of hematopoietic cells ex vivo. Quantitative monitoring of colony
number over the experimental period showed an increased number of hematopoietic
colonies when cocultured with BMSCs seeded on scaffolds with embedded collagen,
whereas the number of colonies stabilized after 1-week of coculture with BMSCs on
collagen-free scaffolds (Figure 6.5F). 3D confocal imaging at the end of the study revealed
the spatial distribution of BMSCs and hematopoietic cells, with some in physical contact
with each other (Figure 6.5G). Collectively these results indicate that the different soluble
milieus produced by BMSCs with and without collagen stimulation can affect
hematopoietic colony forming activity. This also demonstrated that EPS-templated ICC
hydrogel scaffolds are capable of identifying dynamic functional interactions between
hematopoietic and stromal cells ex vivo.
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Figure 6.5. In vitro demonstration of functional bone marrow tissue model using EPStemplated ICC hydrogel scaffolds.
(A) Schematic of bone marrow tissue model with eGFP stromal cells and subsequent
introduction of bone marrow cells from DsRed mice dispersed in methylcellulose medium
for colony-forming assay. (B-D) Comparative ELISA of (B) IL-6, (C) osteoprotegerin
(OPG), and (D) RANKL secretion by BMSCs seeded on collagen and collagen-free ICC
hydrogel scaffolds. (E) Representative fluorescence microscope images of time course
hematopoietic colony-forming activity in BMSC seeded scaffolds on collagen and
collagen-free ICC hydrogel scaffolds. (F) Time course quantification of hematopoietic
colony count (n=3, * P<0.05). (G) Z-projection of 3D confocal microscope images of
stromal (green) and hematopoietic (red) cell spatial distribution in EPS-templated ICC
hydrogel scaffolds.
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6.3.5 Formation of lymphoid mimicking tissue microenvironments in vivo
Subdermal implantation of ICC hydrogel scaffolds has been shown to direct unique
foreign body responses leading to a richly vascularized stromal tissue with prolonged
hematopoietic cell activity. We evaluated if EPS-templated ICC hydrogel scaffolds
induced comparable tissue development to hydrogel scaffolds made with glass beads after
subdermal implantation in FVB mice (Figure 6.6A). Scaffolds fabricated from glass beads
were chosen for comparison because they are commercially available in sizes close to those
achieved with the EPS fabrication technique. Gross observation after four weeks of
implantation revealed EPS and glass-templated ICC hydrogel scaffolds showed similar
tissue development and attraction of large blood vessels (Figure 6.6B). H&E staining
confirmed complete interscaffold tissue development and a comparable pattern of spatial
tissue microenvironments directed by the ICC geometry. In general, fibrotic tissue is
formed within the central region of each pore whereas hematopoietic cells are localized
near the pore surface (Figure 6.6C).
We further characterized the vascular network and attraction of macrophages and
neutrophils via immunohistostaining for CD31, F4/80 and Ly6G, respectively. Tissues
developed in EPS-templated ICC hydrogel scaffolds contained an extensive vascular
network similar to glass-templated ICC scaffolds (Figure 6.6D). Non-degradable synthetic
hydrogels direct macrophage response throughout the entire scaffolds (Figure 6.6E).
Distinct from the widespread vasculature and macrophages, neutrophils were highly
localized in 2-3 sites of each tissue section (Figure 6.6F). Overlaid CD31, F4/80, Ly6G,
and nuclei staining substantiates the spatial distribution of vascular, stromal and immune
cells in an ICC pore cavity (Figure 6.6G). Quantitative analysis of CD31, F4/80, and Ly6G
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positive areas confirmed comparable tissue development between EPS- and glasstemplated ICC hydrogel scaffolds (Figure 6.6H-I). Overall our results indicate that EPStemplated ICC hydrogel scaffolds retain comparable ability to induce characteristic
vascularized

and

hematopoietic

cell

attracting

lymphoid

tissue-mimicking

microenvironments to glass-templated ICC hydrogel scaffolds.

Figure 6.6. Comparison of tissue microenvironment formed in ICC hydrogel scaffolds
made from glass and EPS beads after subdermal implantation.
(A) Experimental schematic of EPS and glass-templated ICC hydrogel scaffold
implantation for in vivo tissue microenvironment formation. (B) Gross images of glassand EPS-templated ICC hydrogel scaffolds in FVB mice after 4 weeks of subdermal
implantation. (C) Comparison of hematoxylin and eosin stained tissue microenvironments.
(D-F) Comparison of immunohistostaining (IHS) for (D) blood vessels (CD31), (E)
macrophages (F4/80) and (F) neutrophils (Ly6G). (G) Overlaid IHS image of blood
vessels, macrophages, neutrophils, and nucleus (DAPI) to visualize the spatial resolution
in the lymphoid tissue mimicking microenvironment. (H-J) Quantitative imaging analysis
of (H) CD31+, (I) F4/80+, and (J) Ly6G+ positive areas (%) (n=6, *P<0.05).
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6.4 Discussion
In this report, we introduced EPS bead-based ICC hydrogel scaffold fabrication.
EPS beads are widely available at low cost. From a material aspect, EPS beads exhibit
intermediate characteristics between solid beads and microbubbles while retaining
mechanical integrity and flexibility. These properties facilitate the production of the
intricate geometry of ICC scaffolds in a fast, cost-effective, and less toxic manner when
compared to existing template materials. In addition, direct inclusion of type I collagen in
the precursor solution has greatly simplified the manufacturing procedure for bioactive
hydrogel scaffolds. These features represent great potential to reduce the technical and cost
barriers in fabricating bioactive ICC hydrogel scaffolds. The presented method for EPStemplated hydrogel scaffolds can be improved further. First, the dimension of EPS beads
is not ideal for modeling trabecular bone cavities in hematopoietic bone marrow and other
lymphoid tissues. This issue can be resolved by reducing the size of expandable
polystyrene resins that are being processed into EPS. Second, the packing of EPS beads is
suboptimal as the low density of EPS beads makes it difficult to apply centrifugation and
agitation-assisted packing methods. This can be improved by benchmarking the previous
methods in building colloidal crystal templates at the air-water interface323-324. Lastly, the
coiled morphology of in situ collagen integration is also suboptimal to maximize the
function of collagen for stromal cell adhesion. Collagen fibers undergo pH dependent
conformational change; collagen fibers are relaxed in an acidic environment whereas they
are coiled configuration in basic solutions325. Alkaline precursor solution likely causes the
collagen fibers to undergo a conformational change. By adjusting the pH in the precursor
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solution, more aligned collagen fibers and better coverage of hydrogel matrix may be
achieved.
Water and ethanol were used to generate the pressurized heated vapor phase
responsible for EPS shrinkage and fusion to form a free-standing template structure.
Although the theoretical temperature of the chamber was lower in pure ethanol samples,
the size reduction was the greatest. This phenomenon may be explained by the solubility
of polystyrene in ethanol and water. Solubility parameters can be estimated from physical
properties, as described by the Hildebrand solubility parameter and Hansen solubility
parameter326. The Hildebrand model defines the parameter δ as the square root of the
cohesive energy density. Cohesive energy density is the negative value of the internal
energy commonly defined U, divided by the molar volume. The Hansen model provides
expansion of application to polar systems via empirical observations to determine
dispersive, polar, and hydrogen-bonding terms. Solubility parameters provide input on
whether polymers will dissolve in solvents, effectively if solubility parameters are similar
the two components are predicted to be miscible. The Hansen solubility parameters δ
(MPa)1/2 for water, ethanol, and polystyrene are 47.9, 26.0, and 18.7, respectively. For
comparison the solubility parameter for the solvent used to dissolve the template,
chloroform is 19 (MPa)1/2. The increased, though overall poor, solubility of polystyrene in
ethanol may provide faster collapse of the foam structure within EPS beads. The beads do
not appear to lose their spherical geometry indicating these changes may occur on a very
small scale. Electron microscopy may provide details on pore structure of EPS beads
processed with different solvents. Additionally, means to calculate solubility parameters of
mixtures are not straightforward. However, other than samples processed with a 50:50

169

mixture, this assessment provides evidence for the two extreme cases of EPS shrinkage as
seen by use of pure vapor phase solutions. Evaluation with solvents with similar solubility
parameter values may further substantiate these claims.
Besides lymphoid tissue modeling, ICC hydrogel scaffolds have been previously
demonstrated to be advantageous in other tissue engineering applications. For example,
ICC geometry made with cell-repulsive hydrogel matrix directed formation of multicellular
hepatocyte and stem cell spheroids with narrow size distribution327-328. Hepatic and
embryonic spheroids demonstrated in vivo relevant cellular processes in toxic nanoparticle
exposure316 and differentiation into lineage cells329, respectively. ICC hydrogel scaffolds
have demonstrated additional in vitro success modeling cartilage330, bone314 and
neuronal331 tissues taking advantage of their unique geometry with tailored biomaterials in
each target application. ICC hydrogel scaffolds have also demonstrated exceptional
capability for rapid vascularization as a function of pore size298. This capability has been
applied for cardiac tissue engineering and wound healing medical devices. The presented
EPS-templated ICC hydrogel scaffold fabrication will leverage these abilities to broader
academic and industrial communities.
ICC hydrogel scaffolds with controlled isotropic spherical pore arrays of hydrogel
matrix has emerged as an important class of biomaterials for tissue engineering. Originally
in the context of lymphoid tissue engineering, ICC scaffolds have many promising
applications both in vitro and in vivo. An important next step in the advancement of ICC
hydrogel scaffolds is improved fabrication techniques that facilitate effective scale up.
Currently, there are no commercial ICC hydrogel scaffolds due to material cost, time, and
safety. The presented work provides a cheaper, faster, and safer method for ICC hydrogel
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fabrication by using EPS and directly mixing collagen fibers within the synthetic hydrogel
matrix. ICC hydrogel scaffolds have already demonstrated many promising applications in
lymphoid tissue engineering and beyond. We envision that the presented EPS beads-based
scaffold fabrication will greatly facilitate broad and practical applications of ICC hydrogel
scaffolds to the research community and enable exploration into translational opportunities
for patients.

6.5 Materials and Methods
All chemicals and cell culture reagents were purchased from Thermo Fisher
Scientific unless otherwise specified. The animal protocol was approved by the University
of Massachusetts Amherst Institutional Animal Care and Use Committee.
6.5.1 Pressurized thermal annealing of EPS beads
EPS beads (Diameter = 1,626 ± 195 µm) obtained from Amazon were loaded into
a perforated stainless-steel mesh container (Diameter = 38 mm, Height = 44 mm) to a
height of 1 cm. The mesh container was transferred to an elevated rack in a 2.5-quart
electric pressure cooker and the cooker was filled with 200 mL of ethanol and water
mixture. Using the “High Pressure” setting on the cooker, an annealing time was set
between 5-30 minutes. The lid was attached, and the pressure valve was closed to prevent
loss of vapor. At the end of annealing, built-up pressure was released before carefully
removing the lid and steel mesh containers. Annealed EPS templates were kept at room
temperature prior to further processing. Template images were acquired with an inverted
tissue culture microscope. Pore size analysis was performed in ImageJ.
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6.5.2 Micro-CT imaging and porosity characterization
Templates fabricated using different annealing conditions and times were scanned
using the CT imager on an IVIS SpectrumCT with a voxel size of 75 µm. Calculation of
void fraction based on micro-CT imaging was performed in MATLAB.
6.5.3 EPS bead-templated ICC hydrogel scaffold fabrication
An acrylamide precursor solution was made with 30 wt% acrylamide monomer and
1.5 wt% bis-acrylamide crosslinker dissolved in nitrogen-purged deionized (DI) water. For
collagen experiments, nitrogen purged DI water was displaced with a 4 mg/mL rat-tail
collagen solution to obtain a final collagen concentration of 2 mg/mL. Prior to
polymerization of the EPS template, a 50 mL centrifuge tube was prepared with laser-cut
acrylic inserts to keep the template fully submerged during polymerization. 10 wt/vol%
ammonium persulfate and N,N,N’,N’-tetramethyl-ethylenediamine (TEMED) were added
to the acrylamide precursor solution such that both were at a final concentration of 0.1 %.
The solution was added to the EPS template-containing centrifuge tube and centrifuged at
4,500 xg for 20 minutes at 4 °C. Tubes were carefully removed from the centrifuge and
left at room temperature to polymerize. Once polymerized, infiltrated EPS templates were
retrieved from the centrifuge tubes and carefully scraped on all sides with a razor blade to
remove excess polymer. Infiltrated EPS templates were placed in chloroform and left
overnight to dissolve EPS beads. A second wash with fresh chloroform was performed to
remove residual EPS before thorough washing with water. Hydrogel gel scaffolds were
sterilized by submerging in 70 % ethanol for 30 minutes. For in vitro and in vivo
applications scaffolds fabricated with 90 % ethanol and annealing time of 30 minutes were
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used. Initially large scaffolds were cut down (Diameter = 6 mm x Height = 2.5 mm) using
a 6 mm biopsy punch and a razor blade. Sterile scaffolds were stored in phosphate-buffered
saline at 4 °C.
6.5.4 Rat tail type I collagen isolation
Type I collagen was isolated from rat tails using serial salt precipitation and
dissolution in acetic acid97. Briefly, tendons were extracted from rat tails using hemostats
and a razor blade, and then dissolved in 3 % (v/v) acetic acid overnight. The resulting
solution was passively filtered through a 500 m mesh and centrifuged for 2 hours at
13,000 xg at 4 oC to remove debris and impurities. Next, the supernatant was collected and
diluted 1:4 by volume in a 30 % (wt/v) NaCl solution at a rate of 350 mL/hr and then left
still for 2 hours. To collect the collagen, the resulting solution was spun down at 8,500 xg
for 45 min at 4 oC, and the precipitated gelatinous collagen harvested. Addition of salt
solution and precipitation was repeated until no more collagen was extracted from the
solution after centrifugation, upon which all collagen material was combined and
resuspended in 0.6 % (v/v) acetic acid. The collagen solution was then dialyzed in 1 mN
HCl, and the concentration determined using lyophilization.
6.5.5 Glass bead-templated ICC hydrogel scaffold fabrication
Soda lime glass beads (Diameter = 650 ± 65 µm) were sorted using an Advantech
Sonic Sifter. Beads dispersed in DI water were gradually loaded into a glass vial (8×35mm)
to a height of 2–2.5mm and were mechanically packed into a lattice structure in an
ultrasonic water bath. Orderly packed glass beads were dried in a 60 °C oven and then
thermally annealed for 4 h in a furnace between 650 and 680 °C. A hydrogel precursor
solution composed of 30 wt% acrylamide monomer, 1.5wt% bis-acrylamide crosslinker,
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0.2 vol% N,N,N′,N′-tetramethylethylenediamine accelerator, and 0.2 vol% 2-hydroxy-2methylpropiophenone photoinitiator in nitrogen-purged DI water was prepared
immediately before use. Precursor solution (150 μl) was infiltrated into the glass bead
template and centrifuged in a microcentrifuge at 8,500 xg for 15min and subsequently
polymerized under a 15W ultraviolet light source for 15min. Polyacrylamide hydrogel–
glass templates were removed from the glass vials the next day to ensure complete
polymerization. Excess hydrogel was removed by scraping the glass bead template with a
razor blade on all surfaces. Glass beads were selectively dissolved in alternating washes of
an acid solution containing a 1:5 dilution of hydrofluoric acid in 1.2M hydrochloric acid
and 2.4M hydrochloric acid (caution: these chemicals are corrosive and must be used in a
fume hood with proper protective gear). Washes were completed on a shake plate, and
solutions were changed every 4h until the beads were removed. Scaffolds were thoroughly
washed with DI water to remove residual acid and lyophilized. Type I collagen isolated
from rat tails was covalently immobilized on the pore surface using Sulfo-SANPAH
conjugate chemistry as previously described101.
6.5.6 Mechanical testing of EPS templates
Mechanical properties were measured using an ElectroForce 5500 (TA
Instruments) equipped with a 50 lb-load cell. A strain rate of 0.02 mm/sec was applied with
a 3 mm platen. Ultimate strength was calculated by taking the maximal force before failure.
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6.5.7 Multiphoton microscopy imaging of collagen fibers via second-harmonic
generation
Collagen fibers on the surface and embedded within hydrogel scaffolds were
imaged using a Nikon A1MP multiphoton microscope equipped with a tunable Ti:Sapphire
laser source set at an excitation wavelength of 850 nm and a 492 nm shortpass filter.
6.5.8 Primary mouse bone marrow stromal cell isolation and culture expansion
A breeding pair of eGFP mice (006567) were purchased from Jackson Laboratories.
A breeding pair of DsRed (005441) was obtained from Dr. Barbara Osbourne. Femurs and
tibias were collected from DsRed or eGFP mice. Bone marrow stromal cells (BMSCs) were
isolated from the bone by centrifugation and cultured in alpha-Modified Eagle Medium
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin. Adherent
cells were cultured for a maximum of 4 passages.
6.5.9 ELISA of mouse IL-6, OPG, and RANKL
EPS scaffolds with and without collagen were seeded with 500,000 adherent eGFP
BMSCs and cultured in the wells of a 48 well plate. The culture was maintained until cells
spread and covered the scaffold surface. 2D tissue culture plastic controls were seeded at a
density of 50,000 cells per well and grown until confluence. Medium was changed every
3 days for the duration of the experiment. At the end of the experiment conditioned media
was collected 48 hours after a media change and frozen at -80 °C. ELISAs were performed
on thawed conditioned media samples using ELISA kits acquired from R&D Systems.
6.5.10 Methylcellulose colony-forming assay
EPS scaffolds were seeded with 500,000 adherent eGFP stromal cells and cultured
in wells of a 48 well plate until all surfaces were covered. Freshly isolated bone marrow
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cells from DsRed mice were resuspended to a concentration of 500 cells/µL in
methylcellulose media (1.27 % alpha-Modified Eagle Medium methylcellulose, 10% fetal
bovine serum, and 1% penicillin-streptomycin). 50,000 cells were carefully added to the
wells containing eGFP BMSCs pre-seeded EPS-templated ICC hydrogel scaffolds and
empty EPS scaffolds. Full well scans were acquired using an EVOS fluorescent microscope
on day 1, 4, 8, 12 and 16. Fluorescent z-stack images were taken by confocal microscope
(Zeiss Cell Observer) and 3D reconstructed images were generated and animated in Nikon
Elements AR v5.2.0. FFMPEG was utilized to downsample and compress the 3D
reconstructions.
6.5.11 Subdermal implantation of scaffolds in mouse models
6-week old FVB mice (001800) were obtained from Jackson Laboratory. Mice
were anesthetized with 1.5% isoflurane before removing dorsal hair with electric clippers
and Nair. 70% of isopropanol wipes were used to sterilize the skin. Mice received 2 mg of
meloxicam/kg mouse weight subcutaneously prior to surgery. Four subcutaneous pockets
were formed in mice and EPS and Glass-templated ICC hydrogel scaffolds were
immediately place within. Wounds were closed with two 7 mm wound clips. Wound clips
were removed after one week. Four weeks after implantation scaffolds were retrieved and
flash frozen in Shandon Cryomatrix embedding resin. Tissue blocks were stored at -80 °C
until use.
6.5.12 Histological characterization
Frozen tissue blocks were sectioned on an NX70 cryostat at a thickness of 20 µm.
Hematoxylin and eosin, and immunohistostaining procedures were performed as
previously described101. CD31 (550274), F4/80 (565409), and Ly6G (557445) primary
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antibodies and anti-Rat AlexaFluor 647 (A21247) secondary antibodies were used in this
study. Brightfield images were acquired on an EVOS FL Auto microscope and fluorescent
images were acquired on a Zeiss Cell Observer SD.
6.5.13 Statistics
Unpaired Student’s t-test was performed for comparison of the mean values in all
quantitative analysis. Statistical significance was determined if p<0.05 for a two-tailed
analysis. All quantitative data represent mean and standard deviation.
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CHAPTER 7
CONCLUSION AND FUTURE DIRECTIONS

7.1 Conclusion
Metastasis remains a critical problem in clinics and therapeutic strategies have not
made significant impact on patient health. The work presented here provides an enabling
tool to better understand disseminated tumor cells (DTCs) and their progression to lethal
metastases and potentially provide translational results to improve patient health. Inverted
colloidal crystal (ICC) hydrogel scaffolds produce standardized and controlled in vivo
niches for a wide variety of studies. The flexibility of ICC scaffolds and implantable niche
models can be leveraged for further tunability. First, the physical and bulk properties of the
scaffold can be altered by changing the pore size, the polymer material, and polymer
properties such as crosslinking density. For example, pore size was shown to alter
vasculature formation and control the diameter of blood vessels. Second, ex vivo cell
seeding enables new cell populations to be directly added to the tissue niche. Here I have
utilized human bone marrow stromal cells to generate niches that actively secrete human
cytokines and more closely model human tissue. Third, changing the implant location
drastically changes the local cell populations and impacts the final cellular and molecular
niche that forms within the pores. Finally, the transplantable capabilities enable extended
experimental duration and open the door to the development of new strategies to model
disease. Here we transplanted to syngeneic hosts of similar age, however one exciting
possibility is transplantation into significantly older hosts to understand how ageing affects
the niche and metastasis.
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The immunomodulatory properties of ICC hydrogel scaffolds prevent fibrotic
encapsulation, typically associated with the later stages of the foreign body response.
Instead a highly vascularize tissue rich in bone marrow derived cells is formed. Here I
heavily relied on these properties to create a receptive niche for circulating tumor cells.
Additionally, I have demonstrated the ability to leverage the benefits of increased
vascularization and altered immune response to transplant lung and liver tissue ectopically
to the subcutaneous space. Maintenance of native tissue properties is an exciting result and
provides evidence that xenotransplantation of mature human tissue may benefit from the
scaffold-assisted approach. Out of patient study of fully mature human tissues in an in vivo
setting could prove to be powerful preclinical models for drug screening and probing basic
biological questions about human tissue.
The central goal of this work was to create new in vivo models that overcome the
limitations present in traditional models of metastasis. I have shown the versatility of
implantable models across several mouse strains: FVB, C57BL/6, and NSG. Additionally,
the implantable niche strategy has been successful in multiple methods of tumor generation
including intravenous, orthotopic, xenografts, and genetically engineered spontaneous
cancer models. The work has addressed very critical problems in DTC dormancy and
metastatic relapse. DTC dormancy models were formed using a transplantable niche
strategy. Primary tumor burden and aggressive metastases in vital organs prevents the
effective study of long-term dormant DTCs. Transplantation of DTC containing niches
enabled long-term observation and identified critical niche components that are associated
with maintenance and activation of dormancy. This was furthered by instigating the niche
to try and force an escape from dormancy. I found that adjuvant therapy, while effective at
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reducing burden initially did not prevent DTC growth long-term. Surgical intervention was
also shown to play a role in increasing the growth of DTCs. These results demonstrate that
ICC scaffolds can capture long-term DTC phenomenon and may reveal targetable factors
that activate metastatic progression.
Finally, I have demonstrated a new fabrication scheme for ICC hydrogel scaffolds.
The entirety of the in vivo metastasis studies performed in this work were performed with
glass beads, however the manufacturing process is laborious, dangerous, and ultimately
costly. Changing to expanded polystyrene beads provided a more scalable approach that
may utilize existing infrastructure for large scale production of ICC hydrogel scaffolds.

7.2 Future Directions
Although several milestones were achieved with the presented work, implantable
niches to study metastasis are still relatively underutilized and the translational potential
remains unmet. The microenvironment is finally being recognized as a key driver of DTC
fate, and new characterization techniques enable deeper analysis into components of the
niche. Single cell RNA sequencing has provided an unparalleled level of cellular detail but
has not been utilized to understand niche evolution around DTCs332. Part of this challenge
has been in capturing DTCs and their immediate niche for analysis. This process requires
total disruption of the tissue, therefore it is not practical to capture the local niche for
analysis. Efforts have been made to adapt single cell RNA sequencing to histological slides
enabling spatial mapping of RNA sequencing data333. This is an exciting direction to detect
minute differences in the DTC niche as cells undergo the transition from dormancy to a
proliferative state and could be applied to long-term dormant DTC containing scaffold
niches. Similar spatial analysis should be performed on the local matrix proteins.
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Techniques such as imaging mass spectrometry provide spatial proteomic analysis and
have been used to understand protein regulation of tumor expansion334. A final analysis to
continue to pursue is of the local secretome. I have provided evidence of changing
secretome after chemotherapy in this work. However, temporal monitoring would provide
a better idea as to how the niche is evolving and provide further mechanistic understanding
of cytokine signaling and inflammatory pathways associated with metastatic progression.
In regard to cytokines and soluble molecules, exosomes are another exciting class of
molecule that should be investigated in the DTC niche. Understanding exosome signaling
during the foreign body response may enable further immune modulation.
The tunable nature of tissue engineered niches can reduce the gap in species-species
differences between mice and human when using animal models. As described here a
humanized niche was formed by pre-seeding the scaffold with human bone marrow stroma
cells. Although not fully representative of the bone marrow, this approach may be used as
a starting point to generate human-relevant stromal niches to study their interaction in an
in vivo setting. For example, human lung stromal cells or human kidney stromal cells could
be seeded onto scaffolds to identify potential differences driven by the stromal cells that
substantiate the altered metastatic growth in typically high and low metastatic tissues,
respectively. In addition to probing the interaction of specific cellular components,
extracellular matrix proteins can be directly investigated using implantable scaffold niches.
For example, fibronectin has been identified as a potential marker for the pre-metastatic
niche development. Increased integration of fibronectin into the scaffold via surface
coating or bulk integration within the polymer matrix may yield significantly different
tissue formation and metastatic potential within the scaffold niches. This approach could
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be applied to other extracellular matrix proteins including specific collagens beyond type
I found in rat tails, elastins, and laminins. I expect that this high level of microenvironment
control will aid in the identification of cellular and molecular factors that drive metastatic
relapse. In addition to changing the potential metastatic capabilities of the scaffolds, unique
translational opportunities may arise from the formation of different tissue
microenvironments by changing the initial cellular and molecular composition of the
scaffolds prior to implantation.
Deeper mechanistic understanding of the DTC niche will ultimately produce
targetable cellular and molecular pathways that enable metastatic growth. Previous work
has demonstrated the ability for scaffold metastasis models to act as a screening platform
based on microarray analysis of the niche. In this dissertation work I have developed new
methods to test syngeneic models in high throughput via transplantation of primary
MMTV-PyMT tumor fragments. Further development as a preclinical screening model
should be pursued and implemented based on literature and future findings. For example,
checkpoint inhibitors are an exciting therapeutic option that have been relatively
unexplored mechanistically within the context of metastatic relapse. This future research
direction using biomaterial DTC niches is important in validating potential mechanisms of
metastatic relapse and maintenance of dormancy, and screening of pre-clinical candidates.
Intravital imaging is a powerful technique that enables real-time observation of
cellular events in a living organism. Extravasation and tracking of disseminated tumor cells
into the brain microvasculature has been shown using a chronic cranial window48. This
model also identified necessary steps that were necessary for metastasis formation
including extravasation out of circulation and remaining in the perivascular space. Another
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approach has been performed to examine the lung microenvironment using a vacuum
stabilized window directly on the lung of a mouse107, 335-336. These windows have been
critical in observing extravasation of cancer cells into the lung tissue and early immune
cell interaction. For example, they have enabled visualization of neutrophil extracellular
traps around pro-metastasis cancer cell lines that had extravasated into the lungs251.
Previously our lab has utilized a dorsal-skin fold window chamber to observe tumor cells
extravasating into the scaffold niche97. I have started to implement this technique with
moderate success. First, scaffolds are implanted to allow for tissue development. During
window engraftment, the skin is stretched around the scaffold such that it is sandwiched
between the skin. Titanium supports are installed over the scaffold and held with a
combination of screws and sutures. One side of the skin is removed, revealing the scaffold
and a cover slip is installed (Figure 7.1a). During imaging red fluorescent dextran is
intravenously administered to visualize blood vessels. Intravenous injection of eGFPMDA-MB-231 or eGFP-PC-3 tumor cells enables observation of tumor cells. Preliminary
results reveal the ability to observe tumor cells and the local vasculature via the window
chamber (Figure 7.1b). Plans have been made to apply an intravital window to chimeric
eGFP mice and introduce fluorescent cancer cells to observe bone marrow cell interaction
with DTCs. Combining this study with adjuvant chemotherapy or surgical intervention
may provide new insight on the dynamic interactions between DTCs and the surrounding
niche during stimuli relevant to patients.
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Figure 7.1. Intravital imaging.
a, Gross image of window chamber engraftment around implanted scaffold. b, Intravital
image of DTC (green) and vessel (red).

Although I have investigated local immune modulation, systemic changes to
immune cell behavior have not been investigated. Previous work in biomaterial
implantation has had success in manipulating dendritic cell homing and immune response
120, 164, 240-242

. Implantable biomaterials have also been observed to reduce metastatic tumor

burden in vital organs by altering CTC recruitment patterns

103-104

. Additionally, an

experiment involving the implantation of human fetal tissue revealed a renewal in
metastatic potential following either radiotherapy or injection of IL-1β

87

. I hypothesize

that implantation of ICC scaffolds has unexplored systemic immunomodulatory properties
that could be utilized for basic biological understanding or leveraged for translational use
in patients. The potential for this research thrust has been demonstrated by the experiments
performed by Krall et. al. whereby dormant tumors were reawakened following
implantation of a biomaterial by mobilization of inflammatory bone marrow cells273.
Similar strategies may provide therapeutic benefit for disease such as chronic fibrosis by
redirecting bone marrow cell activity. Evidence highlighting the important interactions
between the immune system and the intestinal microbiota have become increasingly
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prevalent. Investigation of the role biomaterial implantation has on the microbiome and
vice versa may uncover important immunomodulatory behavior that could have therapeutic
benefit in unforeseen diseases.
I hope the work presented here will convince the community that tissue
engineering approaches and specifically implantable ICC scaffold strategies are powerful
tools to address provocative hypotheses that are challenging to study in traditional systems.
I believe these approaches are still early in their development and their potential has not
yet been realized.
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